Development of a controlled-release platform for investigation of proteases following rotator cuff tear by Trevino, Elda Alicia
DEVELOPMENT OF A CONTROLLED-RELEASE PLATFORM 












Elda Alicia Treviño 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
Department of Biomedical Engineering 
 
 
Georgia Institute of Technology and Emory University 
August 2020 
 
COPYRIGHT © 2020 BY ELDA ALICIA TREVIÑO 
DEVELOPMENT OF A CONTROLLED-RELEASE PLATFORM 







Approved by:   
   
Dr. Johnna S. Temenoff, PhD, Advisor 
Department of Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
 Dr. Manu O. Platt, PhD 
Department of Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
   
Dr. Nick J. Willett, PhD 
Department of Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
 Dr. Edward A. Botchwey, PhD 
Department of Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
   
Dr. Hicham Drissi, PhD 
Department of Orthopaedics 
Emory University 
  
   











Dedicated to Mom and Dad for without you  
both none of these words would be here. 
 
 
Dedicated to Lorena who walked this  






 I would first like to thank my committee for encouraging me to develop the 
knowledge and skills that would make me worthy of an advanced degree. I would like to 
extend a special acknowledgment to my advisor, Johnna Temenoff, who made all this 
work possible. Thank you for patience, encouragement, and mentorship. Your guidance 
has allowed me to develop the skills and connections I needed for the next stage of my 
career. I would also like to thank Dr. Nick Willett, Dr. Edward Botchwey, and Dr. 
Hicham Drissi for their insight and probing questions that allowed me to think more 
broadly about my thesis work. Lastly, I would also like to thank Dr. Manu Platt allowing 
me to work and learn in his laboratory space, which allowed me to master gelatin 
zymography, which was vital to this thesis work. Thank you for teaching to ask more 
probing questions about the world around me and giving me a deep appreciation for the 
role proteases play in our body. Finally, thank you for enlisting me to work with you 
outside of the laboratory. I really enjoyed helping with the various programs you have 
developed and supported within our department and across Georgia Tech. Your 
dedication to fostering student development both inside and outside of the laboratory is 
admirable and your commitment to supporting underrepresented minorities in higher 
education has inspired me to adopt similar goals in the future. 
 I would be remiss if I didn’t also take this opportunity to acknowledge the 
contributions of several mentors at The University of Texas at Austin. I would first like to 
thank Dr. Laura Suggs who encouraged me to apply for the TREX program and for 
allowing me to work in her laboratory for three years. Dr. Suggs was incredibly 
 v 
supportive and wrote countless letters of recommendation on my behalf. I would also like 
to thank my graduate student mentor Dr. Laura Ricles for her patience and mentorship. 
Laura was always very kind to me and modeled how to have a successful career in 
graduate school. Lastly, I would like to thank my Ronald E. McNair advisor, Dr. James 
Brown, otherwise known as the godfather of physics. Dr. Brown and the McNair program 
were instrumental in preparing me to successfully apply for graduate school. Even after 
my accepting the offer at Georgia Tech, Dr. Brown frequently checked in on me and 
reminded me that I had the potential to earn the PhD at the end of my name. 
 I would like to thank members of the Temenoff laboratory past and present. 
Thank you to Jen, Torri, and Liane for helping me at the start of my graduate school 
career. In particular, I would like to thank Torri for treating me like a contributing 
member of the laboratory and always taking the time to talk with me about both science 
and life. I would like to extend a special thank you to Jennifer McFaline-Figueroa, who 
was the laboratory manager when I started my graduate work in the Temenoff laboratory. 
Jennifer and I became great friends and have kept in touch after she left to pursue her 
own advanced degrees. I would not have been able to accomplish everything in my very 
first author paper without fundamental work that she did for the laboratory. I want to 
thank Jennifer for keeping me sane during late summer nights with pizza and Beyoncé 
dance parties. I would also like to thank Jimmy Shah, the undergraduate student I had the 
honor and privilege to mentor in our laboratory. Jimmy was such an incredibly hard 
worker and was constantly asking very insightful questions that kept me on my toes. He 
was an absolute joy in the laboratory, and I am so thankful that he was around to help me 
develop the microfluidic device outlined in chapter 4 of this dissertation. 
 vi 
 Furthermore, I would like to thank my current Temenoff lab mates: Molly, Joe, 
Gilad, Leah, Nettie and Zoe. I would like to thank Molly for being such an incredible 
post-doc to our laboratory. Her value and contribution cannot be quantified. She is 
incredibly knowledgeable and was always willing to help in whatever way she could, and 
I am so grateful for her. She will go on to become an incredibly accomplished faculty 
member and I envy the students she will have the opportunity to mentor. While Joe is 
relatively new in the group, I would like to thank him for his calm disposition and for his 
patience with me and my last minute orders. Joe has been a great addition to our group, 
and I am glad we had the opportunity to cross paths and get to know one another. I would 
like thank Gilad for being a good lab mate and helping with me with surgeries when he 
could. I would like to thank Leah, who has become a wonderful friend and confidant 
during my time in graduate school. I am so thankful to her for always willing to help me 
with surgeries or to be a sounding board to talk through unexpected data or difficulties in 
my personal life. Her friendship significantly improved my time in graduate school 
(*p<0.05). I would like to thank Nettie B. for inspiring me to be my authentic self all the 
time. Nettie’s smile and humor are infectious and her presence in *T - LAB* has only 
had overwhelmingly positive results. Last but certainly not least, I would like to thank 
Zoe for being a wonderful friend and lab mate. I could always count on Zoe for a fun chat 
or unwavering support and encouragement when I had encountered difficulties and was 
feeling down. I am so thankful that I had the opportunity to form these friendships with 
my lab mates. It is an incredible feeling knowing that the people you work with have 
your best interests at heart and genuinely care for you and your wellbeing. I feel very 
lucky to have known each of you and I will miss our chats and laughs very much.  
 vii 
 I would like to extend a special thanks to Dr. Akia Parks and Dr. Simone Douglas 
for sharing their “Platt Lab Magic” with me. While many graduate students are made to 
work with one another, I am thankful that we became real friends and cheered one 
another on as we struggled and overcame this PhD. I would also like to thank my friend, 
Fabrice Bernard, for all his help with the near infrared imaging and analysis in chapter 5 
of this work. Thank you for your seemingly infinite patience with me in completing this 
study. Finally, I would like to thank Dr. Chunlei Zhu and Dr. Younan Xia for their help 
in developing our novel microfluidic device in chapter 4 of this dissertation work.  
 To my friends at Georgia Tech, I would like to extend my heartfelt gratitude for 
lifting me up when I was down and cheering me on when I was up. My graduate school 
experience has been shaped by your friendships. Specifically, I would like to thank 
Sandra, my comadre and very first graduate school friend. I am so glad I racially profiled 
you on Day 1 because it resulted in our beautiful friendship. To Shaquia, I treasure your 
friendship and I am so happy that I have gotten to know you as a friend, scientist, wife, 
and mother. To my long-time friend, Marissa, I am so glad that we had the opportunity to 
get to know one another better once we got to Georgia Tech. It was amazing to have a 
fellow Texan to commiserate with and I thoroughly enjoyed your recurring appearances 
in the Temenoff office space for gossip and chit chat. Finally, to the other two-thirds of 
the triple threat lunch team, Ian and Nusaiba, you both have been so instrumental in 
getting me through this final stretch of graduate school. I cannot thank you both enough 
for being the two amazing humans you both are.  
 To my friends at Emory, or more affectionately known as the Party People™, I 
would like to thank each of you for your friendship, jokes, and willingness to chant to just 
 viii 
about anything. You all have essentially been an assortment of additional parents to 
Lorena and I love you all for it. Specifically, I would like to thank Jessie and Roxana for 
inviting me to Girl’s Night shortly after Edgar and I started dating. I was incredibly 
nervous about making a good impression but you both have given me so much love and 
support that imagining my life without you two is incomprehensible. I would also like to 
thank Jackie and Caro for their love and friendship. You both are wildly passionate, 
smart, incredible women and I am so thankful to call you both friends. Last but certainly 
not least, I would like to thank the fedora boiis, Luis and Seyi. Thank you for treating me 
like a friend and not just Edgar’s girlfriend. You both are incredibly funny, wonderful 
guys and I’m very glad I know you both. *Tips fedora* 
 I would like to extend a particularly special acknowledgement to my partner, 
Edgar Sherman, who has witnessed my every triumph and failure in both life and lab. 
Thank you for keeping me grounded and reminding me that I am a smart, capable, strong 
independent woman who don’t need no man. Thank you for your unwavering love and 
support over these (almost) four years. I definitely could have done it without you, but 
I’m glad I didn’t have to. You have brought so much love, joy, and laughter into my life. 
You are my best friend and I love you very much. 
 Finally, I would like to thank my family, who have relentlessly loved and 
supported me throughout my life. Thank you to my mother, Sylvia Treviño, for ensuring 
that I developed her same work ethic and resilience. Thank you to my father, Arnoldo 
Treviño, who is the best man I know. Thank you for always supporting me and believing 
in me. Thank you to you both for making countless sacrifices and always ensuring that 
Lorena and I were always well taken care of. I would also like to extend gratitude to my 
 ix 
brother, Arnold, for supporting me and cheering me on while he also worked towards an 
advanced degree. With two doctors in the family, we have given our family a lot to brag 
about. Lastly, I would like to thank my daughter, Lorena Sylvia Treviño. Thank you for 
being the most wonderful child a mother could ask for and accompanying me on this very 
long, arduous journey called graduate school. When we first moved to Atlanta, you were 
just a tiny cute first-grader, but over these many years I have seen you grow into an 
incredible young woman. You are a tough, hilarious, intelligent person and I am 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................. IV 
LIST OF TABLES .......................................................................................................... XII 
LIST OF FIGURES ........................................................................................................ XIII 
LIST OF SYMBOLS AND ABBREVIATIONS ............................................................ XV 
SUMMARY ................................................................................................................. XVII 
CHAPTER 1 INTRODUCTION ................................................................................... 1 
1.1 Motivation .......................................................................................................... 1 
1.2 Research Objectives .......................................................................................... 4 
1.3 Ssignificance and Scientific Contribution ....................................................... 9 
CHAPTER 2 BACKGROUND AND LITERATURE REVIEW ............................... 15 
2.1 Glenohumeral Joint and Rotator Cuff .......................................................... 15 
2.2 Rotator Cuff Tear and Treatment ................................................................. 18 
2.3 Proteolytic Degradation .................................................................................. 27 
2.4 Biomaterial Delivery Vehicles ........................................................................ 35 
CHAPTER 3 FULL-THICKNESS ROTATOR CUFF TEAR IN RAT RESULTS IN 
DISTINCT TEMPORAL EXPRESSION OF MULTIPLE PROTEASES IN TENDON, 
MUSCLE, AND CARTILAGE ......................................................................................... 47 
3.1 Introduction ..................................................................................................... 47 
3.2 Materials and Methods ................................................................................... 50 
3.3 Results ............................................................................................................... 56 
3.4 Discussion ......................................................................................................... 69 
3.5 Conclusion ........................................................................................................ 75 
CHAPTER 4 DEVELOPMENT OF NOVEL MICROFLUIDIC DEVICE FOR 
UNIFORM MICROPARTICLE FABRICATION FOR RELEASE OF BROAD, SMALL 
MOLECULE CATHEPSIN INHIBITOR, E-64 ............................................................... 77 
4.1 Introduction ..................................................................................................... 77 
4.2 Materials and Methods ................................................................................... 83 
4.3 Results ............................................................................................................... 92 
4.4 Discussion ....................................................................................................... 101 
 xi 
4.5 Conclusion ...................................................................................................... 110 
CHAPTER 5 THE EFFECT OF SUSTAINED RELEASE OF E-64 ON RELATIVE 
AMOUNTS OF ACTIVE PROTEASES FOUND WITHIN TENDON FOLLOWING 
FULL-THICKNESS ROTATOR CUFF TEAR IN A RAT MODEL ............................ 111 
5.1 Introduction ................................................................................................... 111 
5.2 Materials and Methods ................................................................................. 114 
5.3 Results ............................................................................................................. 120 
5.4 Discussion ....................................................................................................... 130 
5.5 Conclusion ...................................................................................................... 140 
CHAPTER 6 CONCLUSIONS AND RECOMMENDATIONS .............................. 141 
6.1 Summary ........................................................................................................ 141 
6.2 Conclusions .................................................................................................... 146 
6.3 Future Directions ........................................................................................... 153 
APPENDIX A: TROUBLESHOOTING CYSTATIN C RELEASE FROM NOVEL 
MICROFLUIDIC DEVICE ............................................................................................. 162 
A.1. Cystatin C Release From Novel Microfluidic Device ................................. 162 
A.2. Compare Cystatin C Release From Injected Hydrogel And Novel 
Microfluidic Device ................................................................................................... 164 
A.3. Cystatin C Location Test .............................................................................. 166 
APPENDIX B: EXAMPLE CALCULATION OF E-64 RELEASE WITH DQ GELATIN 
FLUOROGENIC SUBSTRATE ASSAY AND E-64 STANDARD CURVE ............... 168 






LIST OF TABLES 
Page 
Table 3.1: Experimental design and outcome measures performed 
in all three joint tissues over time. 51 
 







LIST OF FIGURES 
Page 
Figure 2.1: Chemical structure of poly(ethylene-glycol)-diacrylate 
(PEGDA) and Dithiothreitol (DTT) bound by Michael Type addition. 38 
 
Figure 2.2: Chemical structure of heparin based biomaterials. 41 
 
Figure 3.1: One week after injury tendon undergoes noticeable damage  57 
 
Figure 3.2: One week after injury muscle remains similar to control 58 
 
Figure 3.3: μCT analysis demonstrates that focal defects do not occur 
in the same location on humeral heads between animals 59 
 
Figure 3.4: Contrast enhanced microCT reveals focal defects within 
cartilage 12 weeks post-injury 60 
 
Figure 3.5: μCT analysis demonstrates few differences in humeral 
head bone following injury 61 
 
Figure 3.6: Gelatin zymography of tendon shows significant increase 
of proteases following injury 63 
 
Figure 3.7: Gelatin zymography of muscle shows significant increase 
of proteases following injury 65 
 
Figure 3.8: Gelatin zymography of cartilage shows significant increase 
of proteases following injury 67 
 
Figure 3.9: Immunostaining of tendon shows significantly higher 
prevalence of macrophage (CD68+) and neutrophil (Ly6g+) markers 
in injured tendon 1 week post-injury compared to uninjured control 68 
 
Figure 3.10: Analysis of basal levels of active proteases over time in 
control (uninjured) tissues 69 
 
Figure 4.1: The benchtop set up of our novel microfluidic device 
platform 85 
 
Figure 4.2: Microfluidic device schematic and characterization 94 
 
Figure 4.3: Microparticles fabricated with our novel microfluidic 
device can be made to be fully degradable 95 
 
 xiv 
Figure 4.4: DQ gelatin and Z-FR-AMC fluorogenic substrate assays 
yield different E-64 standard curves 96 
 
Figure 4.5: Components of microfluidic device have an effect on DQ 
gelatin assay fluorescent readings 98 
 
Figure 4.6: E-64 released from PEGDA microparticles fabricated with 
our microfluidic device remains bioactive over 14 days 99 
 
Figure 4.7: Microparticles fabricated with our microfluidic device can 
be tuned to alter release of E-64 by altering polymer weight percent, 
DTT concentration, and initial loading concentration 100 
 
Figure 5.1: Aniline blue loaded PEGDA microparticles were 
successfully injected into the medial third of the supraspinatus tendon 122 
 
Figure 5.2: Tagged E-64 loaded in microparticles remains in the 
rotator cuff significantly longer than soluble tagged E-64 124 
 
Figure 5.3: Cathepsin multiplex gelatin zymography shows significant 
increase in active cathepsin L proteases after injury regardless of 
treatment 127 
 
Figure 5.4: Cathepsin multiplex gelatin zymography shows no active 
cathepsin K after injury regardless of treatment 128 
 
Figure 5.5: MMP multiplex gelatin zymography shows significant 
increase in active MMP-2 proteases after injury regardless of treatment 130 
 
Figure 5.6: Quantification of active protease divided by date of surgery 
suggests it may be a contributing factor to variability 138 
 
Figure A.1: Cystatin C was released from microparticles fabricated 
with our novel microfluidic device 164 
 
Figure A.2: Very low levels of cystatin C was released from hydrogels 
injected into molds with the syringe used in our novel microfluidic 
device platform 165 
 
Figure A.3: Tagged cystatin C predominately remained inside the 
syringe used to inject the discontinuous phase of the microfluidic 
device platform 167 
 
Figure B.1: Example Calculation of E-64 Release with DQ Gelatin 
Fluorogenic Substrate Assay and E-64 Standard Curve 169 
 xv 
LIST OF SYMBOLS AND ABBREVIATIONS 
AcCl Acryloyl Chloride 
AF633 Alexafluor633 
ApMAm N-(3-Aminopropyl) Methacrylamide Hydrochloride  
BCA Bicinchoninic Acid Assay 
CT Computed Tomography 
DTT Dithiothreitol 
E-64 Trans-Epoxysuccinyl-L-Leucylamido(4-Guanidino)Butane 
ECM Extracellular Matrix 
EDC 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide  
EDTA Thylenediamine Tetraacetic Acid 
EVA Ethylene-Vinyl Acetate 
GAG Glycosaminoglycan 
H&E Hematoxylin And Eosin 
Hep-MAm Heparin-Methacrylamide 
LHBT Long Head Biceps Tendon 
Mam Methacrylamide 
MMP Matrix Metalloproteinases 
MRI Magnetic Resonance Imaging 
Na2HPO4 Disodium Phosphate 
NaH2PO4 Monosodium Phosphate 
NIH National Institute Of Health 
NIR Near Infrared  
NMR Nuclear Magnetic Resonance 
NSAID Nonsteroidal Anti-Inflammatory Drug  
OCT Optical Cutting Temperature 
 xvi 
PBS Phosphate Buffered Saline 
PCL Poly(E-Caprolactone) 
PDMS Poly(Dimethyl Siloxane) 
PEG Poly(Ethylene Glycol) 
PEG-4MAL 4-Arm Poly(Ethylene Glycol)-Maleimide 
PEGDA Poly(Ethylene Glycol) Diacrylate 
PEGMMA Poly(Ethylene Glycol) Monomethacrylate 
PLA Poly(Lactic Acid) 
PLGA Poly(DL-Lactic-Co-Glycolic Acid) 
PRL Physiological Research Laboratory 
PVA Poly(Vinyl Alcohol) 
PVC Poly(Vinyl Chloride) 
ROI Region of Interest 
SHG Second Harmonic Generation 
Sulfo-NHS N-Hydroxysulfosuccinimide   
TIMP Tissue Inhibitor Of Metalloproteinases 
UV Ultraviolet 
wt% Weight Percent 




Surgical reattachment of torn rotator cuff tendons has a high rate of re-tear 
(failure) and the procedure does not reverse joint tissue degeneration present at the time 
of surgery. Following rotator cuff tear, three different joint tissues (tendon, muscle, and 
articular cartilage) develop degenerative changes. A possible cause for the extensive joint 
tissue degeneration observed following rotator cuff tear is the prolonged activation of 
proteases, which are specialized enzymes whose primary function is to degrade proteins. 
Systemic delivery of several protease inhibitors have been tested in human clinical trials 
to for a variety of diseases including osteoarthritis and osteoporosis, but all have been 
abandoned due to off-target effects. However, local delivery of protease inhibitors could 
reduce disease progression without deleterious side effects.  
The long-term goal of this dissertation was to understand how proteases 
contribute to joint tissue degeneration (tendon, muscle, and cartilage) after rotator cuff 
tear. Understanding the spatial and temporal distribution of upregulated proteases after 
rotator cuff tear can best inform therapeutic treatments to prevent degeneration, which 
would result in improved surgical outcomes after rotator cuff tear re-attachment surgery. 
First, using a rat model of rotator cuff tear that has been shown to replicate degenerative 
damage seen in humans, we investigated active proteases in each joint tissue over time. 
Second, we designed a novel microfluidic device to fabricate uniformly sized 
microparticles that can be loaded with protease inhibitors for subsequent use in vivo. 
Also, we reinvented a currently available fluorogenic substrate assay for the detection of 
E-64 (a broad, small molecule cathepsin inhibitor), which was our desired therapeutic. 
Lastly, we tested our E-64 loaded microparticles system on supraspinatus tendon tissue in 
 xviii 
our rat model of rotator cuff tear as a test bed to elucidate the effect of sustained release 







CHAPTER 1  INTRODUCTION  
1.1 Motivation 
Rotator cuff tears, including partial and full-thickness tears of the supra- and 
infraspinatus tendons, are among the most common shoulder injuries. It is estimated that 
approximately 34% of the population has a partial or full-thickness tear [1].  Following 
rotator cuff tear, all of the joint tissues are affected including the tendon, its respective 
muscle, and articular cartilage. After rotator cuff injury, tendon becomes disorganized 
with decreased collagen content [2], while muscle atrophies and is infiltrated with fibrous 
tissue and fatty deposits [3]. Additionally, the force balance between tendons of the 
rotator cuff is disrupted, which may lead to the development of osteoarthritic changes in 
the articular cartilage including loss of glycosaminoglycan (GAG) content, increased 
surface roughness, and loss of cartilage tissue [4,5].  
Rotator cuff tear treatment includes use of nonsteroidal anti-inflammatory drugs 
(NSAIDs), physical therapy, and possibly surgical reattachment of the torn tendon. 
Surgical re-attachment includes stitching the torn tendon onto the humeral head bone via 
a bone tunnel. It is considered to be a very painful procedure and has variable 
documented re-tear rates from 30-94% [6,7]. Surgical re-attachment of the tendon aims to 
restore the force balance between tendons of the shoulder but does not reverse or halt 
degeneration that has already occurred in the tendon, its respective muscle, or articular 
cartilage. Additionally, there is a positive correlation between the level of degeneration in 
the muscle at the time of re-attachment and re-tear rates [8].  
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A possible cause for the extensive joint tissue degeneration observed following 
rotator cuff tear is the prolonged activation of proteases. Proteases are specialized 
enzymes whose primary function is to degrade proteins. Of particular interest are cysteine 
cathepsins and matrix metalloproteinases (MMPs), which play a role in many facets of 
homeostasis within the human body including extracellular matrix remodeling, bone 
resorption, and intracellular protein turnover [9–11]. However, these two families of 
proteases have also been observed to be upregulated in a variety of degenerative diseases 
in orthopaedics, including atrophy of the tibialis anterior muscle [12], osteoarthritis of the 
knee [13], and tendinopathy [14,15]. This work specifically investigated both cathepsin 
and MMP families of proteases in joint tissues after rotator cuff tear to better understand 
how they may contribute to characteristic degeneration seen after injury.  
The implication that proteases are a potential cause for tissue degeneration in 
musculoskeletal diseases makes protease inhibitors an appealing potential treatment. 
Several protease inhibitors have been tested in human clinical trials to treat dysregulated 
cathepsins and MMPs, but all have been abandoned due to off-target effects [16,17]. 
These clinical trials have tested the safety and efficacy of protease inhibitors using 
systemic delivery, meaning both healthy and diseased tissues are equally exposed to the 
therapeutic treatment. As mentioned previously, proteases play a variety of roles in the 
human body and thus are not localized to any one area of the body. Consequently, 
regulated proteases in healthy tissue may be inhibited and prevented from performing 
their normal functions, causing negative side effects including headache, gastrointestinal 
disturbance, lung fibrosis, and skin lesions [16]. Moreover, systemic delivery requires a 
much larger amount of therapeutic molecules in order to achieve a detectable effect in the 
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diseased tissue, which will only receive a small fraction of the initial dose [18]. Thus, 
local, sustained delivery of protease inhibitors could reduce disease progression without 
deleterious side effects and with reduced amounts of therapeutic molecules to reduce 
cost-barriers to treatment. 
To achieve local, sustained delivery of protease inhibitors, many laboratories have 
enlisted the use of polymer-based microparticles, such as those formed from 
poly(ethylene glycol) diacrylate, PEGDA [19–22]. Microparticles can be synthesized a 
variety of ways, but fabrication by way of microfluidic device has distinct advantages. 
Benefits of using a microfluidic device include fabrication of uniformly sized 
microparticles, which eliminates the need for filtering microparticles that are too small or 
too large, which is common in other types of synthesis. The ability to keep all fabricated 
microparticles thusly reduces waste of polymer materials and allows for the incorporation 
of expensive ligands or crosslinkers. Additionally, with complete control over the 
microfluidic device size and phase speeds, we were able to adjust the size of our 
microparticles for future studies. 
Development and characterization of our novel microfluidic device allowed us to 
select a desirable set of parameters to investigate other applications. First, we were able 
to confirm that therapeutic molecules could be loaded into our uniformly sized 
microparticles, which expanded the number of uses of our novel microfluidic device 
platform. Specifically, we loaded broad, small molecule inhibitor, E-64 into our 
microparticles and confirmed consistent sustained release over 14 days. With this 
evolution, we evaluated how varying several microparticle components would alter 
release of our small molecule in vitro over time. In addition to showing that E-64 release 
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could be tuned by altering the microparticle make up, this study established that 
biologically relevant amounts of E-64 could be released from our microparticles. Thus, 
we assessed in vivo release of E-64 indirectly via chemical modification with near 
infrared dye and near infrared imaging.  
Finally, this thesis work resulted in the fabrication of a microparticle vehicle 
loaded with a broad, small molecule protease inhibitor injected into a rat model of rotator 
cuff tear. The purpose of this final study was to understand how this treatment altered 
active protease levels after injury and if degeneration of tendon tissue could be reduced or 
prevented. The research in this thesis contributes foundational knowledge to develop 
therapeutic strategies to halt joint tissue degeneration after rotator cuff tear and improve 
surgical outcomes following tendon re-attachment surgery. 
1.2 Research Objectives 
The long-term goal of this dissertation was to understand how proteases 
contribute to joint tissue degeneration (tendon, muscle, and cartilage) after rotator cuff 
tear. Understanding the spatial and temporal distribution of upregulated proteases after 
rotator cuff tear can best inform therapeutic treatments to prevent degeneration, which 
would result in improved surgical outcomes after rotator cuff tear re-attachment surgery. 
First, using a rat model of rotator cuff tear that has been shown to replicate degenerative 
damage seen in humans [23], we investigated active proteases in each joint tissue 
(tendon, muscle, and cartilage) over time. Second, we designed a novel microfluidic 
device to fabricate uniformly sized microparticles that can be loaded with protease 
inhibitors for subsequent use in vivo. Also, we reinvented a currently available 
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fluorogenic substrate assay for the detection of E-64 (a broad, small molecule cathepsin 
inhibitor), which was our desired therapeutic. This was important because previous 
therapeutic use of E-64 had been limited to systemic, soluble injections of known 
amounts because E-64 is unable to be quantified by other standard methods [24,25]. 
Lastly, we tested our E-64 loaded microparticles system on tendon tissue in our rat model 
of rotator cuff tear to elucidate the effect of sustained release of a broad cathepsin 
inhibitor on active proteases.  
The rationale for this thesis project is that a comprehensive understanding of the 
spatial and temporal distribution of destructive proteases after rotator cuff tear injury and 
uniformly-sized inhibitor loaded microparticles for localized therapeutic treatment of 
proteases can together reduce joint tissue degeneration after rotator cuff tear and improve 
surgical outcomes of tendon re-attachment surgery. The overall hypotheses for this thesis 
project are that (1) there are spatial and temporal differences in active protease levels in 
joint tissues following rotator cuff tear and (2) localized treatment with protease inhibitor 
(E-64)-loaded microparticles into tendon tissue at the time of injury will result in a 
significant decrease in active protease levels (cathepsins and MMPs) relative to injury 
alone.  These hypotheses were tested using the following three aims: 
Specific Aim 1: Characterization Of Active Proteases (Cathepsins And MMPs) And 
Structural Damage Within Joint Tissues (Tendon, Muscle, And Cartilage) 
Following Rotator Cuff Tear.  
In rotator cuff tear injuries, the supraspinatus tendon is the most commonly torn 
tendon. Subsequent to supraspinatus tendon tear, the supraspinatus muscle undergoes 
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muscle atrophy, fibrous infiltration, and develops fatty deposits throughout the muscle 
[3]. The torn tendon also causes a force imbalance in the shoulder and articular cartilage 
of the glenohumeral joint can undergo osteoarthritic changes including loss of 
glycosaminoglycan (GAG) content, increased surface roughness, and loss of cartilage 
tissue [4,5].  To replicate this damage in a rat model, previous work has shown that the 
injury requires transection of supraspinatus and infraspinatus tendons as well as 
denervation of the subscapular nerve, which directly enervates the supraspinatus muscle 
[23]. 
The objectives of this aim were to assess degenerative damage in joint tissues 
following rotator cuff tear in a rat animal model and characterize active proteases (both 
cathepsin and MMP families) spatially and temporally between the onset of injury and 
the manifestation of tissue degeneration. The hypothesis of this aim was that acute, full-
thickness rotator cuff tear would result in significantly more active proteases (cathepsins 
and MMPs) early after tendon injury (1 week after transection), with delayed responses 
from cartilage and muscle (3-12 weeks after injury). Additionally, we hypothesized that 
protease upregulation timing would coincide with manifestation of visible tissue damage 
(as assessed by histology and/or μCT imaging) in each tissue. Following transection of 
the supraspinatus and infraspinatus tendons as well as denervation of the suprascapular 
nerve in the animal model, we assessed protease activity (cathepsins and MMPs) within 
the supraspinatus tendon, supraspinatus muscle, and humeral head cartilage via gelatin 
zymography at 1, 3, and 12 weeks post-injury. We assessed structural damage to tendon 
(cellular infiltration and changes in collagen alignment and orientation) via hematoxylin 
and eosin and second harmonic generation imaging 1 week after injury. Degeneration of 
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muscle was evaluated by quantifying fibrous infiltration via Masson’s Trichrome staining 
1 week after injury. Lastly, cartilage degeneration was assessed via micro-computed 
tomography at 1 and 12 weeks after injury. 
Specific Aim 2: Development Of Novel Microfluidic Device For Uniform 
Microparticle Fabrication For Release Of Broad, Small Molecule Cathepsin 
Inhibitor, E-64. 
Thus, the first objective of this aim was to develop a novel microfluidic device to 
fabricate uniformly sized poly(ethylene glycol) diacrylate (PEGDA) microparticles. To 
characterize the system, we varied several parameters of the system including continuous 
phase speed, discontinuous phase speed, and surfactant concentration in the continuous 
speed. This variation allowed us to better understand the range of microparticle sizes that 
could be achieved with our system. Previous microfluidic device work has asserted that 
particle size can be tuned by varying the speed of each phase independently. For 
example, a faster continuous or discontinuous phase would result more frequent particle 
pinch off, resulting in smaller microparticles [26]. Additionally, microfluidic devices that 
employ immiscible phases for particle formation use surfactants (such as span-80) to 
stabilize the shape of particles and prevent coalescence of particles [27]. It has been 
shown that particle size will vary with surfactant concentration below a certain threshold 
limit, which is dependent on the system and surfactant used [28]. The first hypothesis of 
this aim was that microparticle size would be inversely proportional to the speed of both 
the continuous and discontinuous phases. Additionally, we hypothesized that 40% span-
80 would yield significantly smaller microparticles compared to 20% span-80 with any 
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given set parameters. We assessed microparticle size distribution using light microscopy 
and size analysis in ImageJ (NIH). 
The second objective of this aim was to characterize release of E-64 in vitro over 
time using different fabrication parameters in our microfluidic device system. To 
determine the limits of E-64 release from our microparticles fabricated with our 
microfluidic device we varied: polymer weight percentage (10 wt% and 20 wt%), 
dithiothreitol (DTT) concentration (5 mM and 10 mM), and initial loading concentration 
(167 µg and 333 µg). Incorporation of DTT into the polymer network allows for 
hydrolytic degradation of PEGDA. The second hypothesis of this aim was that E-64 
release over 14 days could be tuned based on the aforementioned parameters. 
Specifically, we hypothesized that larger polymer wt% would result in less E-64 release 
over time. Use of larger polymer wt% creates a smaller mesh size and can delay the 
diffusion of molecules out of the polymer network [29]. Second, we hypothesized that 
larger amounts of DTT would result in greater release of E-64 over a longer period of 
time due to faster degradation and increased spacing between polymer chains. Third, we 
hypothesized that greater initial loading of E-64 would result in a larger amounts of E-64 
released over 14 days. Finally, we hypothesized that E-64 would achieve sustained 
released from our microparticles and remain bioactive over 14 days. E-64 bioactivity and 
release was assessed using a DQ Gelatin Fluorogenic Substrate Assay (Thermofisher). 
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Specific Aim 3: The Effect Of Sustained Release Of E-64 On Relative Amounts Of 
Active Proteases Found Within Tendon Following Full-Thickness Rotator Cuff Tear 
In A Rat Model. 
In Aim 1 of this study, we found our rat model of rotator cuff tear showed 
significantly more active cathepsin L and MMP-2 in tendon 1 week following injury [30]. 
The objective of this aim is to understand how the proteolytic network responds to local 
cathepsin inhibition within the tendon 1 week after injury.  The hypothesis of this aim is 
that E-64 loaded microparticle delivery to supraspinatus tendon will result in significantly 
less active cathepsin proteases after rotator cuff tear compared to injury only, soluble E-
64 treatment, and unloaded microparticle treatment. Previous work has demonstrated that 
active cathepsin proteases can cleave and activate MMPs [31]. Thus, we hypothesize that 
detection of decreased levels of active cathepsin will correspond to significantly less 
active MMP proteases.  
Our rat model of rotator cuff tear includes transection of the supraspinatus and 
infraspinatus tendons as well as denervation of the suprascapular nerve. At the time of 
surgical injury, treatments were directly injected into the supraspinatus tendon. We 
injected each treatment into the proximal third of the tendon and assessed active protease 
levels (cathepsins and MMPs) within that same region of the supraspinatus tendon using 
multiplex gelatin zymography 1 week after injury.  
1.3 Significance and Scientific Contribution 
Many treatment strategies have focused primarily on restoring the affected muscle 
due to its distinctive increasingly severe degeneration, which is considered the primary 
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reason for failed re-attachment surgeries [23]. However, this work showed that 
degeneration progressed throughout all three joint tissues (tendon, muscle, and cartilage) 
when rotator cuff tear was left untreated. Tendon exhibited significant protease 
upregulation at 1 and 3 weeks after injury, with the manifestation of degeneration after 1 
week. Conversely, muscle exhibited significant protease upregulation at 1 and 3 weeks 
with the manifestation of degeneration at 3 weeks only [19]. Similarly, cartilage exhibited 
significant protease upregulation at 1 week, but degeneration was only detectable at the 
12 week assessment. Overall, this work found that degeneration occurs in all three joint 
tissues following rotator cuff tear, therefore rotator cuff tear treatment strategies should 
include tendon and cartilage consideration in addition to muscle. Additionally, this work 
investigated active protease upregulation relative to the manifestation of degeneration in 
joint tissues after rotator cuff tear, which suggests that active protease upregulation, while 
brief, could have lasting effects on the health of joint tissue. 
We found each tissue experienced a unique combination of active cathepsins and 
MMP proteases, which changed over time. Specifically, tendon showed upregulated 
cathepsin L at 1 week and upregulated MMP-2 at 1 and 3 weeks after injury, muscle 
demonstrated significantly more active cathepsin L at 1 and 3 weeks and significantly 
more MMP-2 at 3 weeks after injury, and cartilage presented with significantly more 
active cathepsin L and K 1 week after injury. Interestingly, we detected a pattern whereby 
cathepsin proteases tended to occur concurrently or preceded active MMP proteases after 
rotator cuff tear. A large portion of previous work has investigated MMP inhibition to 
halt or reduce tissue degeneration [32–34], but this work suggests that significant 
degenerative damage may have already occurred prior to the activation of MMPs by 
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activated cathepsin proteases. Thus, this work demonstrates a strong need to investigate 
cathepsin proteases are a potential upstream therapeutic target to prevent tissue 
degeneration. 
The research outlined in this dissertation is significant because we investigated 
active proteases in joint tissues (tendon, muscle, and cartilage) after rotator cuff tear in a 
rat model with similar degenerative damage seen in humans over time [23]. 
Understanding the temporal and spatial distribution of active proteases within joint 
tissues would better inform ideal intervention times and therapeutic strategies for each 
afflicted tissue. Taken together, this could reduce joint tissue degeneration and yield 
better surgical outcomes following tendon re-attachment procedures.  
In terms of technology, the work in this thesis provides laboratories and 
researchers with a new, simple microfluidic device platform that can synthesize 
uniformly sized microparticles in a variety of sizes. A device such as this has practical 
applications in a variety of fields including drug delivery and tissue engineering 
[19,20,35–37]. The ability to form microparticles that will incorporate materials loaded 
into the discontinuous phase allow the user to reduce material waste which may include 
polymers, crosslinkers, or proteins of interest with the confidence that it will be 
incorporated into a biomaterial carrier of a desired size. In addition, we found that our 
novel microfluidic device can incorporate therapeutic molecules into microparticles for 
sustained release, which expands potential uses of this new technology.  
In addition to designing a novel microfluidic device, we also redesigned a 
currently available fluorogenic substrate assay for E-64 quantification in solution. E-64 is 
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the small molecule analog of the endogenous cysteine cathepsin inhibitor [38] and has 
been shown to irreversibly bind cathepsins L, S, and K [39,40]. Previously, therapeutic 
use of E-64 had been limited to systemic, soluble injections of known amounts because 
E-64 is unable to be quantified by other standard methods, which would be required to 
investigate E-64 release from a biomaterial carrier in vitro [24,25]. For example, 
antibodies to E-64 do not exist and therefore an ELISA cannot be used. E-64 does not 
contain a ring structure and therefore cannot be detected using an absorbance reading on 
a plate reader [41]. Furthermore, E-64 cannot be detected on Bicinchoninic Acid assay 
(BCA) or Pierce Coomassie assay, which are to commonly used protein quantification 
assays. While vendor websites (including Millipore-Sigma and Selleck Chem) have listed 
high-performance liquid chromatography (HPLC) as the chosen method used to purify E-
64, there is limited information on how to replicate the protocol, the limit of detection of 
E-64, and if microparticle materials would interfere with E-64 detection and 
quantification. Thus, the reinvention of the currently available DQ gelatin fluorogenic 
substrate assay allows our laboratory and others to more easily quantify E-64 release 
from biomaterial carriers, which may increase its use for therapeutic applications. 
For the purposes of this dissertation, we also developed a tendon injection 
protocol and demonstrated that therapeutic molecules loaded into microparticles remain 
at the site of injection significantly longer than soluble injection. Previous work that 
aimed to treat tendons with injection-based therapies, described various injection 
protocols including injection into the subacromial space, the supraspinatus muscle, or 
simply into the rotator cuff repair site [42–45]. However, in this work we demonstrated 
we can consistently inject our microparticles directly into the proximal third of the 
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supraspinatus tendon. Additionally, through the use of tagging E-64 with a near infrared 
dye, we demonstrated that E-64 loaded into microparticles persists in the rotator cuff area 
over 21 days. This suggests that our platform has the capacity to provide sustained 
treatment to a localized area. 
This dissertation work is the first step in investigating protease contribution to 
joint tissue degeneration after rotator cuff tear. While our treatment with E-64 loaded 
microparticles did not yield reduced levels of active proteases, additional work is 
warranted to better determine the cellular source of active proteases and the localization 
of proteases (intra vs. extracellular) to improve the efficacy of our microparticle delivery 
treatment. This work demonstrates the complexity of the proteolytic network and 
demonstrates that the challenges in developing therapeutic strategies for diseases 
characterized by dysregulated proteases may not be straightforward. After further 
refinement of this animal model, such a system could be used to probe the role of 
protease inhibition in both tendon degeneration, as well as, more broadly, acute 
inflammation in musculoskeletal tissues. 
The work outlined in this dissertation first identified specific protease targets 
within joint tissues over time. This information provided a baseline to develop a plan for 
more tailored treatment in our rat model of rotator cuff tear. Second, this thesis work 
provided two new technological advancements to subsequently be used to treat 
dysregulated proteases in vivo. Our novel microfluidic device allows us to fabricate 
suitably sized microparticles loaded with therapeutic molecules in a high throughput way. 
Additionally, we reinvented a currently available fluorogenic substrate assay that allows 
E-64 (whose uses had been previously limited by detection methods) to be investigated as 
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a potential therapeutic treatment.  The culmination of this thesis work allowed us to test a 
localized protease-inhibitor based treatment to treat upregulated proteases in 
supraspinatus tendon in an established rat model of rotator cuff tear. The contribution of 
this body of work provides key first steps therapeutic strategy to improve the current gold 
standard of treatment following rotator cuff tear. The ability to locally inhibit proteases 
may provide clinical therapeutic treatment for diseases characterized by significant 
protease-mediated degeneration and also provide a platform to investigate the intricacies 




CHAPTER 2  BACKGROUND AND LITERATURE REVIEW 
2.1 Glenohumeral Joint and Rotator Cuff 
Three bones form the shoulder: the scapula, the clavicle, and the humerus [46]. 
The glenohumeral joint of the shoulder is a ball and socket joint, whereby the head of the 
humerus (humeral head) is the ball and the glenoid cavity of the scapula is the socket. 
The humeral head is considerably larger than the glenoid cavity and they share a limited 
interface, which provides the shoulder a very high level of mobility. Consequently, the 
glenohumeral joint is stabilized by a network of connective tissues including the rotator 
cuff. The rotator cuff is composed of four muscles [46]. All four muscles of the rotator 
cuff (supraspinatus, infraspinatus, teres minor, and subscapularis) are attached to the 
humeral head through their respective tendons, which fuse to form a continuous structure 
near the site of insertion [47].  
2.1.1 Tendon Structure and Function 
 Tendons are a class of fibrous connective tissue that connects muscle to bone. 
Tendon tissue is predominately composed of collagen and tenocytes (fibroblast-like 
tendon cells) within a well-ordered extracellular matrix [48]. Tendon tissue is linear with 
hierarchical structure. Type I collagen is the smallest unit of tendon. Collagen is 
composed of three polypeptides that assemble into a triple helix. Triple helical collagen is 
assembled into fibrils. The fibril level of organization contains a high level of 
intermolecular cross-linking, which increases the overall tensile strength of the tendon 
tissue [49]. Collagen fibrils are assembled into collagen fibers in a crimped pattern, 
which allows for 1-3% elongation of tendon [50,51]. This protects the tendon from injury 
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following a sudden increase in mechanical loading. Tenocytes, the cells of the tendon, are 
located between collagen fibers and are responsible for maintaining the extracellular 
matrix. The extracellular matrix between collagen fibers contains proteoglycans such as 
aggrecan and decorin, which attract water in order to reduce friction and allow fibers to 
glide past one another under mechanical loading [52,53]. Collagen fibers are further 
assembled into fascicles surrounded by endotendon, a connective tissue that surrounds 
individual strands of tendon [52]. Tendon fascicles are subsequently bundled and 
surrounded by epitenon to form the tendon. The epitenon houses a network of blood 
vessels, lymphatic vessels, and neurons that maintains tenocytes [52].  The hierarchical 
arrangement of collagen within tendons allows extensive deformation under axial 
loading: wavy fibrils can be uncrimped, twisted triple helical collagen molecules can be 
straightened, and finally collagen can be uncoiled at the molecular level [47].  
2.1.2 Muscle Structure and Function 
The four muscles of the rotator cuff are skeletal muscles. Skeletal muscles are 
voluntary muscles that function to move the human skeletal system. The smallest 
structural unit of skeletal muscle is the muscle fiber, which is a single cylindrical muscle 
cell. Individual muscle fibers are bundled together to form a fascicle, which is surrounded 
by endomysium connective tissue [54]. Muscle fascicles are bundled together and 
surrounded by perimysium connective tissue to form the muscle surrounded by the 
epimysium [54]. Blood vessels and nervous tissue run the length of the muscle between 
fascicles, which ensure muscle tissue is vascularized and enervated [54].  
 17 
The muscles of the rotator cuff include the supraspinatus, infraspinatus, teres 
minor, and subscapularis and are responsible for movement of the arms. The 
supraspinatus muscle originates from the supraspinous fossa in the scapula [47] and is 
responsible for overhead abduction of the arm. The infraspinatus and teres minor muscles 
originate from the infraspinatus fossa and fibrous septum [47]. The infraspinatus and 
teres minor muscles allow for external rotation of the arm [55,56] and together exert 
posterior force to keep the humeral head within the glenoid cavity [57]. The subscapularis 
muscle originates from the subscapular fossa [47] and provides an anterior force to 
balance the force of the infraspinatus and teres minor muscles and keep the humeral head 
in the glenoid cavity [57]. 
2.1.3 Cartilage Structure and Function 
Cartilage is a specialized connective tissue found on the ends of bones to provide a 
smooth surface for movement of joints. In the shoulder, cartilage is located at the end of 
the humeral head and in the glenoid cavity. Cartilage is composed primarily of type II 
collagen and aggrecan proteoglycans to create a solid extra-cellular matrix [47]. The cells 
found in cartilage and responsible for its maintenance are called chondrocytes. Cartilage 
tissue contains four zones of varying composition, namely the superficial, middle, deep, 
and calcified zones. The superficial zone consists primarily of densely packed type II and 
type IX collagen oriented parallel to the articular surface [47,58]. A large population of 
chondrocytes care found in the superficial zone and normally present with a flat and 
elongated morphology [58]. The middle zone contains the highest percentage of 
proteoglycans and collagen fibers are randomly oriented [47,58]. Chondrocytes found in 
the middle zone have a spherical morphology and are found at a lower concentration 
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[58]. The cartilage deep zone contains large collagen fibers oriented perpendicular to the 
articular surface [47]. Chondrocytes in the deep zone are slightly elongated and oriented 
parallel to the collagen fibers (perpendicular to the articular surface) [58]. A thin line at 
the bottom of the deep zone is called the tidemark and marks the division of the calcified 
and non-calcified zones [58]. The calcified zone is transitional to the subchondral bone 
directly beneath the cartilage, which minimizes the stiffness gradient between cartilage 
and bone [59]. The collagen found in the deep zone originates in the calcified zone, 
which anchors cartilage to bone [58]. Chondrocytes in the calcified zone are scarce and 
are hypertrophic [58]. 
2.2 Rotator Cuff Tear and Treatment 
2.2.1 Rotator Cuff Tear and Prevalence 
Injury of the shoulder usually involves a partial or full-thickness tear of one or more 
rotator cuff tendons [60]. It is estimated that 34% of the population has a partial or full-
thickness tendon tear in at least one shoulder [1]. Additionally, it has been documented 
that risk of rotator cuff tear increases with age, whereby 50% of patients over 60 years of 
age present with a partial or full-thickness tendon tear in at least one shoulder [1]. Rotator 
cuff tendon tear can occur by acute trauma to the shoulder such as a fall or chronic 
overuse of the shoulder [61]. In the case of chronic overuse, small molecular changes can 
occur in tendon over time and result in a partial thickness tear. If left untreated, the partial 
tear can propagate in size and cause a full-thickness tear of the tendon and result in 
degeneration of neighboring muscle, cartilage, and bone [47,61].  
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2.2.2 Tendon Degeneration In the Context of Rotator Cuff Tear 
Tendon is a metabolically active tissue that has the capacity to adapt to changes in 
mechanical loading. Specifically, tenocytes have been shown to upregulate collagen 
expression and synthesis in response to strain [62]. Conversely, an increase in catabolic 
protease expression and collagen turnover has been seen following exercise [63]. Thus, a 
balance exists between anabolic and catabolic factors to maintain tendon health. In the 
case of chronic tendon overuse, there is a net negative balance whereby more collagen is 
being lost than replaced. Thus, chronic overuse of tendon results in the development and 
accumulation of microinjuries creating a mechanically inferior connective tissue. Human 
patients presenting with shoulder pain in the absence of a tendon tear are subsequently 
diagnosed with tendinosis or tendinopathy. Characteristic changes of tendon experiencing 
chronic overuse include cell rounding of tenocytes, reduced tenocyte numbers, increased 
apoptosis, increased proteoglycan content, and disorganization of collagen [64]. 
Additionally, tear of any rotator cuff tendon causes additional strain to neighboring intact 
tendons due to the disrupted force balance, which results in increased tendon stiffness 
[65]. 
An acute tear in one or more of the rotator cuff tendons causes an inflammatory 
response. During the inflammatory response, vasodilation increases blood flow and 
vascular permeability allows a greater influx of inflammatory cells to enter the site of 
injury [66]. The recruited inflammatory cells, including neutrophils, produce cytokines 
and growth factors that elicit cellular recruitment of macrophages [66]. Neutrophils and 
macrophages at the site of injury secrete proteases  for the purpose of clearing debris, 
wound healing, and tissue remodeling [67–69].  Unfortunately, the human rotator cuff 
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tendons do not have a high capacity for self-renewal and healing [66]. However, 
following repair the recruited inflammatory cells can influence resident tenocytes to 
proliferate and produce a disorganized collagen scar at the repair site [66]. Nevertheless, 
without surgical intervention, rotator cuff tendons undergo extensive degeneration 
including fiber disorganization and decreased collagen content [2]. 
2.2.3 Muscle Degeneration after Rotator Cuff Tear 
Following rotator cuff tendon tear, the accompanying muscle will similarly 
experience degeneration after injury. Specifically, the muscle will atrophy [70] and 
develop fatty deposits within the muscle belly, [3] which prevent normal muscle 
contraction [47]. Human patients presenting with shoulder pain can be imaged with 
computed tomography (CT) or magnetic resonance imaging (MRI) to test for muscle 
atrophy and fatty infiltration, two hallmarks of rotator cuff tear. Additionally, several 
groups have found fibrous scar tissue development within muscles after rotator cuff tear 
in several animal models including sheep, rat, and rabbit [23,71,72]. The addition of 
fibrous infiltration as a hallmark of muscle degeneration after rotator cuff tear preceded 
atrophy and fatty infiltration because it cannot be differentiated from muscle tissue on CT 
or MRI scans in humans.   
2.2.4 Cartilage/Bone Degeneration after Rotator Cuff Tear 
Articular cartilage in the glenohumeral joint is located on the humeral head and 
the glenoid cavity. As mentioned previously, the humeral head and glenoid cavity are not 
perfectly matched in size. This size difference is overcome by creating a force balance 
around the humeral head with the tendons and muscles of the rotator cuff. Together, this 
 21 
force balance keeps the humeral head appropriately aligned with the glenoid cavity. Thus, 
even a single tendon tear causes a disruption in the force balance and an increased risk of 
articular cartilage degeneration, eventually resulting in the development of osteoarthritis 
of the shoulder [5]. Specifically, after a rotator cuff tendon tear the articular cartilage will 
demonstrate cartilage tissue loss, increased surface roughness, softening of subchondral 
bone, and a decrease in proteoglycan content [4,47,73].  
Under normal conditions, the humeral head bone experiences mechanical stress 
from rotator cuff muscles transmitting forces through tendon. However, following a 
rotator cuff tear, the humeral head will no longer experience mechanical loading at the 
tendon insertion site and eventually cause a decrease in bone density, which is 
characteristic of subchondral bone osteoporosis [54]. Furthermore, tear of the 
supraspinatus tendon causes upward displacement of the humeral head, which can cause 
erosion of the acromion [5]. 
2.2.5 Current Treatment of Rotator Cuff Tears 
Current guidelines by American Academy of Orthopaedic Surgeons does not offer 
recommendations on how to decide which patients would benefit from invasive vs. non-
invasive rotator cuff tear treatment. The current gold standard of treatment to treat rotator 
cuff tear include regimented nonsteroidal anti-inflammatory drugs (NSAIDs), physical 
therapy, and potentially surgical reattachment of the torn tendon [74]. Surgical re-
attachment includes anchoring the torn tendon onto the humeral head bone via a bone 
tunnel. One group reviewed national hospital and ambulatory surgery databases and 
found that in a single decade the number of rotator cuff tear surgeries increased by 141% 
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[75]. Interestingly, they also found that there was a significant shift from open rotator 
cuff repair surgery to arthroscopic rotator cuff repair surgery [75]. Nevertheless, surgical 
reattachment surgery has a documented re-tear rate of 30-94% [6,7]. Instance of tendon 
re-tear following surgical reattachment has been found to correlate to muscle 
degeneration (muscle atrophy and fatty infiltration) at the time of surgery, tendon tear 
size (partial vs. full-thickness), and patient age [76–78]. The most common method of 
tendon reattachment failure is the tendon pulling away from the sutures in the humeral 
head [79].  
The purpose of surgically reattaching a torn rotator cuff tendon is to restore the 
force-balance of the glenohumeral joint and manage patient pain. Interestingly, treatment 
does not always involve reattachment of every torn tendon. If a patient presents with tears 
in both the supraspinatus and infraspinatus tendons, repair of the infraspinatus alone 
would restore the force balance [57]. Additionally, injury to the rotator cuff tendons can 
cause damage to adjacent tendons, including the long head of the biceps tendon (LHBT). 
Tenodesis or tenotomy of the LHBT has shown a reduction in pain with minimal effect 
on the force balance of the glenohumeral joint [80]. In a rat model of multiple rotator cuff 
tears, transection of the LHBT improved shoulder function and reduced joint damage 
[81]. 
Ultimately, the primary function of surgical reattachment of a torn rotator cuff 
tendon is to restore the force balance of the shoulder. However, even in the case of a 
successful reattachment (no re-tear), the procedure does not treat degeneration that has 
already occurred in the tendon, its respective muscle, or articular cartilage. Current 
surgical reattachment procedures do not replicate the tendon-to-bone insertion site and 
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the reattached tendon does not regain normal structure after being anchored to the 
humeral head [61]. Similarly, patients presenting with low to moderate muscle atrophy at 
the time of reattachment surgery have shown maintenance of degeneration (no 
improvement) over time after surgical repair [82]. However, patients with severe muscle 
degeneration at the time of reattachment will continue to atrophy and develop advancing 
fatty infiltration [82]. Additionally, cartilage loss and subchondral bone softening that 
occurred prior to surgical reattachment will not be reversed [5]. 
Most recently, there has been a deliberate push to advocate for early surgical 
repair of rotator cuff tendons [83]. Non-invasive methods have been shown to improve 
patient-reported outcomes (including strength and reduced pain) and overall 
improvement in glenohumeral joint kinematics [83], but the improvements can be 
temporary. Instead, small asymptomatic tears have been shown to progress in size and 
consequently advance to full-thickness tears with concomitant pain and decreased 
shoulder function [84,85]. While early intervention could prove beneficial, many patients 
are either asymptomatic or ignore increasing pain and therefore do not seek medical 
attention until after considerable degeneration has occurred, which limits treatment 
options [83].  
2.2.6 Animal Models of Rotator Cuff Injury 
Animal models provide a platform for researchers to study the etiology of 
tendinopathy and joint degeneration after rotator cuff tear. The use of animal models 
allows us to analyze tissue at all stages of injury and allow the use of terminal methods, 
which cannot be performed in humans. Several animal models have been used to 
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investigate rotator cuff tear injuries including rat [23,86,87], mice [88,89], sheep 
[71,90,91], and rabbit [72,92,93]. However, the Soslowsky group evaluated 33 different 
animals on a 34 point checklist to determine their appropriateness to serve as an animal 
model of rotator cuff injuries and found that rats were the only animal that satisfied each 
criteria [94]. Despite rats being quadrupeds, they share similar shoulder anatomy to 
humans. Specifically, the supraspinatus tendon passes under the acromial arch and 
normal forward locomotion causes the rat supraspinatus tendon to repetitively pass under 
the acromion, which can replicate overuse injuries seen in humans [94]. 
Several different animal models exist to replicate different aspects of rotator cuff 
injury. An animal model that undergoes surgical transection of one or more rotator cuff 
tendons can be used to study acute rotator cuff tendon tear caused by trauma which 
stimulates an inflammatory response or be used as a test bed to treat degenerative damage 
seen in humans [30]. An animal model that performs sustained downhill running would 
replicate chronic tendon injuries caused by repetitive overhead motion (overuse injury) 
[14,15]. Several studies have performed a combination of overuse and acute injuries in 
their animal models to mimic patients such as athletes or laborers that are likely to 
resume activities soon after surgical treatment [65,95]. Furthermore, to better replicate 
the human condition, several studies have performed surgical reattachment of torn rotator 
cuff tendons on animal models both at the time of injury and several weeks afterward 
[71,96,97]. 
Most often, laboratories develop animal models of acute rotator cuff tendon tear 
in order to recreate degenerative damage seen in humans. Human patients that have 
suffered a rotator cuff tear often seek treatment after significant degeneration has already 
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occurred including atrophy and fatty infiltration of rotator cuff muscles [83]. Thus, 
several groups have sought to mimic this degenerative damage in rodent animal models 
in order to test therapeutic interventions [4,23,87–89,98,99]. Several groups have 
developed personalized acute rotator cuff tear models for their purposes. The Soslowsky 
laboratory has tested several variations of rotator cuff tear including: transection the 
supraspinatus tendon alone [100], transecting both the supraspinatus and infraspinatus 
tendons [87], and transecting the supraspinatus and subscapularis tendons [101]. The 
Feeley laboratory has developed rotator cuff tear animal models in both rats [23] and 
mice [88]. Additionally, they have tested various injuries including tear of both the 
supraspinatus and infraspinatus tendons [4,88,89,98] and a much more severe injury that 
involved transection of the supraspinatus, infraspinatus, and teres minor tendons [23].  
As can be expected different injuries models (one vs. two vs. three tendon tears) 
will cause different levels of degeneration. The Feeley laboratory demonstrated that 
massive rotator cuff tear (transection of the supraspinatus, infraspinatus, and teres minor 
tendons) in rats resulted in significant muscle atrophy of the supraspinatus and 
infraspinatus muscles 2 weeks after injury [23]. Additionally, they demonstrated that 
massive rotator cuff tear resulted in significant fibrous infiltration of the supraspinatus 
and infraspinatus muscles, while only the infraspinatus muscle developed significant fatty 
infiltration 6 weeks after injury [23]. Similarly, the Feeley laboratory transected both the 
supraspinatus and infraspinatus tendons in mice and found significant atrophy in both 
muscles 12 weeks after injury [88]. However, they found that neither muscle developed 
significant fatty infiltration 12 weeks after injury [88]. Additionally, the Feeley 
laboratory found that transection of the supraspinatus and infraspinatus tendons caused 
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significant degeneration of humeral head cartilage and glenoid cartilage 12 weeks after 
injury [4].  
The supraspinatus tendon is the most commonly ruptured tendon of the rotator 
cuff in humans [102] and often presents with significant atrophy and fatty infiltration 
[103]. Therefore, the aforementioned animal models of rotator cuff tear did not 
sufficiently mimic degeneration seen in humans with tendon transection alone. Thus, the 
Feeley laboratory sought to increase muscle degeneration in their animal models of 
rotator cuff tear by the addition of denervation of the suprascapular nerve, which directly 
enervates the supraspinatus muscle. They found that the combination injury of massive 
rotator cuff tear (transection of the supraspinatus, infraspinatus, and teres minor tendons) 
and denervation did not cause additional atrophy, fibrous infiltration, or fatty infiltration 
to either the supraspinatus or infraspinatus muscles in rats [23]. However, in a mouse 
model that underwent transection of supraspinatus and infraspinatus tendons and 
denervation of the suprascapular nerve, they found the combination injury caused 
significantly more muscle atrophy of the supraspinatus and infraspinatus muscles relative 
to either injury alone [88]. Similarly, they found the combination injury caused 
significantly more fibrous infiltration compared to either injury alone [88]. Interestingly, 
they found that denervation alone caused significantly more fatty infiltration in both the 
supraspinatus and infraspinatus muscles compared to tendon transection alone [88]. The 
combination injury did not cause significantly more fatty infiltration in the supraspinatus 
muscle compared to denervation alone, but the injury was additive in the infraspinatus 
muscle [88]. Furthermore, they found that transection of the supraspinatus and 
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infraspinatus tendons alone caused similar damage compared to denervation alone in 
humeral head and glenoid cartilage [4]. 
2.3 Proteolytic Degradation 
A possible cause for the extensive joint tissue degeneration observed following 
rotator cuff tear is the prolonged activation of proteases. Proteases are specialized 
enzymes whose primary function is to degrade proteins. Of particular interest are cysteine 
cathepsins and matrix metalloproteinases (MMPs), which play a role in many facets of 
homeostasis within the human body including extracellular matrix remodeling, bone 
resorption, and intracellular protein turnover [9–11]. However, these two families of 
proteases have also been observed to be upregulated in a variety of musculoskeletal 
diseases, including atrophy of the tibialis anterior muscle [12], osteoarthritis of the knee 
[13], and tendinopathy [14,15]. 
2.3.1 Cysteine Cathepsins 
 There are 11 members of the cysteine cathepsin family of proteases [11]. 
Cathepsins proteases are responsible for a variety of homeostatic functions including 
extracellular matrix remodeling, bone resorption, and intracellular protein turnover [11]. 
The 3D structure of cysteine cathepsins is generally conserved and consists of two 
domains. The left and right domains form an inverted cone shape with the catalytic active 
site located at the top. The left domain contributes an active cysteine reside to the 
catalytic active site, while the right domain provides an active histidine residue. Together, 
these two catalytic residues form the thiolate-imidazolium ion pair, which is essential for 
the proteolytic activity of cathepsins [11].  
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 The cathepsin family of proteases has been observed in a variety of 
musculoskeletal disease states. Not surprisingly, the cathepsin family of proteases 
includes cathepsin K and cathepsin V, which are considered to be the most potent 
collagenase [104] and elastase [105] respectively. Cathepsin K is highly expressed in 
osteoclasts, but dysregulation has implicated it in the development of osteoporosis and 
osteoarthritis of the knee [10,16]. Additionally, upregulated levels of cathepsin K have 
been found in calcified human tendons and a rabbit model of flexor tendon injury 
[106,107]. Cathepsin L has been shown to have the capacity to cleave multiple 
extracellular matrix proteins including type I collagen, type IV collagen, type XVIII 
collagen, elastin, fibronectin, and laminin [108,109]. Additionally, cathepsin L has been 
shown to be upregulated in instances of muscle atrophy in both rats and mice [104,110]. 
Cathepsin S is a potent elastase and has been shown to be expressed by endothelial cells 
and macrophages [109]. Additionally, active macrophages have been shown to express 
cathepsins L, S, and V [105] and cathepsin B is required for TNF-a secretion, which is a 
mediator of the inflammatory response [111]. 
Due to the highly destructive nature of cathepsin proteases, they are tightly 
regulated by various methods including required cleavage for activation, pH sensitivity, 
and endogenous inhibitors. Cathepsins are synthesized as inactive proenzymes, which 
require cleavage of the N-terminus for activation. Cathepsins can be activated by other 
proteases or autocatalytically under acidic pH conditions [11,112]. Most cathepsins are 
lysosomes proteases and are optimally active at acidic pH. However, cathepsin L has 
been shown to cleave multiple extracellular matrix proteins at neutral pH, while  
cathepsin S, is also active at neutral and even mildly alkaline pH [11,109]. Thus, cellular 
 29 
necrosis and subsequent exposure to active cathepsins is mitigated by cathepsin pH 
sensitivity. Lastly, cathepsins are regulated by a large family of inhibiters, including 
cystatins, thyropins, and serpins [11]. Stefins are considered to be intracellular cathepsin 
inhibitors, while cystatins and thyropins inhibit extracellular cathepsins. Cathepsin 
inhibitors tightly bind the active site of cathepsin proteases in a reversable way, which 
prevents substrate binding [11].  
2.3.2 Cystatin C and  E-64 
The cystatin family of inhibitors are responsible for inhibiting lysosomal cysteine 
proteases, including the cathepsin family of proteases. Cystatin C is the most prominent 
inhibitor of the cystatin family and is produced by most nucleated cells [109]. Cystatin C 
binds cathepsins in a tight, yet reversible fashion [113]. Inflammation can influence 
cystatin C secretion depending on the cell type. Specifically, it has been shown that 
cystatin C production decreases in mouse peritoneal macrophages following treatment 
with pro-inflammatory molecules [114], while human gingival fibroblasts increased the 
secretion of cystatin C following treatment with pro-inflammatory cytokines [115].  
In addition to cystatin C, trans-Epoxysuccinyl-L-leucylamido(4-
guanidino)butane, more commonly known as E-64 is also an inhibitor of the cysteine 
cathepsin family of proteases. E-64 is the isolated active site of cystatin C, and therefore 
considered to be the small molecule analog of cystatin C [38]. Thus, E-64 is a cell 
impermeable, small molecule, broad cathepsin inhibitor [39]. E-64 has been shown to 
have the capacity to irreversibly bind cathepsins L, S, and K [39,40]. In addition to the 
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therapeutic potential of E-64, analogs of E-64 have been developed to uncover the crystal 
structure of many cathepsin proteases [11].  
Since the discovery of E-64 in 1977, there have been high hopes for its use to 
treat diseases characterized by upregulated proteases that result in significant tissue 
degeneration, such as cathepsin K mediated osteoporosis. A study performed in mice 
suffering from sickle cell anemia found that daily E-64 injections improved trabecular 
bone density and mechanical properties of femurs compared to mice with untreated sickle 
cell anemia [25]. However, human clinical trials that have used cathepsin proteases 
inhibitors have all been abandoned due to off-target effects [16]. More recently, several 
groups have aimed to create E-64 analogs with increased specificity to inhibit a specific 
cathepsin subtype as opposed to all cysteine cathepsin proteases [16]. However, off-target 
effects could be mitigated and development of a more specific cathepsin inhibitor would 
not be required if E-64 treatment could be localized to the site of disease or injury with a 
biomaterial carrier. However, the use of E-64 with a biomaterial carrier has been 
challenging due to the inability to detect it in solution to quantify release in vitro. E-64 is 
a small molecule and thusly does not have a readily available ELISA kit and does not 
have a ring structure that can be detectable with color changes or fluorescent light 
excitation/emission. Thus, the development of an assay to detect and quantify E-64 would 
increase the usefulness of E-64 as a therapeutic treatment for diseases characterized by 
upregulated cathepsin proteases.  
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2.3.3 Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of 23 zinc-dependent 
endopeptidases that play a role in a variety of biological functions including cell 
proliferation, cell migration, tissue remodeling, wound healing, and angiogenesis [116].  
MMPs have similar overall 3D structure, usually consisting of a propeptide region, a 
zinc-containing catalytic domain, a linker peptide, and a hemopexin domain [117,118]. 
MMPs can be found  as secreted proteins or membrane-bound proteins and are optimally 
active a physiological pH [119]. 
The MMP family of proteases can be categorized by their substrates. MMP -1, -8, 
and -13 are collagenases and have the ability to cleave triple helical collagen at a single 
location, which generates characteristic ¾ and ¼ collagen fragments [104,118]. MMP-3 
and -10 are stromelysins which are secreted into the extracellular space and play a role in 
immunity and would healing [116,118]. Additionally, stromelysins are responsible for 
activating proMMP collagenases and proMMP-9 [118]. MMP-7 and -26 are matrilysins 
and can degrade type IV collagen, laminin, and entactin [118]. Additionally, MMP-26 
has been shown to cleave and activate proMMP-9 [118]. The gelatinases of the MMP 
family are MMP-2 and -9 and can degrade a broad spectrum of extracellular matrix 
proteins including type I, IV, V, VII, X, IX collagen, elastin, fibronectin, aggrecan, 
vitronectin, and laminin [120]. MMPs that cannot be classified into the aforementioned 
subgroups are labeled as “other archetypal MMPs” and include MMP-12, -19, 20, and -
27. MMP-12 is the most potent elastase of the MMP family but can also cleave other 
extracellular matrix proteins including aggrecan, fibronectin, laminin, and type IV 
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collagen [118,120]. MMP-19 is characteristically destructive of basement membrane 
proteins including type IV collagen, gelatin, and aggrecan [121]. 
Collectively, the MMP family of proteases is capable of degrading all 
extracellular matrix components [118]. Thus, MMPs have been implicated in several 
musculoskeletal diseases. Specifically, MMP-1 activity has been shown to be 
significantly greater in human supraspinatus tendon following rupture [122] and MMP-1 
and -3 have been shown to be upregulated within synovial fluid following rotator cuff 
tendon tear in humans [123]. Additionally, MMP-2, -9, and -13 have been shown to be 
more active in osteoarthritic cartilage compared to healthy cartilage in both humans and 
rats [124,125], while increases in MMP-2 and -9 activity positively correlated with the 
occurrence of muscle atrophy in rats [110,126]. MMP-19 has been detected in the 
inflamed synovium of patients suffering with rheumatoid arthritis [127]. MMP-12 is 
highly expressed in macrophages [128] but is also secreted by hypertrophic chondrocytes 
and osteoclasts [129].  
Expression and translation of MMPs is maintained at low basal levels, but can 
readily be increased in response to stimuli including inflammatory cytokines, growth 
factors, cellular interactions, or extracellular matrix protein binding [130]. In the absence 
of regulation, the destructive nature of MMPs would completely degrade any 
extracellular matrix protein. MMP are primarily regulated at the transcriptional level 
[118], but the presence of endogenous inhibitors also provide a level of MMP regulation. 
The family of endogenous MMP inhibitors is called the Tissue Inhibitor of 
Metalloproteinases (TIMPs). Four TIMPs have been identified that inhibit MMPs with 
varying affinity [9]. TIMP-3 has the broadest inhibition spectrum and unlike the other 
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three TIMPs is found tightly bound to extracellular matrix proteins [9]. TIMP-2, TIMP-3, 
and TIMP-4 have been found to bind and inhibit MMP-2, while TIMP-1 and TIMP-3 
have been shown to bind and inhibit MMP-9 [9].  
2.3.4 Complexity of Proteolytic Network 
The proteolytic network consists of all families of proteases and their naturally 
occurring inhibitors. The purpose of this vastly complex network is to maintain an 
appropriate ratio of proteases and inhibitors to achieve homeostasis within the body. For 
example, in the instance of wound healing, there is an increase in protease levels relative 
to their inhibitors in order to breakdown and clear any injured or diseased tissue and 
allow for the movement and replacement of healthy cells and tissue. However, in a 
disease state or chronic injury, such as rheumatoid arthritis, the ratio of inhibitor to 
protease becomes unstable and the amount of inhibitor is insufficient to prevent vast 
digestion of collagen resulting in irreplaceable degeneration of cartilage tissue [131].  
Proteolytic network complexity is further heightened due to interactions of 
proteases within the same family and with other protease families. Specifically, it has 
been shown that cathepsin S in the presence of substrate and cathepsin K would 
preferentially cleave and degrade cathepsin K [132]. Similarly, it has been shown that 
cathepsin K and cathepsin cannibalize one another in the presence of tendon ECM [133]. 
Additionally, degradation of type I collagen and tendon ECM was enhanced following 
sequential introduction of cathepsin K followed by cathepsin L relative to each cathepsin 
protease alone, which suggests cooperation between cathepsin proteases [133]. Lastly, it 
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has been documented that cathepsin proteases have the capacity to cleave and activate 
MMPs [31].  
While type I collagen is a substrate for multiple proteases, they do not all act on 
collagen equally. Cathepsins L, B, and S has been shown to have the ability to cleave 
collagen I within the telopeptide region, which is involved in intra- and intermolecular 
bonds between collagen units and generates type I collagen monomers [104]. Conversely, 
cathepsin K has the ability to cleave type I collagen in its native triple helix at multiple 
locations, which generates collagen fragments of various sizes [104]. Interestingly, 
MMP-1, -2, -8, and -13 have the ability to cleave type I collagen in its native triple helix 
but at a single site, which generates characteristic ¼ and ¾ fragments [104]. 
Investigation of protease inhibitors for the therapeutic purpose of treatment 
degenerative diseases characterized by prolonged upregulated proteases has further 
highlighted the complexity of the proteolytic network. It was observed in MDA-MB-231 
cells (epithelial, human breast cancer cell line) that in the presence of broad cathepsin 
inhibitors E-64 and cystatin C, a decrease in the amount of active cathepsin L was seen, 
but paradoxically an increase in the amount of active cathepsin S was detected [38]. 
However, MCF-7  (breast cancer cell line) and MCF10A cells (human breast 
epithelial cell line) did not demonstrate increased cathepsin S levels in the presence and 
absence of E-64 treatment [38]. Additionally, THP-1 cells (human monocyte cell line) 
treated with E-64 caused a significant increase in active cathepsin S and V but a decrease 
in active cathepsin L [38]. Furthermore, it has been shown that bolus treatment of cystatin 
C can cause cellular endocytosis, which subsequently traffics cystatin C to the lysosome 
where it is less potent due to the acidic environment [38] and not fulfilling its intended 
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purpose. Together, this demonstrates that broad spectrum inhibitors can cause unexpected 
upregulation of cathepsin proteases, which could depend on the cell type and the location 
of the protease (intracellular vs. extracellular). Thus, perturbing the proteolytic network is 
vital to both seeking therapeutic treatments for a variety of diseases as well as gain 
fundamental knowledge of the vast and complex network of proteases and inhibitors that 
play a vital role in many basic homeostatic functions. 
2.4 Biomaterial Delivery Vehicles 
The implication that proteases are a potential cause for tissue degeneration in 
musculoskeletal diseases makes protease inhibitors an appealing potential treatment. 
Several protease inhibitors have been tested in human clinical trials to treat dysregulated 
cathepsins and MMPs, but all have been abandoned due to off-target effects [16,17]. 
These clinical trials have tested the safety and efficacy of protease inhibitors using 
systemic delivery, meaning both healthy and diseased tissues are equally exposed to the 
therapeutic treatment. As mentioned previously, proteases play a variety of roles in the 
human body and thus are not localized to any one area of the body. Consequently, 
regulated proteases in healthy tissue may be inhibited and prevented from performing 
their normal functions, causing negative side effects including headache, gastrointestinal 
disturbance, lung fibrosis, and skin lesions [16]. Moreover, systemic delivery requires a 
much larger amount of therapeutic molecules in order to achieve a detectable effect in the 
diseased tissue, which will only receive a small fraction of the initial dose [18]. Thus, 
local, sustained delivery of protease inhibitors could reduce disease progression without 
deleterious side effects and with reduced amounts of therapeutic molecules to reduce 
cost-barriers to treatment. 
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2.4.1 Microparticles for Drug Delivery 
 Microparticles are a frequently used biomaterial vehicle for therapeutic drug or 
protein delivery [134]. Compared to larger biomaterial vehicles (such as bulk hydrogels), 
microparticles have several important advantages. First, microparticles are injectable, 
which is important for clinical applications. Second, they provide a high surface area to 
volume ratio, which permits greater release of loaded drugs or proteins [134]. While 
hydrogels can be made to be injectable, it would require exposure to free radical initiators 
and could negatively affect both the patient and the delivered therapeutic [135–137]. 
Lastly, microparticle fabrication is highly customizable. Microparticles can be made from 
a variety of synthetic or natural materials and include specialized crosslinkers [138]. 
Additionally, microparticles can be directly injected into the diseased or injured 
tissue of choice including tendon, muscle, or the intra-articular space of cartilage, which 
would localize treatment to the desired area. Compared to systemic delivery, there are 
several advantages of using a microparticle vehicle to deliver therapeutics drugs or 
proteins. Systemic delivery is a bolus dose of therapeutic drug, whereas microparticles 
have the capacity to achieve sustained delivery over a longer period of time [134]. 
Sustained delivery is advantageous because fewer doses would be required, which could 
improve patient compliance. Sustained, localized release of therapeutic drugs is less 
likely to cause off-target effects, which has been observed in patients treated with 
cathepsin inhibitors [16]. Moreover, systemic delivery requires a much larger amount of 
therapeutic molecules in order to achieve a detectable effect in the diseased tissue, which 
will only receive a small fraction of the initial dose [18]. Decreasing the required amount 
to achieve a therapeutic dose would also reduce cost barriers to treatment.  
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2.4.2 Poly(ethylene-glycol)-Based Microparticles 
Poly(ethylene-glycol) (PEG) is an attractive polymer that is commonly used in 
biomaterial applications because it is hydrophilic, does not adsorb many proteins in vivo, 
and is easily modified [139]. PEG can be chemically modified for a variety of purposes 
including for the purposes of chemical crosslinking, the addition of peptide binding 
sequences, and to enhance degradation. PEG can be functionalized with acrylate, thiol, or 
maleimide groups to allow for chemical crosslinking to itself, which is required for 
microparticle fabrication [21]. Additionally, peptide sequences can be chemically bound 
to PEG to allow for cellular attachment. PEG has been previously functionalized with 
two integrin binding peptides. Specifically, the RGD tripeptide, which is a common 
cellular recognition sequence found on many extracellular matrix [21] proteins and the 
GFOGER hexapeptide, which is the cellular recognition sequence found on triple helical 
collagen [140].  
Poly(ethylene-glycol)-diacrylate (PEGDA) is a hydrolytically degradable polymer 
due to the presence of an ester bond on the backbone (as can be seen in Figure 2.1 below) 
[141]. However, the time scale for degradation is several months, which is significantly 
longer than needed for many applications for acute treatment [141]. Thus, many groups 
have incorporated crosslinkers to increase the rate of PEGDA degradation. Our group has 
previously incorporated dithiothreitol (DTT) into our PEGDA network to increase the 
susceptibility of the ester bond [142]. Previous work has demonstrated that microparticle 
degradation rate is proportional to DTT levels incorporated into the microparticle 
network [143]. Furthermore, release of loaded therapeutics could be modulated by the 
hydrolytic degradation rate. For example, slower degradation could result in sustained 
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release over a longer period of time [134]. Another method that has been used to increase 
hydrolytic degradation of PEG is the addition of poly(lactic acid) (PLA) [29]. It has been 
shown that the degradation rate of PEG-PLA hydrogels can be tuned by adjusting the 
polymer content of the hydrogel and the length of the hydrolytically degradable PLA 
segments [29]. 
 
Figure 2.1: Chemical structure of poly(ethylene-glycol)-diacrylate (PEGDA) and 
Dithiothreitol (DTT) bound by Michael Type addition. Adapted from Tellier LE, 
Treviño EA, Brimeyer AL, Reece DS, Willett NJ, Guldberg RE, Temenoff JS. Intra-
articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in 
a rat model of osteoarthritis. Biomaterials science. 2018;6(5):1159-67. 
However, degradation of PEG-based materials is not limited to hydrolytic 
degradation, they can also be modified to undergo degradation by specific enzymes such 
as matrix metalloproteinases (MMPs) for on demand release of cargo. One study 
modified PEGDA with an MMP-1 susceptible peptide so that degradation was dictated 
by macrophage infiltration [144]. Protease-sensitive crosslinkers have also been used to 
provide enhanced control of biomaterial degradation to match cellular infiltration or 
release therapeutic molecules in response to active protease cleavage [22,145]. 
Additionally, other groups have incorporated enzyme-labile caprolactone units into PEG-
based hydrogels [146,147]. This system allows the user to dictate the rate of degradation 
by controlling the delivery of exogenous lipase [146,147]. Overall, PEG-based materials 
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are highly customizable and can be broadly applied to a variety of purposes and 
therapies. 
Numerous hydrolytically degradable PEG-based hydrogel systems have been 
developed for controlled delivery of biomolecules. Fluvastatin, which has been shown to 
stimulate BMP-2 production in osteoprogenitors, was released from PEG-
monomethacrylate (PEGMMA) functionalized with lactic acid to allow for hydrolytic 
degradation [148]. In this work, lactic acid of varying repeat units was incorporated into 
the network, to better understand how Fluvastatin release could be tuned by degradation 
rate [148]. All groups released 100% of loaded Fluvastatin, but the rate was dependent on 
the speed of degradation [148]. Specifically, the fastest degrading hydrogel (greatest 
number of lactic acid repeat units) achieved 100% release by day 7, while the medium 
degrading gel achieved 100% release by day 13 and the slowest degrading gel (lowest 
number of lactic acid repeat units) achieved 100% release by Day 18 [148]. Another 
group used eight-arm PEG-acrylate and DTT crosslinkers to investigate how degradation 
rate affected the release of a covalently bound fluoroscopic probe [149]. The fluoroscopic 
probe was covalently bound to the PEG-acrylate network via the reactive thiol group on 
the fluoroscopic probe and the acrylate group on PEG [149]. Thus, release of the 
fluoroscopic probe was dependent on hydrolytic degradation of the resulting ester bond. 
They found faster degradation resulted in faster achievement of 100% fluoroscopic probe 
release by day 8, while relatively slower degradation resulted in 100% release of the 
fluoroscopic probe after 10 days [149].  
Furthermore, PEG-based hydrogel systems with protease-sensitive crosslinkers 
have also been developed for controlled delivery of biomolecules. One group fabricated 
 40 
PEGDA microparticles crosslinked with an MMP-1 sensitive peptide and tested the 
release of an encapsulated small molecule (dexamethasone) and model protein 
(biotinylated horseradish peroxidase) [144]. They found increasing rates of release in the 
presence of increasing amounts of collagenase [144]. Specifically, 100% of loaded 
dexamethasone was released after 15 hours in the presence of 3 µg/mL of collagenase, 
while the same amount of loaded dexamethasone was not released until 25 hours of 
incubation in the presence of 0.6 µg/mL [144]. Similarly, 100% of loaded biotinylated 
horseradish peroxidase was released after 25 hours of incubation in the presence of 3 
µg/mL of collagenase, while incubation without collagenase only resulted in 50% release 
of loaded biotinylated horseradish peroxidase after 25 hours [144]. Another group 
assessed the release of covalently bound VEGF in a 4-arm poly(ethylene glycol)-
maleimide (PEG-4MAL) microgel with protease-sensitive crosslinker VPM and 
hydrolytically degradble DTT [22]. VEGF was covalently bound to the PEG-4MAL 
network via the reactive thiol group on VEGF and the thiol group on PEG [22]. They 
found PEG-4MAL gels with incorporated VMP in the presence of collagenase achieved 
100% release of loaded VEGF after 70 hours of incubation [22]. Additionally, they 
demonstrated that PEG-4MAL gels with incorporated VMP or DTT in the presence of 




Figure 2.2: Chemical structure of heparin based biomaterials. (A) Chemical structure 
of degradable heparin-based biomaterial fabricated via Michael type addition and free 
radical polymerization. (B) Disaccharide Unit of Heparin glycosaminoglycan. Adapted 
from Tellier LE, Treviño EA, Brimeyer AL, Reece DS, Willett NJ, Guldberg RE, Temenoff 
JS. Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage 
damage in a rat model of osteoarthritis. Biomaterials science. 2018;6(5):1159-67. 
Lastly, PEG can be functionalized with additional biomolecules to modulate 
controlled release. Heparin is a negatively charged glycosaminoglycan that is naturally 
produced by mast cells [150]. Heparin has been extensively used in PEG-based 
biomaterials applications because it is biocompatible, relatively non-toxic, and 
inexpensive [151]. The highly negative charge of heparin makes it an attractive material 
for release of positively charged proteins and has been shown to protect bound proteins 
[35,152–154]. Heparin is negatively charged due to the presence of various sulfate groups 
along the backbone. Our laboratory has the capacity to selectively remove sulfate groups 
from heparin, which have been shown to modulate protein release and can alter the 
protective properties of heparin [35,153]. Our laboratory and others have used heparin 
and its desulfated analogs for a variety of studies. We previously found that native 
heparin can maintain bone morphogenetic protein-2 (BMP-2) activity under thermal 




























desulfated forms of heparin were unable to protect BMP-2 from thermal stress to the 
same extent [153]. Similarly, we found that incorporation of more sulfated heparin into 
PEG-based microparticles caused faster microparticle degradation, significantly more 
BMP-2 release, and significantly more BMP-2 bioactivity compared to more desulfated 
heparin microparticle groups [35]. Additionally, we found that incorporation of more 
sulfated heparin into PEG-based hydrogels resulted in greater amounts of anti-
inflammatory, small molecule, positively charged crystal violet [36]. Furthermore, we 
found that fully sulfated heparin and N-desulfated heparin significantly enhanced the 
anti-plasmin activity of TSG-6 activity in vitro. We found that treatment with 10% N-
desulfated heparin microparticles loaded with TSG-6 prevented significant knee 
degeneration in an rat model of osteoarthritis [20]. While heparin can be used to 
modulate sustained release of positively charged proteins, it can also be used to sequester 
positively charged proteins [37]. 
2.4.3 Microfluidic Devices 
 Historically our laboratory and others have fabricated microparticles with a 
homogenizer and a water-in-oil emulsion system [19,20,35,37,152]. A major drawback of 
this system is the inability to control microparticle size, which generates microparticles 
with a wide distribution of sizes. Fabricating microparticles that are too large or small 
would consequently require filtering, which wastes materials and time. Furthermore, in 
order to use the microparticles to release therapeutics, the therapeutics would need to be 
loaded onto the microparticles after fabrication (post-loading), which would require more 
time and waste potentially expensive therapeutics. Post-loading is inherently wasteful 
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because therapeutic molecules do not necessarily bind microparticles with 100% 
efficiency [35,153].  
An alternative method to fabricate microparticles is the use of a microfluidic 
device, which have become increasingly popular due to their distinct advantages [26]. 
Microfluidic devices create a water-in-oil emulsion at a small scale, which allows for 
greater control of microparticle size [26]. Thus, microfluidic devices can synthesize 
uniformly sized microparticles, which eliminates the need for filtering and reduces 
material waste and time. Additionally, the characteristic control of a microfluidic device 
ensures that all of the polymer solution is introduced into the device and turned into 
microparticles. Thus, any expensive crosslinkers added to the polymer solution will be 
incorporated into the resulting microparticles, which eliminates waste. Furthermore, 
therapeutics can also be added to the polymer solution, eliminating the time and 
therapeutics waste characteristic of post-loading.   
To fabricate microparticles with a microfluidic device two immiscible phases are 
used: the continuous phase and the discontinuous phases. In a water-in-oil system, the 
continuous phase would consist of oil and the discontinuous phase would consist of the 
water soluble polymer solution. Unlike a homogenizer that creates a water-in-oil 
emulsion through mechanical or shear force, a microfluidic device creates an emulsion by 
uniform breakup of a stream of the discontinuous phase [26]. Microparticle size can be 
tuned by adjusting several parameters. Previous work has shown that higher phase speeds 
cause increased shear stress on the microparticle droplet [26]. The increased shear stress 
causes more frequent discontinuous phase stream break-up and consequently generates 
smaller microparticles [26]. When the microparticle droplet is smaller than the syringe 
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needle, the force applied is negligible [26]. However, as the discontinuous phase is 
continuously injected via the syringe pump, the microparticle droplet will increase in size 
and the applied force will similarly increase [26]. The increased force on the 
microparticle droplet causes it to be pinched off from the tip of the needle [26].  
Furthermore, microparticle size can be tuned by the amount of surfactant used in 
the system. It has previously been shown that particle size decreases with increasing 
amounts of surfactants [28]. Microfluidic devices that utilize immiscible phases to 
fabricate microparticles use surfactants to stabilize the shape of the microparticles and 
prevent coalescence of microparticles [27]. There is a thermodynamic driving force 
towards homogenization of the system whereby all microparticles coalesce and minimize 
contact with the oil-based continuous phase [27]. To overcome this thermodynamic 
driving force, surfactants are added to stabilize microparticles. Without the addition of 
surfactants, when microparticle droplets come into close contact the continuous phase 
between them will be depleted and allow the microparticle droplets to coalesce [27]. 
However, in the presence of surfactants on any two microparticle droplets, steric 
repulsion of the surfactant molecules will prevent the depletion of the continuous phase, 
which lengthens the time to continuous phase depletion and stabilizes both microparticles 
droplets against coalescence [27]. Previous groups that have investigated surfactants in 
the context of microfluidic devices have found that microparticle stability increases with 
increasing amounts of surfactants, which result in microparticle sizes of decreasing size 
[28,155]. However, using increasingly greater amounts of surfactant will eventually 
result in a microparticle size plateau, where the microparticle droplets are saturated with 
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surfactant molecules. The surfactant threshold varies depending on microparticle droplet 
size, the surfactant used, and the size of the microfluidic device [28]. 
Various microfluidic device systems have been developed for fabrication of 
microparticles with a variety of uses.  Of particular interest, microfluidic device platforms 
have been developed that allow for incorporation of additional biomolecules and cellular 
encapsulation [156]. The Garcia laboratory fabricated a poly(dimethyl siloxane) (PDMS) 
microfluidic device using soft lithography and flow-focusing microfluidic chip [156]. 
They were able to fabricate uniformly sized PEG-4MAL microparticles with incorporated 
hydrolytically degradable crosslinker DTT, cell binding peptide RGD, and encapsulated 
islet cells [156]. They demonstrated that they could fabricate these complex 
microparticles with a size range from 137 – 300 µm by varying the continuous flow rates 
[156]. Additionally, they demonstrated selective permeability of loaded biomolecules 
depending on the size [156]. Specifically, they showed that microparticles loaded with 
insulin and glucose achieved near 100% release over 70 hours, while larger molecules 
such as immunoglobulin G (IgG) achieved about 25% release over 70 hours [156]. They 
demonstrated that encapsulated islet cells maintained high levels of viability over at least 
8 days post-fabrication [156].  
While PDMS-based microfluidic devices have the capacity to fabricate 
microparticles with a wide range of applications, there are several drawbacks to using this 
platform. Namely, the channels can leak and become clogged with polymer debris in the 
course of microparticle fabrication [26], which would compromise microparticle yield 
and quality. Additionally, many organic solvents are incompatible with PDMS  molds 
because they can cause swelling [26] and compromise the flow of the immiscible phases. 
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More recently, several laboratories have begun to investigate simple microfluidic devices 
to overcome the characteristic problems of PDMS molds [26]. The Xia laboratory has 
fabricated a simple microfluidic device consisting of poly(vinyl chloride) (PVC) tubing, a 
syringe needle, and a glass capillary tube [26]. Their microfluidic device prevents the 
discontinuous phase from coming into contact with the capillary wall, which eliminates 
the risk of clogging seen in PDMS molds [26]. The Xia laboratory microfluidic device 
was able to synthesize microparticles from hydrophobic polymer poly(e-caprolactone) 
(PCL) and hydrophilic, natural polymer gelatin [26]. In this microfluidic device platform, 
the discontinuous and continuous phases are introduced using syringe pumps with 
independently adjustable flow rates and allowed to mix at the end of the syringe needle 
[26]. The PCL microparticles were fabricated in an oil-in-water emulsion with a 
poly(vinyl alcohol) (PVA) continuous phase and were solidified via solvent extraction 
and evaporation in the collection phase, which also consisted of PVA [26]. The PCL 
microparticle size range with this simple microfluidic device platform was 75 – 230 µm 
[26]. Using the same microfluidic device, the Xia laboratory also fabricated gelatin 
microparticles with a continuous phase of toluene and span-80 [26]. Gelatin 
microparticles were collected in a solution of ethanol to allow for crosslinking and can be 
vacuum dried prior to use [26].  
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CHAPTER 3  FULL-THICKNESS ROTATOR CUFF TEAR IN 
RAT RESULTS IN DISTINCT TEMPORAL EXPRESSION OF 




 Rotator cuff tears, including partial and full-thickness tears of the supra- and 
infraspinatus tendons, are among the most common shoulder injuries and result in over 
75,000 surgical repairs annually [157]. Following rotator cuff tear, several tissues are 
negatively affected including the tendon, its respective muscle, and articular cartilage in 
the shoulder joint. Such damage includes tendon disorganization with decreased collagen 
content [2], muscle atrophy, and fibrous tissue and fatty deposits within the muscle [3]. 
Additionally, the force balance between tendons of the rotator cuff is disrupted, which 
may lead to the development of osteoarthritic changes in the articular cartilage including 
loss of glycosaminoglycan (GAG) content, increased surface roughness, and loss of 
cartilage tissue [4,5]. 
While damage to joint tissue following rotator cuff tear is well documented, the 
exact biochemical processes responsible for extracellular matrix (ECM) turnover that 
contribute to this damage remain unknown. In joint tissues, both ECM components and 
 
 
1 Portions of this chapter were adapted from Treviño EA, McFaline-Figueroa J, Guldberg RE, Platt MO, 
Temenoff JS. Full‐thickness rotator cuff tear in rat results in distinct temporal expression of 
multiple proteases in tendon, muscle, and cartilage. Journal of Orthopaedic Research. 2019 Feb;37(2):490-
502. 
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the proteases that degrade them are secreted for the purposes of tissue remodeling [9]. 
For example, tenocytes have been shown to alter the rate of collagen synthesis [62] as 
well as protease secretion [63] in response to changes in mechanical loading. 
Furthermore, an acute injury such as rotator cuff tendon tear could incite an inflammatory 
response, whereby inflammatory cells such as neutrophils and macrophages would be 
recruited to the area. It is well known that inflammatory cells have the capacity to secrete 
proteases [67,68] that may further contribute to the net shift towards ECM degeneration. 
Thus, an imbalance between anabolic and catabolic factors through the increased 
presence of active proteases could be responsible for the decrease in ECM components, 
such as collagen and elastin [47,66], observed following rotator cuff tendon tear.  
Cathepsins are papain-family cysteine proteases known to be some of the most 
powerful elastases and collagenases, are often associated with ECM remodeling and 
therefore warrant investigation in rotator cuff tear pathology [69]. Cathepsin K, 
canonically associated with osteoclasts and bone remodeling, has been previously 
observed in osteoporosis and osteoarthritis [10,38]. In particular, prior work has 
identified a positive correlation between amount of cathepsin K present and osteoarthritis 
severity in mice [158] and cathepsin L has been shown to be upregulated in instances of 
muscle atrophy in both rats and mice [104,110]. Additionally, our previous work 
investigating tendinopathy [14,15] has demonstrated upregulated cathepsin activity in the 
tendon at 4 and 8 weeks of overuse in a rat model.  
Furthermore, matrix metalloproteinases (MMPs), zinc-dependent endopeptidases 
that play a role in ECM remodeling, have been previously implicated in tendon 
degeneration, muscle atrophy, and osteoarthritis development. Specifically, MMP-1 
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activity has been shown to be significantly greater in human supraspinatus tendon 
following rupture [122] and MMP-1 and -3 have been shown to be upregulated within 
synovial fluid following rotator cuff tendon tear in humans [123]. Additionally, MMP-2, 
-9, and -13 have been shown to be more active in osteoarthritic cartilage compared to 
healthy cartilage in both humans and rats [124,125], while increases in MMP-2 and -9 
activity positively correlated with the occurrence of muscle atrophy in rats [110,126].  
Both the cathepsin and MMP families contain potent collagenases and elastases, 
and thus are often seen in the same degenerative injury. For example, cathepsin L and 
MMP-2 have been observed to be upregulated in instances of muscle atrophy [110,126]. 
Interestingly, while both families of proteases can cleave collagen, they do so at different 
locations within the molecule and at different catalytic rates [104], and thus may act 
synergistically to enhance ECM degradation.  Furthermore, cathepsins have the ability to 
cleave and activate pro-MMPs [31], which suggests they can work sequentially to digest 
collagen and promote tissue degradation [104].  Due to their shared substrates and cross-
activation, it is important to investigate both families of enzymes individually and in 
connection to one another to better understand how proteases play a role in tissue 
degeneration after rotator cuff tear. 
Thus, using early, middle, and late time points (1, 3, and 12 weeks respectively), 
the objective of this study was to characterize the protease activity profile over time in 
joint tissue following acute, full-thickness rotator cuff tear, and to relate these results to 
the timing of observed tissue structural damage, as monitored by histology or 
microcomputed tomography (μCT) imaging. To our knowledge, no work has investigated 
both families of proteases within all three soft tissues of the joint after full-thickness 
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rotator cuff tears. We hypothesize that acute, full-thickness rotator cuff tear will result in 
significantly more protease activity (cathepsins and MMPs) early after injury in 
supraspinatus tendon (1 week), with delayed responses from cartilage and supraspinatus 
muscle (3-12 weeks after injury). Additionally, we hypothesize that protease upregulation 
timing will coincide with manifestation of visible tissue damage (as assessed by histology 
and/or μCT imaging) in each tissue. A summary of outcome measures for each tissue 
over time can be found in Table 1. 
3.2 Materials and Methods 
3.2.1 Surgical Procedure and Outcome Measure Time Points 
Rotator cuff injury was induced using a method previously established [19,88].  
This animal model was chosen as muscle degeneration, an outcome we aim to 
characterize in this study, does not occur to a large degree in other models, such as 
tendon transection only, in rats [23]. Male Sprague-Dawley rats (N=30 total, 250-300 g 
initial weight and 8-10 weeks old) were used in accordance with protocols approved by 
the Georgia Institute of Technology Institutional Animal Care and Use Committee 
(Protocol #A15050).  To induce injury, on the left side of the animal, a 5 mm portion of 
the suprascapular nerve was resected, and both the supraspinatus and infraspinatus 
tendons were transected at the insertion into the humeral head.  The wound was closed 
using Vicryl 4-0 absorbable sutures (Ethicon) and wound clips.  The right forelimb of 
each animal served as an internal, uninjured contralateral control. Because rats are 
quadrupeds and do not have a dominant forelimb for daily activities, we did not deem it 
necessary to randomize for this study. 
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Table 3.1: Experimental design and outcome measures performed in all three joint 
tissues over time. 
 1 week 3 weeks 12 weeks 
Supraspinatus 
Tendon 
Zymography (N=6) Zymography (N=8) Zymography (N=6) 
Histology (N=3) - - 
Supraspinatus 
Muscle 
Zymography (N=6) Zymography (N=8) Zymography (N=6) 
Histology (N=3) - - 
Humeral Head 
Cartilage 
Zymography (N=6) Zymography (N=6) Zymography (N=3) 
EPIC μCT (N=8) - EPIC μCT (N=8) 
 
Time points for this study were chosen based on previous data from our 
laboratory as well as when we expected to see significant structural damage in each 
tissue. Due to the acute injury of the tendon, we expected to observe damage to this tissue 
soon after injury and chose 1 week to capture effects of acute inflammation [159]. For 
muscle, we have previously shown significant fibrous tissue infiltration (indicative of 
muscle degeneration) 3 weeks following tendon injury [19]. In our previous studies with 
tendon overuse injuries [15], we have observed concomitant humeral head cartilage 
damage by 12 weeks after tendon injury onset.  
3.2.2 Histology 
Following tissue isolation, supraspinatus muscles and tendons (N=3) were fixed 
with 4% paraformaldehyde, embedded in optimum cutting temperature (OCT), and 
frozen in a liquid nitrogen-cooled ethanol. Supraspinatus muscle tissue was cross-
sectioned and supraspinatus tendon tissue was sectioned longitudinally in 7 μm slices 
using a cryostat (CryoStar NX70, Thermo Fisher). Supraspinatus muscle sections were 
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stained with Masson’s trichrome and hematoxylin and eosin (H&E) stains (VWR and 
Richard Allan Scientific respectively). Supraspinatus tendon sections were stained with 
H&E and both tissues were imaged using light microscopy (Nikon TE2000). For 
analysis, eight sections of supraspinatus tendon (each section was imaged at both 
proximal and distal ends) per sample and 12 sections of supraspinatus muscle per sample 
were used.  
3.2.3 Quantification of Collagen Alignment in Tendon 
Tendon sections (N=3) were imaged using a Zeiss 710 NLO inverted confocal 
microscope (Carl Zeiss Microscopy) with a mode-locked Ti:Sapphire Chameleon Ultra 
laser (Coherent Inc.) in combination with non-descanned detection (NDD) to visualize 
the collagen fibers and quantify their orientation and distribution as previously described 
[160]. The laser was set to 800 nm and emission was filtered from 380 - 430 nm. Second 
harmonic generation (SHG) images were collected using a Plan-Apochromat 20x 
objective and Zeiss ZEN software. The fiber direction was estimated using OrientationJ 
distribution, an ImageJ plug-in (NIH) developed for directional analysis.  A distribution 
of local angles was generated for each optical slice, where 0° aligned to the horizontal 
axis (length-wise along the tendon) and ± 90° to the vertical axis. The mean and standard 
deviation of collagen fiber orientation was calculated from the distribution of each image. 
For analysis, eight sections of supraspinatus tendon (each section was imaged at both 
proximal and distal ends) were used. 
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3.2.4 Micro-computed Tomography (μCT) 
Humeral head samples (N=8) were analyzed by EPIC-μCT (Equilibrium 
Partitioning of an Ionic Contrast-Microcomputed tomography) based on established 
techniques [15,161]. EPIC-μCT involves the use of a contrast agent to better visualize 
less radio-opaque tissues, such as cartilage. In this work, Hexabrix (Covidien) was 
employed, which is negatively charged and is therefore electrostatically repulsed due to 
the high amounts of negative charge on biomolecules such as proteoglycans found in 
cartilage. Therefore, cartilage attenuation is inversely related to proteoglycan content 
within the tissue.  
Following isolation at 1 and 12 weeks following injury, humeral heads were 
submerged in a 10% Hexabrix solution at 37°C for 30 min. Humeral heads were scanned 
in the sagittal plane with the μCT50 (Scanco Medical) at 45 kVp, 200 μA, and a 600 ms 
integration time. Following segmentation and reconstruction, control and injured humeral 
heads were evaluated for cartilage volume, cartilage thickness, and cartilage attenuation 
using Scanco evaluation software. Hexabrix was removed from humeral head sample by 
incubating in PBS at 37°C for 30 min. The same contrast-enhanced scans were used to 
analyze subchondral and trabecular bone via Scanco evaluation software. Analysis of 
subchondral bone included thickness, volume, and density, while trabecular bone 
included volume and density. Additionally, the same scans were used to evaluate the 
subchondral bone directly under focal defects at 12 weeks. Control humeral heads were 
evaluated in the same region of the humeral head with equivalent numbers of slices. 
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3.2.5 Multiplex Gelatin Zymography 
Following sacrifice, joint tissues were collected. Supraspinatus tendon and muscle 
were isolated together and then separated through fine-dissection under a 
stereomicroscope (Leica model: 165FC). Cartilage was carved from the humeral head 
using a scalpel. Tissues were homogenized using a sample grinding kit (GE Healthcare 
Life Sciences) and zymography lysis buffer (consists of 20 mM Tris-HCl, 5 mM EGTA, 
150 mM NaCl, 20 mM glycerol-phosphate, 10 mM NaF, 1 mM sodium orthovanadate, 
1% Triton-X 100, and 0.1% Tween 20 in 500 mL deionized water) with 0.1 mM freshly 
added leupeptin to stabilize proteins. Protein concentration was determined by microBCA 
kit (Thermo Fisher).  
Cathepsin and MMP zymography was performed as previously described 
[69,162]. For supraspinatus muscle and tendon tissues (N=6-8), 15 μg of protein under 
non-reduced conditions were loaded on either 12.5% (cathepsin) or 10% (MMP) SDS–
polyacrylamide gels laden with 0.2% gelatin substrate. For cartilage tissues (N=3-6), 10 
μg of protein under non-reducing conditions were loaded onto 7.5% SDS–polyacrylamide 
gels laden with 0.2% gelatin substrate into both cathepsin and MMP gels. Recombinant 
proteins were used as positive controls on all gels. Recombinant cathepsin K (Enzo) was 
used for cathepsin zymograms at pH=6, recombinant cathepsin L (R&D Systems) was 
used for cathepsin zymograms at pH=4, and recombinant MMP-2 (R&D Systems) was 
used for MMP zymograms.  
After separation by size, gels were washed in their respective renaturing buffer to 
allow proteases to return to active confirmation. Gels were incubated in their respective 
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assay buffer at 37°C for 18 hours to allow degradation of gelatin within gels. After 
rinsing with DI water, gels were stained with Coomassie Brilliant Blue (Thermo Fisher) 
for 1 hour at room temperature and constant agitation and destained for 1 hour under the 
same conditions. Gels were imaged using ImageQuant LAS 4000 (GE Healthcare) and 
densitometry analysis was performed using ImageJ (NIH).  
3.2.6 Immunostaining 
Immunostaining of supraspinatus tendon 1 week following injury (N=3) was used 
to confirm the presence of inflammatory cells within the joint. Supraspinatus tendon 
sections were rinsed with PBS to remove OCT and blocked with 5% goat serum (R&D) 
for 1 hour at room temperature. Ly6g+ FITC primary antibody (abcam ab25024) diluted 
in 5% goat serum (1:100) was applied to sections for 1 hour at room temperature in the 
dark. CD68+ primary antibody (abcam ab955) was applied to sections (1:200) and 
incubated overnight at 4°C in a humid chamber. Following three PBS washes, secondary 
antibody (abcam ab150113) was added to sections (1:500) for 1 hour at room temperature 
in the dark. Following antibody incubation, sections were washed with PBS and 
incubated with Hoechst (1:1,000) counterstain (Sigma-Aldrich) for ten minutes at room 
temperature in the dark. Following three PBS washes, sections were mounted and imaged 
immediately using confocal microscopy (Zeiss). Incubation with secondary antibody 
alone (i.e. no primary antibody) was used as a negative control to verify the absence of 
non-specific binding. To quantify the number of inflammatory cells within the tendon, 
ImageJ (NIH) was used to count total Hoechst stained cells and CD68+ or Ly6g+ cells 
using the color threshold analysis tool. Data is presented as total number of immune cells 
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divided by total cells. The same parameters were used for injured and control images. 
Eight sections of supraspinatus tendon per sample were stained and quantified.  
3.2.7 Statistical Analysis 
Power analysis (G*Power software) was performed on prior data [14,15] for both 
zymography (α = 0.05, β = 0.8, Δ = 0.48) and μCT (α = 0.05, β = 0.8, Δ = 0.75) to 
determine number of animals required for this study.  Prior to statistical analysis, we 
performed a Shapiro-Wilk normality test to ensure our data was normally distributed and 
could undergo parametric tests. For humeral head evaluation (bone and cartilage) via 
μCT and zymography analysis with multiple time points, statistical significance was 
determined using a two-way ANOVA and Tukey’s post-hoc test (p ≤ 0.05) in GraphPad 
on raw values. Densitometry analyses of zymograms are graphed as fold change 
compared to uninjured contralateral control samples. For humeral head evaluation of 
bone at a single time point, a student t-test (two-tailed, p ≤ 0.05) was used. To determine 
collagen alignment within supraspinatus tendon tissue for different samples, a student’s t-




H&E staining revealed that the control supraspinatus tendon showed dense, 
aligned collagen fibers and elongated cells at both the proximal and distal sections of the 
tendon 1 week following injury. In contrast, the injured supraspinatus tendon 
demonstrated cellular infiltration and changes in collagen alignment and orientation at 
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both the proximal and distal portions of the tendon (Figure 3.1a). The average alignment 
of collagen fibers in the control supraspinatus tendon relative to 0° was 8.5° ± 16.7°  
(distal) and 9.9° ± 16.0° (proximal), while the injured tendon had an average collagen 
alignment of -11.8° ± 51.7° (distal) and -8.3° ± 46.9° (proximal). The control 
supraspinatus tendon had significantly more aligned collagen fibers compared to the 
injured supraspinatus tendon at 1 week following injury (Figure 3.1b). Supraspinatus 
muscle samples were qualitatively analyzed using both H&E and Masson’s trichrome. 
Both stains revealed similar morphology in control and injury muscle fibers, with little 
evidence of fibrous degeneration at this time point (Figure 3.2). 
 
 
Figure 3.1: One week after injury tendon undergoes noticeable damage. (A) H&E 
staining of longitudinally-sectioned tendon reveals damage 1 week after injury, indicated 
by changes in collagen structure and cellular infiltration (arrowheads) (B) Second 
Harmonic Generation images of collagen within tendon sections with quantification of 
orientation distribution. The average alignment of collagen fibers in the control 
supraspinatus tendon relative to 0° was 8.5° ± 16.7°  (distal) and 9.9° ± 16.0° (proximal), 
while the injured supraspinatus tendon had an average collagen alignment of -11.8° ± 
51.7° (distal) and -8.3° ± 46.9° (proximal) relative to 0°. The orientation of collagen 
fibers in injured supraspinatus tendon was significantly different from control (p<0.05). 




Figure 3.2: One week after injury muscle remains similar to control. H&E and 
Masson’s trichrome staining of muscle cross-sections shows no differences compared to 
uninjured control 1 week after injury. Scale bar is 100 μm. 
3.3.2 EPIC-μCT Analysis of Humeral Articular Cartilage, Subchondral Bone, and 
Trabecular Bone 
Some animals developed localized loss of cartilage (focal defects) by 12 weeks 
following rotator cuff injury (4 of 8 animals), while no focal defects were observed in 
control cartilage or injured cartilage at 1 week (Figure 3.4a). Focal defects had an average 
volume of 0.12 ± 0.09 mm3 and did not manifest in similar regions of the humeral head 
cartilage between animals (Figure 3.3). Previous work investigating rat knee cartilage 
demonstrated consistent defects in the medial third of cartilage in an animal model of 
osteoarthritis [161]. Despite the presence of focal defects in half of injured animals, there 
were no significant differences in cartilage volume, thickness, or attenuation (inversely 
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related to (GAG) content) between control and injury groups at either time point (Figure 
3.4b). Analysis of humeral head subchondral bone showed no significant differences in 
bone volume, thickness, or density between injured and uninjured groups at either time 
point (Figure 3.5a-c). However, within each group, there was a significant increase in 
subchondral bone volume, thickness, and density, between 1 and 12 weeks. Analysis of 
trabecular bone at 12 weeks showed no significant differences in bone volume between 
injury and control groups (Figure 3.5d-e). Analysis of subchondral bone directly under 
the focal defect showed no difference in thickness, but significantly greater bone density 
(Figure 3.5f-g) on the injured side compared to control at 12 weeks. 
 
 
Figure 3.3: μCT analysis demonstrates that focal defects do not occur in the same 
location on humeral heads between animals. 3D reconstruction of humeral head 
cartilage thickness with overlaid bone 12 weeks following injury. Black box indicates 




Figure 3.4: Contrast enhanced microCT reveals focal defects within cartilage 12 
weeks post-injury. (A) contrast enhanced microCT of humeral heads. Loss of cartilage 
(focal defects) highlighted in white box. Defects present in 4 out of 8 animals. N=8. scale 
bar = 1mm. (B) Evaluation of cartilage thickness, cartilage volume, and cartilage 




Figure 3.5: μCT analysis demonstrates few differences in humeral head bone 
following injury. (A) Subchondral bone volume (B) Subchondral bone thickness (C) 
Subchondral bone density (D) Trabecular bone volume (E) Trabecular bone density (F) 
Subchondral bone thickness directly under focal defect (G) Subchondral bone density 
directly under focal defect. A-E: N=8, F-G: N=4 *p<0.05, & indicates significantly 
different from 1 week samples. 
 
3.3.3 Active Cathepsins and MMPs in Supraspinatus Tendon 
Active cathepsin L was found in pH4 and pH6 cathepsin zymograms between 37 
and 25 kDa (Figure 3.6a and 3.6c) and pro- and mature MMP-2 were detected in MMP 
zymograms (Figure 3.6e) between 50 and 75 kDa at all three time points (1, 3, and 12 
weeks post-injury). Densitometric analysis revealed significantly higher amounts of 
active cathepsin L in injured supraspinatus tendon with an average of 5 fold increase over 
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control supraspinatus tendon at 1 week post-injury (Figure 3.6b and 3.6d). Additionally, 
active MMP-2 was significantly increased in injured supraspinatus tendon with an 
average of 10 fold increase over control supraspinatus tendon at 1 and 3 weeks post-
injury (Figure 3.6f). There were no significant changes in protease activity at 12 weeks 
compared to control. Additionally, we investigated the amount of active protease over 
time within control supraspinatus tendon (Figure 3.10a-c). We found that there is a 
significant increase in the amount of active cathepsin L from 1 week to 3 weeks with a 




Figure 3.6: Gelatin zymography of tendon shows significant increase of proteases 
following injury. (A-B) cathepsin (pH=4 buffer) zymography gel and densitometry 
quantification (C-D) cathepsin (pH=6 buffer) zymography gel and densitometry 
quantification (E-F) MMP zymography gel and densitometry quantification. 




3.3.4 Active Cathepsins and MMPs in Supraspinatus Muscle 
Active cathepsin L was found in pH4 and pH6 cathepsin zymograms between 37 
and 25 kDa (Figure 3.7a and 3.7c) and pro- and mature MMP-2 were detected in MMP 
zymograms (Figure 3.7e) between 50 and 75 kDa at all three time points (1, 3, and 12 
weeks post-injury). Densitometric analysis of cathepsin pH6 and cathepsin pH4 
zymograms revealed significantly higher active cathepsin L (~5 fold increase) in injured 
supraspinatus muscle compared to control supraspinatus muscle at 1 week post-injury 
(Figure 3.7b and 3.7d). Additionally, cathepsin pH6 zymograms showed a continued 
increase in active cathepsin L (~5 fold increase) 3 weeks after injury (Figure 3.7d). The 
amount of active cathepsins within the supraspinatus muscle was comparable to the 
uninjured control at 12 weeks following injury. Active MMP-2 was significantly 
increased in injured supraspinatus muscle with an average 4 fold increase over control 
supraspinatus muscle at 3 weeks post-injury (Figure 3.7f), while there were no significant 
changes in the amount of active MMP at 1 and 12 weeks compared to control.  
Additionally, we investigated the amount of active protease over time within 
control supraspinatus muscle (Figure 3.10d-f). Cathepsin pH4 zymograms demonstrated 
a significant increase in the amount of active cathepsin L from 1 week to 3 weeks with a 
plateau between 3 and 12 weeks, whereby the amount of active cathepsin L is maintained 
(Figure 3.10d). Conversely, cathepsin pH6 zymograms demonstrated low levels of 
cathepsin L with a significant increase in the amount of active cathepsin L at 12 weeks 




Figure 3.7: Gelatin zymography of muscle shows significant increase of proteases 
following injury. (A-B) cathepsin (pH=4 buffer) zymography gel and densitometry 
quantification (C-D) cathepsin (pH=6 buffer) zymography gel and densitometry 
quantification (E-F) MMP zymography gel and densitometry quantification. 




3.3.5 Active Cathepsins and MMPs in Humeral Head Cartilage 
Following injury, active cathepsin L was found in pH4 cathepsin zymograms 
between 25 and 37 kDa (Figure 3.8a) at all three time points (1, 3, and 12 weeks), while 
active cathepsin K was found in pH6 cathepsin zymograms around 75 kDa (Figure 3.8c) 
at 1 week in cartilage (no cathepsin K was found at 3 or 12 week time points). 
Densitometric analysis revealed significantly higher active cathepsin L (3 fold difference) 
and active cathepsin K (6 fold difference) at 1 week following injury compared to control 
(Figure 3.8b and 3.8d). Active MMP-2 and MMP-9 were found at all three time points (1, 
3, and 12 weeks) following injury at 50 to 75 kDa and 75 to 100 kDa respectively (Figure 
3.8e). However, we detected no significant differences in the amount of active MMPs 
(Figure 3.8f and 3.8g). Due to limited sample availability and small sample size, we were 
unable to perform statistical analysis on 12 week cartilage samples. Bands with a 
molecular weight higher than 75 kDa were not analyzed due to the inability to correctly 
identify the protease associated with these bands. Additionally, we investigated the level 
of active proteases over time within humeral head cartilage (Figure 3.10g-j) and found no 
significant differences between 1 and 3 weeks for cathepsins or MMPs. Due to the small 
sample size for 12 week cartilage, we were unable to draw statistical comparisons with 
previous time points.  
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Figure 3.8: Gelatin zymography of cartilage shows significant increase of proteases 
following injury. (A-B) cathepsin (pH=4 buffer) zymography gel and densitometry 
quantification (C-D) cathepsin (pH=6 buffer) zymography gel and densitometry 
quantification (E-G) MMP zymography gel and densitometry quantification. 
Recombinant protein used as standard: cathepsin L, cathepsin K, MMP-2 respectively. 
*p<0.05. N=3. 12 week cartilage samples cannot be statistically analyzed due to low 
sample size. 
3.3.6 Immunostaining for inflammatory cells 
Staining for CD68+ and Ly6g+ cells indicated that both macrophages and 
neutrophils were present within supraspinatus tendon 1 week following injury (Figure 
3.9). We found the average percentage of CD68+ cells were 24.1 ± 9.1% of all cells, 
while Ly6g+ cells were 31.0 ± 17.3% of all cells in injured supraspinatus tendon. 
Dissimilarly, control supraspinatus tendon had no CD68+ or Ly6g+ cells. Both 
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inflammatory cell types were seen within the proximal and distal regions of the 
supraspinatus tendon. Moreover, we found significantly more total cells within injured 
supraspinatus tendon with an average of 198 ± 54 cells per region of interest, while 
control supraspinatus tendon had an average of 103 ± 15 cells per region of interest.  
 
Figure 3.9: Immunostaining of tendon shows significantly higher prevalence of 
macrophage (CD68+) and neutrophil (Ly6g+) markers in injured tendon 1 week 
post-injury compared to uninjured control. Quantitative analysis via color 
thresholding demonstrated there was significantly more CD68+ cells in injured 
supraspinatus tendon  (24.1 ± 9.1% of all cells) compared to 0% in control tendon 
(p<0.05). Additionally, there was significantly more Ly6g+ cells in injured supraspinatus 
tendon (31.0 ± 17.3% of all cells) compared to 0% in control supraspinatus tendon 




Figure 3.10: Analysis of basal levels of active proteases over time in control 
(uninjured) tissues. (A-C) Basal levels of cathepsin L and MMP-2 in supraspinatus 
tendon. N= 6-8. (D-F) Basal levels of cathepsin L and MMP-2 in supraspinatus muscle. 
N=6-8. (G-J) Basal levels of cathepsin L, cathepsin K, MMP-2, and MMP-9 in humeral 
head cartilage. N=3-6. *indicates significantly different from 1 week active protease 
levels (p<0.05). & indicates significantly different from 3 week active protease levels. 12 
week cartilage samples cannot be statistically analyzed due to small sample size. 
3.4 Discussion 
This work employed an established animal model to replicate damage that has 
been observed in tendon, muscle, and humeral head cartilage following acute, full-
thickness rotator cuff tear in humans [5,10,110,122,124]. As demonstrated in Figure 3.1, 
changes were observed in supraspinatus tendon morphology as early as 1 week, which 
was expected due to the transection of both the supraspinatus and infraspinatus tendons. 
Conversely, the supraspinatus muscle, which is not directly injured in this model, but 
suffers from secondary effects, such as lack of neural stimulation and mechanical 
loading, appeared comparable to control supraspinatus muscle at 1 week (Figure 3.2). 
However, our laboratory has previously shown significant fibrous infiltration of the 
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supraspinatus muscle in this animal model at 3 weeks post-injury [19] and maintenance 
of similar levels of fibrous tissue up to 6 weeks, which aligns with other groups using 
similar animal models of rotator cuff injuries [23,88].  
Using contrast-enhanced EPIC–µCT, we were unable to detect any differences in 
cartilage volume, thickness, or attenuation 12 weeks following injury (Figure 3.4b). Prior 
work investigating denervation and tendon transection separately in a rat model has 
shown loss of safranin O staining in humeral head cartilage at 12 weeks [4], which should 
correspond to an increase in cartilage attenuation via EPIC-µCT [163,164]. However, 
because these results were found in a different injury model and employed a different 
technique, a direct comparison is limited. Additionally, we showed the presence of 
cartilage erosion (focal defects) within humeral head cartilage in half of all injured 
animals by 12 weeks. The lack of statistical difference in cartilage volume despite the 
presence of focal defects could be due to the fact that only half of the animals developed 
them, thus we would need a much larger sample size to demonstrate differences. 
Alternatively, it is possible the volume of cartilage lost as a focal defect was not large 
enough to render the overall volumes different between groups. Previous work examining 
humeral head cartilage following rotator cuff injury has demonstrated increased surface 
roughness and loss of tidemark integrity of humeral head cartilage 12 weeks post-injury 
in rats [4], but no indication of cartilage loss or erosion. However, contrast-enhanced 
µCT allows analysis of the entire humeral head and is a powerful tool to detect small 
defects in cartilage (Figure 3.3) that may be difficult to visualize through histological 
analysis [165]. A strong relationship between rotator cuff tear and subsequent 
degeneration of humeral head and glenoid cartilage has been seen in humans [5,73], 
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suggesting that this animal model at least partially recapitulates this aspect of human 
pathology. 
Further µCT analysis revealed no differences in subchondral bone thickness, 
volume, or density as well as no differences in trabecular bone volume or density 
between control and injury groups at either time point. However, we found a significant 
increase in subchondral bone volume, thickness, and density between 1 and 12 weeks 
regardless of injury (Figure 3.5a-c). This is likely due to animal growth over time. Thus, 
it is possible that changes to subchondral bone properties caused by the injury were 
concealed by this normal growth. Nevertheless, we detected subchondral bone density 
increased directly beneath the focal defects 12 weeks following injury (Figure 3.5). Other 
studies have demonstrated overall bone loss in the humeral head of rats 12 weeks 
following transection of the supraspinatus and infraspinatus tendons followed by tendon 
reattachment [166]. These differences could be the result of differences in tendon injury 
vs. injury + repair models. Current methods for tendon reattachment in rodents, whereby 
a hole is drilled through the humeral head to allow suturing of the tendon, will 
intrinsically create bone loss. Previous findings show a correlation between chronic 
rotator cuff injuries presenting with cartilage loss and decreased bone density in humans 
[5], suggesting that this model does not fully recapitulate aspects of bone pathology at the 
time points studied. However, significantly denser subchondral bone directly under the 
focal cartilage defects was detected in our model. This aligns with previous literature 
investigating instances of osteoarthritis in the knee of humans in which an increase in 
bone mineral density is considered an early sign of osteoarthritis [167,168].  Combined 
with the presence of focal defects at 12 weeks, this model does appear to partially 
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replicate the increased risk of developing osteoarthritis following rotator cuff tear seen in 
humans [5]. 
Examining zymography results in each tissue, overall temporal protease activity 
profiles were different between cathepsins and MMP-2. Specifically, cathepsins were 
more active in the first week, while MMP-2 maintained prolonged activity in the 
supraspinatus tendon between 1 and 3 weeks and increased only at 3 weeks in 
supraspinatus muscle. These findings align with previous work showing cathepsins can 
activate MMPs [31] and could also indicate the possibility of cathepsins and MMP-2 
sequentially acting on collagen to increase degradation [104]. Cathepsin L, present in 
both supraspinatus tendon and muscle in this work, is associated with protein turnover 
and tissue remodeling [108]. Cathepsin L has been shown to have the ability to cleave 
collagen I within the telopeptide region, which is involved in intra- and intermolecular 
bonds between collagen units [104]. Cathepsin L activity prior to MMP-2 activity would 
leave MMP-2 to cleave shorter collagen I molecules and enhance overall tissue 
degeneration. Similarly in cartilage, where no significant MMP-2 was detected, cathepsin 
K, which is typically associated with bone remodeling [169], has the ability to cleave 
type I collagen in its native triple helix at multiple locations [104], which would allow for 
significant degradation without the aid of MMP-2. Thus, the type of protease and the 
order of appearance could have a large effect on the degree of degeneration observed in 
each tissue.  
As a part of this study, we also investigated basal levels of active proteases 
change over time in each tissue. Cathepsin pH4 zymograms of supraspinatus tendon and 
muscle, showed a significant increase in active cathepsin L from 1 week to 3 weeks with 
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no significant differences between 3 and 12 weeks, suggesting a plateau of active 
protease amounts after 3 weeks. In contrast, we did not observe any significant changes 
in the amounts of active MMP-2 over time in either of these tissues (Figure 3.10a-f), and 
no differences in active proteases over time in cartilage (Figure 3.10g-j). These findings 
are generally consistent with previous studies showing increased cathepsin activity in 
aged animals [170]. However, it should be noted that, in this work, we normalized the 
amount of active protease in the injured tissue to the uninjured contralateral control at 
each time point, therefore removing the confounding factor of age and time from the 
main comparisons in this work, which examined effect of injury. 
In the supraspinatus muscle, significant upregulation of cathepsin L (associated 
with muscle atrophy in rats [110]) is observed at 1 week before obvious muscle 
fibrosis/atrophy could be observed at 3 weeks [19] (Figure 3.7). Furthermore in Figure 
3.8, we see significant upregulation of active cathepsin K in cartilage at 1 week prior to 
visible damage at later time points (12 weeks). Thus, the onset of protease activity 
upregulation may not necessarily correlate with visible signs of damage. Previous 
findings have linked overactive proteases to degenerative damage because they were 
found simultaneously. For example, MMP-2 and -9 upregulation was detected in the 
presence of increasing muscle atrophy in rats [110,126]. Additionally, it was confirmed 
that cathepsin K concentration correlated to osteoarthritic severity in the knees of mice 
[158]. However, this work shows that proteases may be upregulated before the 
development of visible tissue damage and could be used as a potential biomarker to 
indicate risk for downstream damage. Additionally, this suggests that protease 
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upregulation, while brief, may have lasting effects on joint tissue and provides targets for 
early treatment to reduce tissue damage after traumatic injury to the shoulder.  
By examining the temporal expression of proteases in multiple joint tissues 
simultaneously, this work begins to explore the biochemical relationship between acute 
damage to one tissue and eventual degradation of surrounding tissues. However, the 
cellular source of proteases has yet to be fully identified and are likely a combination of 
several tissue-resident cells, as well as cells recruited due to injury, as proteases released 
in one area can diffuse throughout the joint. Resident cells of the joint tissues, including 
tendon, muscle, cartilage, and synovium have all shown to be capable of producing 
proteases [63,110,131,158,171]. In addition to joint tissue cells, recruited inflammatory 
cells, such as macrophages and neutrophils, have the capacity to release proteases 
[67,68]. We have verified the presence of macrophages and neutrophils in the injured 
supraspinatus tendon in this animal model after 1 week (Figure 3.9) and have found 
increased levels of myloid cells, particularly macrophages, in the supraspinatus muscle at 
1 week after acute tendon injury in previous work [19].  Further investigation of the 
cellular source of these enzymes would help better understand the causes of the varied 
protease profiles observed in this work. 
Regardless, protease activity returned to baseline by 12 weeks following injury in 
both the supraspinatus tendon and supraspinatus muscle. This observation could be due to 
a general resolution of the acute inflammatory response over this time period. Prior work 
has shown inflammatory resolution is complete by 21 days following blunt dissection of 
Achilles tendon in rabbits [159]. In addition, this phenomenon could be caused, in part, 
by biological protease regulation, whereby proteases can both activate [112] and 
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cannibalize one another [132]. We have previously demonstrated cathepsin S has the 
ability to de-activate cathepsin K when present simultaneously [132]. Protease return to 
basal levels by 12 weeks also suggests their upregulation is a transient response to injury 
and that there may be a limited time window to prevent tissue degeneration through 
protease inhibition.  
Inherent limitations of this study include the animal model chosen. Humans and 
rats have similar shoulder anatomies, but rats are quadruped animals and thus do not 
experience mechanical loading in the same way [94]. Additionally, while chosen due to 
the fact that this animal model developed shoulder joint damage similar to that seen in 
humans [5,10,110,122,124], this is an acute injury, which is not identical to how damage 
develops in humans in the clinical setting. A sham surgery control would have allowed 
the ability to distinguish how the surgery itself, which includes splitting the deltoid 
muscle to visualize the rotator cuff, can contribute to joint tissue degeneration. We did 
not investigate protease activity within the synovium or the presence of protease 
inhibitors over time following injury, although current findings indicate that this would 
be an interesting future study. Lastly, this study did not directly determine the biological 
cause of the visible tissue damage seen in the animal model of acute rotator cuff tear. 
3.5 Conclusion 
This work demonstrates that tissue degeneration occurs in supraspinatus tendon, 
supraspinatus muscle and humeral head cartilage after transection of the supra- and 
infraspinatus tendons in a rat model of full-thickness rotator cuff tear, and that there is 
significant protease upregulation in all three tissues, each with different temporal profiles. 
Interestingly, increased protease activity was found at early time points in all tissues 
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tested, even though only the tendon was injured directly. Both cathepsin L and MMP-2 
activity were upregulated in supraspinatus tendon at 1 week in Figure 3.6, which 
coincided with visible damage. Conversely, supraspinatus muscle tissue experienced 
upregulated cathepsin L activity at 1 week with no obvious structural damage at this time 
point in Figure 3.7. Active cathepsin K and L were upregulated in cartilage 1 week after 
injury (Figure 3.8), and subsequent damage in the form of focal defects at 12 weeks 
following injury was found in ~half of all animals (Figure 3.4). A more comprehensive 
understanding of biochemical changes to joint tissue over time following rotator cuff tear 
will better inform ideal intervention times and treatments for each tissue. These results 
demonstrate concomitant degeneration in a number of rotator cuff tissues after traumatic 
injury and suggest that early intervention addressing multiple tissues simultaneously may 






CHAPTER 4  DEVELOPMENT OF NOVEL MICROFLUIDIC 
DEVICE FOR UNIFORM MICROPARTICLE FABRICATION 
FOR RELEASE OF BROAD, SMALL MOLECULE CATHEPSIN 
INHIBITOR, E-64 
4.1 Introduction 
 Cathepsins are a cysteine-family of proteases responsible for a variety of 
homeostatic functions throughout the body including extracellular matrix remodeling, 
bone resorption, and intracellular protein turnover [11]. However, upregulated cathepsins 
have been implicated in a variety of degenerative diseases, including atrophy of the 
tibialis anterior muscle [12], osteoarthritis of the knee [13], and tendinopathy [14,15]. 
Several clinical trials have investigated systemic delivery of cathepsin inhibitors as 
therapeutic treatments to reduce and halt tissue degeneration. However, systemic delivery 
results in healthy and diseased tissues experiencing equal exposure to the protease 
inhibitor treatment, which may prevent regulated proteases from performing their normal 
functions. Additionally, systemic delivery requires a very high amount of therapeutic 
molecules in order to achieve a detectable effect in the diseased tissue, which will only 
receive a small fraction of the initial dose [18]. Presently, all clinical trials utilizing 
cathepsin protease inhibitors have been abandoned due to severe side effects including 
headache, gastrointestinal disturbance, lung fibrosis, and skin lesions [16]. These severe 
effects are likely caused by inhibition of regulated cathepsins in healthy tissues. 
An alternative strategy to systemic delivery is employing the use of a biomaterial 
vehicle for localized delivery of inhibitor therapeutics to the site of disease or injury. 
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Microparticles are advantageous biomaterial vehicles because they are injectable, have 
the capacity to deliver a large quantity therapeutic drugs due to the high surface area to 
volume ratio, can be directly injected into the diseased tissue, and require substantially 
less drug compared to systemic delivery [18]. For example, mice suffering with sickle 
cell anemia were treated with daily systemic injection of E-64 at a concentration of 5 
mg/kg (~ 125 µg) [25], while our animal model of rotator cuff tear characterized in 
chapter 3 (Aim 1) would only require 4 µg of E-64 to achieve a 1:1 molar ratio with 
cathepsin L 7 days after injury. Additionally, our microparticle delivery platform would 
not require daily injections if microparticles are designed for sustained release of E-64. 
Our laboratory has extensively used microparticles for localized therapeutic 
delivery. For example, our group has previously shown a significant increase in the 
recruitment of anti-inflammatory cells in the supraspinatus muscle following injection of 
SDF-1a loaded microparticles in our rat model of rotator cuff tear [19]. Furthermore, our 
group previously used microparticles for localized delivery in an animal model of 
osteoarthritis [20]. We injected TSG-6 loaded microparticles into the joint space of the 
knee in a rat model of osteoarthritis and found significantly reduced cartilage 
degeneration following injury compared to soluble TSG-6 injections [20]. Additionally, 
the Botchwey laboratory has previously injected poly(DL-lactic-co-glycolic acid) 
(PLGA) microparticles for sustained release of small molecule FTY720 [172]. FTY720 
has been shown to recruit monocytes and stimulate wound healing [172]. They found that 
injection of FTY720-loaded PLGA microparticles into the supraspinatus muscle of a 
mouse model of rotator cuff tear resulted in decreased levels of supraspinatus muscle 
atrophy compared to unloaded PLGA microparticles [172]. Another group encapsulated 
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BMP-2 in alginate and PLGA microparticles to enhance bone regeneration [173]. They 
found significantly more new bone formation following BMP-2 loaded PLGA treatment 
compared to no treatment and BMP-2 release from a collagen–hydroxyapatite scaffold 
(accepted gold standard of treatment) [173]. Thus, localized delivery of therapeutic 
molecules via microparticle carrier has the potential to treat diseases and reduce severe 
side effects that have been seen in systemic delivery. 
There are many methods to fabricate microparticles for localized treatment, but 
microfluidic devices are becoming increasingly popular due to their distinct advantages. 
Advantages of using a microfluidic device platform include: fabrication of uniformly 
sized microparticles in a wide range of sizes [156], the ability to convert the entire 
polymer solution into microparticles, and the ability to incorporate additional 
biomolecules into the microparticle network. Taken together, fabricating microparticles 
with a microfluidic device reduces material waste, has a reduced number of fabrication 
steps, and reduces waste of potentially expensive therapeutics used for microparticle 
release.  
To fabricate microparticles with a microfluidic device two immiscible phases are 
used: the continuous phase and the discontinuous phases [26]. In a water-in-oil system, 
the continuous phase would consist of oil and the discontinuous phase would consist of 
the water soluble polymer solution. Microparticle size can be tuned by adjusting several 
parameters including continuous phase speed, discontinuous phase speed, and surfactant 
concentration. Previous work has shown that higher phase speeds cause increased shear 
stress on the microparticle droplet [26]. The increased shear stress causes more frequent 
discontinuous phase stream break-up and consequently generates smaller microparticles 
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[26]. When the microparticle droplet is smaller than the outlet, the force applied is 
negligible [26]. However, as the discontinuous phase is continuously injected via the 
syringe pump, the microparticle droplet will increase in size and the applied force will 
similarly increase [26]. The increased force on the microparticle droplet causes it to be 
pinched off from the tip of the needle [26]. Furthermore, microparticle size can be tuned 
by the amount of surfactant used in the system. It has previously been shown that particle 
size decreases with increasing amounts of surfactants [28]. Microfluidic devices that 
utilize immiscible phases to fabricate microparticles use surfactants to stabilize the shape 
of the microparticles and prevent coalescence of microparticles, which also ensures a 
smaller microparticle size [27]. 
E-64 (trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane) is a small 
molecule, broad inhibitor of the cysteine cathepsin family of proteases [39]. E-64 is the 
small molecule analog of the endogenous cysteine cathepsin inhibitor, cystatin C [38]. E-
64 has been shown to irreversibly bind cathepsins L, S, and K [39,40]. A previous study 
tested daily systemic injections of E-64 in a mouse model of sickle cell anemia, which 
develops characteristic osteoporosis caused by chronic upregulation of cathepsin K [25]. 
They found that treatment with E-64 improved trabecular bone density and mechanical 
properties of femurs compared to mice with untreated sickle cell anemia [25]. At present, 
therapeutic use of E-64 has been limited to soluble injections due to the inability to 
quantify E-64 in solution, which would be required for in vitro testing with a biomaterial 
carrier.  
Our laboratory and others have previously used poly(ethylene glycol) diacrylate 
(PEGDA) based microparticles for delivery of therapeutic drugs and proteins [19,20]. 
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PEGDA is attractive polymer that is commonly used in biomaterial applications because 
it is hydrophilic and can be tailored to achieve controlled release over a variety of 
timescales through changing polymer network properties and drug loading [139]. 
Previously in our laboratory, we have covalently attached dithiothreitol (DTT) to PEGDA 
to increase the susceptibility of the resulting ester bond for hydrolytic degradation [142]. 
Previous work has demonstrated that microparticle degradation rate is proportional to 
DTT levels and inversely proportional to polymer weight percentage (wt%) of the 
microparticle network [143]. It has been shown that slower degradation can result in 
therapeutic release over a longer period of time or an increase in total therapeutic released 
over time [134,143]. Similarly, increased polymer weight percentage in the microparticle 
formulation creates a smaller mesh size, which can delay release of the loaded therapeutic 
and generate sustained release over time [134]. Lastly, it has been shown that loading 
larger amounts of therapeutic drugs into biomaterials can cause an increase in overall 
release [134].  
 Given the perceived gap in sustained release capability for cathepsin inhibitors, 
the first objective of this aim was to develop and characterize a microfluidic device to 
fabricate uniformly sized PEGDA microparticle carriers. We characterized microparticle 
size, degradation time, and ability to incorporate biomolecules. To characterize range of 
microparticle size that could be achieved with our novel microfluidic device, we varied 
several parameters including continuous phase speed, discontinuous phase speed, and 
surfactant concentration in the continuous phase. To characterize microparticle 
degradation, we varied polymer weight percent and amount of DTT incorporated into the 
network. To determine if our microfluidic device had the ability to incorporate additional 
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biomolecules into the polymer network, we added fluorescently tagged heparin (as a 
model biomolecule) to the discontinuous phase prior to microparticle fabrication. We 
hypothesized that microparticle size would be inversely proportional to the speed of both 
the continuous and discontinuous phases. Additionally, we hypothesized that 40% span-
80 would yield significantly smaller microparticles compared to 20% span-80 with any 
given set parameters. Furthermore, we hypothesized that decreased polymer weight 
percentage and increased DTT concentration would result in faster degradation of 
microparticles over time. Decreased polymer weight percentage would require the fewest 
number of degradation events to achieve degradation [29] and the incorporation of 
increased amounts of DTT has been shown to increase the rate of hydrolytic degradation 
[143]. Lastly, we hypothesized that the addition of heparin into the discontinuous phase 
of our microfluidic device would result in incorporation of heparin into our PEGDA 
microparticles.  
The second objective of this aim was to characterize release of E-64 from 
microparticles. E-64 is a broad, small molecule cathepsin inhibitor and was used as a 
model therapeutic for this aim. In order to understand how our microparticle system 
could tune E-64 release, we varied several parameters including: initial amount of E-64 
loaded into the discontinuous phase, polymer weight percent, and amount of DTT 
incorporated into the network. Setting up a matrix of conditions to test the release of E-64 
will allow us to choose a set of parameters to use in our rat model of rotator cuff tear in 
chapter 5 (Aim 3). We hypothesized that E-64 release over 14 days could be tuned based 
on the aforementioned parameters. Specifically, we hypothesized that increased polymer 
weight percent would cause delayed diffusion of E-64 from microparticles and result in a 
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significant decrease in total E-64 released over 14 days. We hypothesized that increased 
DTT concentration would result in faster diffusion of E-64 out of microparticles due to 
larger spacing between polymer chains and result in overall greater amount of E-64 
released over 14 days. Lastly, we hypothesized that a greater initial loading of E-64 into 
the discontinuous phase would produce microparticles with a higher amount of E-64 and 
result in significantly more E-64 released over 14 days.  
4.2 Materials and Methods 
4.2.1 Poly(ethylene glycol) diacrylate (PEGDA) Synthesis and Characterization 
A 1:8 molar ratio of 3.4 kDa poly(ethylene glycol) (Sigma) to acryloyl chloride 
(AcCl, Sigma) was reacted in dichloromethane (DCM) solution as described previously 
[142]. Next, triethylamine (TEA, Sigma) was used as a catalyst to yield linear PEGDA by 
its addition in a dropwise fashion into a solution composed of a 1:1 molar ratio of TEA to 
AcCl. To determine the degree of PEGDA functionalization (number of acrylate groups), 
we performed proton nuclear magnetic resonance (1H NMR). PEGDA was reconstituted 
in deuterated H2O (Sigma) at a concentration of 10 mg/mL and run on a Bruker Avance 
III spectrometer at 400 Hz and analyzed using iNMR software as described previously 
[20,153].  
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4.2.2 Microfluidic Device and Microparticle Sizing2 
To construct the microfluidic device, a 30-gauge needle (BD) was bent at a 45° 
angle and was pierced through miniature ethylene-vinyl acetate (EVA) tubing 
(McMaster) such that the bent portion was parallel to the EVA tubing wall. We cut off 
the cap of a 1.7 mL microcentrifuge tube and using a razor blade cut out three areas to fit 
the EVA tubing and the 30-gauge needle. The device was sealed with epoxy resin 
(Sigma) to cover holes and prevent leaking. A schematic of our microfluidic device set 
up can be seen in the insert within Figure 4.1.  
The continuous phase consisted of mineral oil (VWR) and span-80 (Sigma). The 
discontinuous phase consisted of PEGDA, DTT (Sigma), and L0290 photoinitiator (TCI). 
The L0290 photoinitiator was dissolved in phosphate buffered saline (PBS, Fisher) to a 
final concentration of 20 mg/mL. PEGDA and DTT were resuspended in L0290 
photoinitiator and allowed to incubate at 37 °C for 30 minutes in the absence of light to 
allow for Michael Type addition crosslinking. Following this incubation, E-64 (Sigma) 
was added to the polymer solution and incubated at 37 °C in the absence of light for an 
additional 30 minutes. The polymer solution was loaded into a 1 mL syringe (Hamilton) 
and covered in foil to prevent light exposure and premature crosslinking.  
The discontinuous phase was injected into the EVA tubing via 30-gauge needle. 
Both the continuous and discontinuous phases were injected into the microfluidic device 
 
 
2 This protocol was developed with the Xia laboratory and was based on previously published work: Choi 
SW, Cheong IW, Kim JH, Xia Y. Preparation of uniform microspheres using a simple fluidic device and 
their crystallization into close‐packed lattices. Small. 2009 Feb 20;5(4):454-9. 
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via syringe pumps as can be seen in Figure 4.1. The EVA tubing was coiled under an 
ultraviolet (UV) lamp to allow the microparticles to crosslink, which is also labeled in 
Figure 4.1. To certify uniform crosslinking between trials, we ensured that the center of 
the coiled tubed registered a minimum intensity of 15 mW/cm2. The EVA tubing emptied 
into a 50 mL conical tube for microparticle collection.  
 
Figure 4.1: The benchtop set up of our novel microfluidic device platform. The 
discontinuous phase and continuous phase are injected into the microfluidic device 
via syringe pumps. The insert demonstrates how the microfluidic device is constructed. 
The 30-gauge needle is bent at 45 ° and inserted into the EVA tubing. The red dotted line 
indicates the puncture area that is sealed with epoxy resin to prevent leaking. The EVA 
tubing is coiled under the UV light source to ensure microparticle crosslinking and to 
reduce counter space. The EVA tubing empties into a 50 mL conical tube, where the 





EVA tubing coiled 














Once the discontinuous phase was spent, the collected microparticles were 
centrifuged at 2,000 xg for 5 minutes to force all microparticles to the bottom of the 
conical tube. The majority of the mineral oil and span-80 solution was removed with a 
serological pipette ensuring that the microparticle pellet was not disturbed. The 
microparticles were washed two times with pure mineral oil and gentle vortexing 
followed by centrifugation of 2,000 xg for 5 minutes. Lastly, microparticles were washed 
and resuspended in PBS. 
To determine the range of microparticle size that could be achieved with our 
microfluidic device, several parameter ranges were tested. The continuous phase speed 
was varied from 100 – 500 μL/min, while the discontinuous speed was varied from 1 – 5 
μL/min. Additionally, the amount of span-80 was tested at 20% and 40% of the 
discontinuous phase volume with all speed variables. Microparticles were imaged using 
light microscopy (Nikon TE2000) and sizing was determined using the measure plug in 
within ImageJ (NIH).  
4.2.3 Fabrication of Microparticles with Fluorescently-Tagged Heparin 
Heparin was functionalized with methacrylamide (Hep-MAm) in order to allow 
covalent crosslinking into the microparticle as described previously [37]. Briefly, 200 mg 
of heparin sodium salt from porcine intestinal mucosa (Millipore-Sigma) was 
resuspended in 10 mL of phosphate buffer (40 mg Na2HPO4 and 4.5 g NaH2PO4 in 100 
mL dH2O) under constant stirring with a stir bar and stir plate. After heparin dissolved 
into solution, 180 mg of sulfo-NHS (Millipore-Sigma) and 180 mg of APMam 
(Polysciences Inc.) were added to the heparin solution. After the sulfo-NHS and APMam 
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dissolved in solution, 150 mg EDC was added to the solution and the reaction was placed 
on ice under constant stirring. We allowed the reaction to proceed for 2 hours before 
adding another 150 mg of EDC to the heparin solution. After another 4 hours, the Hep-
MAm was dialyzed (Spectrum Labs) for two days, freeze dried (Labconco), and stored at 
-20 °C until use.  
Hep-MAm was fluorescently tagged with AlexaFluor633 (AF633, Invitrogen) in 
order to visualize glycosaminoglycan distribution within microparticles fabricated with 
our novel microfluidic device. Hep-MAm was dissolved in 0.1 M Na2HPO4 solution (pH 
= 6) at a10 mg/mL concentration and reacted with 10 mM EDC and 5.7 μM AF633 at 
room temperature for 90 minutes. Fluorescently tagged Hep-MAm (Hep-MAm-AF633) 
was subsequently dialyzed for two days, freeze dried, and stored at -20 °C using the same 
protocol as described above.  
For microparticle fabrication with our novel microfluidic device PEGDA and 
DTT were first resuspended in L0290 photoinitiator and allowed to incubate at 37 °C for 
30 minutes in the absence of light. Following this incubation, Hep-MAm-AF633 was 
added to the polymer solution and incubated at 37 °C in the absence of light for an 
additional 30 minutes. The microfluidic device was run as previously described in 
Section 4.3.1. PEGDA based Hep-MAm-AF633 microparticles were imaged using 
confocal microscopy (Zeiss 700). 
4.2.4 Microparticle Degradation 
 To assess degradation of microparticles fabricated with our novel microfluidic 
device we tested the following formulations: 10 wt% 5 mM DTT, 10 wt% 10 mM DTT, 
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20 wt% 5 mM DTT, and 20 wt% 10 mM DTT. We placed the microparticles of each 
formulation (N=3) in 1.7 mL low-binding tubes at 37 °C under constant agitation. At 
each degradation test time point the microparticles were vortexed thoroughly to ensure 
adequate mixing and 20 μL of solution containing microparticles was taken and pipetted 
onto a microscope glass side and covered with coverslip to slow evaporation of water 
during imaging. The presence of microparticles was observed and captured using light 
microscopy (Nikon TE2000). The solution used for imaging was replaced with an equal 
volume of PBS at each time point. 
4.2.5 Fluorogenic Substrate Assay: Z-FR-AMC and Cathepsin L 
To assess inhibitory capacity for cathepsin L, recombinant cathepsin L (R&D 
Systems) was used with Z-FR-AMC Fluorogenic Peptide Substrate Assay (R&D 
Systems). Preparation of reagents was performed according to manufacturer guidelines. 
To assess percent inhibition the following was prepared in a 96 well plate: 100 μL of 
undiluted E-64 microparticle supernatant (N=3-4), 20 μL of Z-LR-AMC stock, and 100 
μL of cathepsin L (concentration: 50 ng/mL) in reaction buffer. The positive control 
included 100 μL of PBS (the E-64 microparticle solution), 100 μL of cathepsin L in 
reaction buffer, and 20 μL Z-LR-AMC. The blank for the solution consisted of 100 μL 
reaction buffer (no cathepsin L), 100 μL PBS, and 20 μL Z-LR-AMC stock. The 
cathepsin L solution was added once all standard and sample wells were prepared 
because it is a continuous (non-terminal) assay. Per manufacturer guidelines, samples 
were incubated at room temperature for 1 hour prior to reading on a fluorescent plate 
reader at 380/460nm.  
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4.2.6 Fluorogenic Substrate Assay: DQ Gelatin and Cathepsin K 
To assess inhibitory capacity for cathepsin K, recombinant cathepsin K (Enzo) 
was used with a DQ Gelatin Fluorogenic Substrate Assay (Thermo). Preparation of 
reagents was performed according to manufacturer guidelines. To assess percent 
inhibition the following was prepared in a 96 well plate: 100 μL of undiluted E-64 
microparticle supernatant (N=3-4), 20 μL of DQ gelatin stock, and 100 μL of cathepsin K 
(concentration: 1.3 μg/mL) in reaction buffer. The positive control included 100 μL of 
phosphate buffer saline (the E-64 microparticle solution), 100 μL of cathepsin K diluted 
in reaction buffer, and 20 μL DQ gelatin. The blank for the solution consisted of 100 μL 
reaction buffer (no cathepsin K), 100 μL PBS, and 20 μL DQ gelatin stock. The cathepsin 
K solution was added once all standard and sample wells were prepared because it is a 
continuous (non-terminal) assay. Per manufacturer guidelines, samples were incubated at 
room temperature for 1 hour prior to reading on a fluorescent plate reader at 495/515 nm.  
To determine E-64 release, a standard curve of known amounts of E-64 was tested 
concurrently with supernatant samples and analyzed by fitting a one-phase decay line 
(Prism). Previous work in the Platt laboratory has demonstrated that a minimum of 5 
picomoles of cathepsin K per well is required to obtain an adequate signal on the DQ 
gelatin assay [132]. Thus, the E-64 standard curve tested varying molar ratios of E-64 to 
cathepsin K, including: 1:20, 1:10, 1:5, 1:1, 2:1, 5:1, 10:1, and 20:1. Samples calculated 
to be outside of the standard curve range when testing for inhibition were subsequently 
diluted and rerun to calculate release. For the purposes of testing the standard curve 
boundaries we also tested the following ratios of E-64 to Cathepsin K: 100:1, 200:1, 
500:1, and 1,000:1. 
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4.2.7 Fluorogenic Substrate Assay: Inhibition and Interference Assay 
To test the limits of the redesigned DQ gelatin Fluorogenic Substrate Assay, we 
tested the ability of each microparticle component and continuous phase component to 
individually inhibit cathepsin K. The microparticle components tested include PEGDA, 
DTT, and L0290. The amount of each component was calculated based on the makeup of 
the discontinuous phase used to make microparticles. Thus, we used the same amount of 
each component that would be present in solution if we could instantaneously degrade a 
single batch of microparticles. Additionally, we tested diluted amounts of mineral oil and 
span-80 to replicate poor washing. For the inhibition test, each component was treated 
identically to supernatant samples. The positive control included 100 μL of PBS, 100 μL 
of cathepsin K diluted in reaction buffer, and 20 μL DQ gelatin. The blank for the 
solution consisted of 100 μL reaction buffer (no cathepsin K), 100 μL PBS, and 20 μL 
DQ gelatin stock. The cathepsin K was added to each well at the same time because it is a 
continuous (non-terminal) assay. Per manufacturer guidelines, samples were incubated at 
room temperature for 1 hour prior to reading on a fluorescent plate reader at 495/515 nm.  
To distinguish whether the tested components were in fact inhibiting cathepsin K 
or potentially interfering with the assay, we conducted an interference assay. For this 
particular test each well first added DQ gelatin and cathepsin K in reaction buffer to each 
well. We allowed the reaction to proceed for 30 minutes at room temperature protected 
from light. After imaging the plate (495/515 nm) to establish baseline, we added the 
components to their respective test wells and immediately read the plate again to 
determine interference. The positive control wells were given an equal amount of PBS at 
the same time components were added to test wells. 
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4.2.8 E-64 Bioactivity and Release from Microparticles 
To assess release of E-64 from loaded microparticles, the microparticles were 
placed in 1.7 mL low-binding microcentrifuge tubes with a total volume of 0.5 mL on 
rotor at 37 °C. At Days 1, 2, 3, 5, 7, 10, and 14 the E-64 loaded microparticles were 
centrifuged and the supernatant was removed and frozen at -20 °C. An equal volume of 
PBS with calcium and magnesium ions replaced the supernatant volume at each time 
point. The supernatant bioactivity was tested with both cathepsin L and K as described in 
methods 4.4.2. Example calculations for E-64 release can be found in Appendix B. 
4.2.9 Statistical Analysis 
 To assess microparticle size as a function of continuous phase speed, 
discontinuous phase speed, and span-80 content we used a non-parametric ANOVA test 
and the Kruskal-Wallis post-hoc test (p≤ 0.05) in GraphPad. For analysis of microfluidic 
device component inhibition on cathepsin K in the DQ gelatin fluorogenic substrate assay 
we performed a one-way ANOVA and Tukey’s post-hoc test (p ≤ 0.05) in GraphPad. For 
analysis of microfluidic device component interference with the DQ gelatin fluorogenic 
substrate assay we performed a two-way repeated measures ANOVA and Tukey’s post-
hoc test (p ≤ 0.05) in GraphPad. For analysis of percent inhibition of unloaded 
microparticles vs E-64 loaded microparticles we performed two-way repeated measures 
ANOVA and Tukey’s post-hoc test (p ≤ 0.05) in GraphPad. 
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4.3 Results 
4.3.1 PEGDA Characterization 
The 1H NMR analysis demonstrated that the batch of PEGDA used in this body of work 
was ~55% functionalized.  
4.3.2 Microfluidic Device Size Characterization 
 A detailed schematic of the microfluidic device can be seen in Figure 4.1 and 
4.2a. Analysis of microparticle size showed that our microfluidic device could synthesize 
PEGDA microparticles ranging from approximately 25 to 400 μm (Figure 4.2d and 4.2e). 
In alignment with our hypothesis, we saw that microparticle size was inversely 
proportional to both the continuous and discontinuous phase speeds (Figure 2d and 2e). 
Interestingly, 40% span-80 yielded significantly smaller microparticles compared to 20% 
span-80 at a single speed (Figure 2d). The parameters ultimately chosen for E-64 release 
studies (discontinuous phase speed: 3 μL/min, continuous phase speed: 500 μL/min, and 
40% span-80) resulted in uniform size distribution of microparticles as seen in Figure 
4.2b with an average size of 69.6 ± 16.7 μm and a polydispersity index of 0.25.  
In terms of biomolecule incorporation, we added fluorescently labeled heparin 
(Hep-Mam-AF633) to the discontinuous phase prior to fabricating microparticles with 
our microfluidic device. We imaged the resulting microparticles with confocal 
microscopy. We detected fluorescently labeled heparin (Hep-Mam-AF633) within all 
microparticles fabricated with our novel microfluidic device as seen in Figure 4.2c. 
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4.3.3 Microparticle Degradation 
Microparticles were tested for degradation periodically over 77 Days (11 weeks) as seen 
in Figure 4.3. We found that only the 10 wt% 10 mM microparticles had completely 
degraded by Day 77, while all other formulations (10 wt% 5 mM DTT, 20 wt% 5 mM 
DTT, and 20 wt% 10 mM DTT) had not.  
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Figure 4.2: Microfluidic device schematic and characterization. (A) Schematic of our 
novel microfluidic device. (B) Histogram of microparticles synthesized with continuous 
phase speed of 500 μL/min and discontinuous phase speed of 3 μL/min with 40% span-
80. Phase contrast image of PEGDA microparticles. Scale bar = 100 μm. N=3 
microparticle batches. (C) PEGDA microparticles fabricated with fluorescently tagged 
heparin (AlexaFluor633-Hep-MAm). Scale bar = 100 μm. (D) Plot of microparticle 
diameter as a function of the discontinuous phase flow rate. The continuous flow rate was 
kept at 500 μL/min. N=3 microparticle batches. Error bars = standard deviation. (E) Plot 
of microparticle diameter as a function of the continuous phase flow rate with 20 and 
40% span-80. The discontinuous flow rate was kept at 3 μL/min. N=3 microparticle 
batches. Error bars = standard deviation. *p<0.05 = significantly different microparticle 
size compared to other speed with the same span-80 concentration. &p<0.05 = 
significantly different microparticle size compared to other span-80 concentration at the 
same speed.  
 

































































































Figure 4.3: Microparticles fabricated with our novel microfluidic device can be 
made to be fully degradable. Variable parameters tested include polymer weight percent 
(wt%) and dithiothreitol (DTT) concentration (mM). We found 10 wt% 5 mM DTT, 20 
wt% 5 mM DTT, and 20 wt% 10 mM DTT microparticles did not fully degrade by Day 




























4.3.4 E-64 Standard Curve with Cathepsin K and Cathepsin L 
We tested a standard curve of known amounts of E-64 on the DQ gelatin 
(cathepsin K) and Z-FR-AMC (cathepsin L) fluorogenic substrate assays. We found that 
cathepsin K and the DQ gelatin fluorogenic substrate assay generate an E-64 standard 
curve that can be fit to a one-phase decay trend line (Figure 4.4). Conversely, cathepsin L 
and the Z-FR-AMC fluorogenic substrate assay did not generate an E-64 standard curve 
that could be fit to a trend line (Figure 4.4). Thus, the DQ gelatin assay with cathepsin K 
was chosen to calculate E-64 release in subsequent experiments. While the entire 
standard curve shown below was used to find the one-phase decay equation, only samples 
with a fluorescent intensity reading at or above the standard curve value for 500 ng/mL 
were used to calculate release. Thus, if the cathepsin K activity signal was too high for a 
particular value, the sample was rerun at a higher dilution. 
 
Figure 4.4: DQ gelatin and Z-FR-AMC fluorogenic substrate assays yield different 
E-64 standard curves. Cathepsin K and the DQ gelatin fluorogenic substrate assay 
generate an E-64 standard curve that can be fit to a one-phase decay trend line (dotted 
line). Cathepsin L and the Z-FR-AMC fluorogenic substrate assay did not yield an E-64 
standard curve with an acceptable trend line. N=3-5. Error bars = standard deviation. 
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4.3.5 Inhibition and Interference Assays 
We tested the capacity of our microfluidic device components to individually 
inhibit cathepsin K and interfere with the DQ gelatin fluorogenic substrate assay. The 
discontinuous phase components included: PEGDA, DTT, and L0290 photoinitiator. The 
continuous phase components included: span-80 and mineral oil. We found that the total 
amount of PEGDA in our system has a maximum potential inhibitory effect of 38.1% ± 
0.07% compared to control. We found that the total amount of DTT in our system has a 
maximum potential inhibitory effect of 17.2% ± 1.13% compared to control. We found 
that the total amount of L0290 in our system has a maximum potential inhibitory effect of 
11.7% ± 1.56% compared to control. We found diluted span-80 remaining in our system 
(due to poor washing) has a maximum potential inhibitory effect of 17.6% ± 0.57% 
compared to control. We found diluted mineral oil remaining in our system (due to poor 
washing) has a maximum potential inhibitory effect of 1.55% ± 1.34% compared to 
control. Overall, all microfluidic device components except diluted mineral oil 
significantly inhibit cathepsin K activity relative to positive control (Figure 4.5a). 
We found that the addition of PEGDA to the DQ gelatin fluorogenic assay has the 
potential to decrease the fluorescent signal (interference) by 13.8% ± 0.28%. We found 
that the addition of DTT to the DQ gelatin fluorogenic assay has the potential to decrease 
the fluorescent signal by 13.3% ± 0.78%. We found that the addition of L0290 to the DQ 
gelatin fluorogenic assay has the potential to decrease the fluorescent signal by 14.7% ± 
0.57%. We found that the addition of diluted span-80 to the DQ gelatin fluorogenic assay 
has the potential to decrease the fluorescent signal by 29.1% ± 2.33%. We found that the 
addition of diluted mineral oil to the DQ gelatin fluorogenic assay has the potential to 
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decrease the fluorescent signal by 10.5% ± 0.99%. Overall, the addition of any 
component of our microfluidic device platform will cause interference of the fluorescent 
signal (Figure 4.5b).  
 
Figure 4.5: Components of microfluidic device have an effect on DQ gelatin assay 
fluorescent readings. (A) PEGDA, DTT, L0290, and diluted span-80 have a significant 
inhibitory effect on cathepsin K relative to the positive control (+ control) as indicated by 
the blue asterisk *p<0.05. (B) All components of our microfluidic device significantly 
interfere with the fluorescent signal in the DQ gelatin fluorogenic assay relative to the 
positive control (no inhibitor is present) indicated by the blue asterisk *p<0.05. N=3. 
Error bars = standard deviation. 
 
4.3.6 Released E-64 from PEGDA Microparticles Inhibit Cathepsin K and Cathepsin L 
 E-64 loaded microparticles inhibited cathepsin L and cathepsin K significantly 
more than unloaded microparticles (Figure 4.6). Microparticles alone have virtually no 
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Figure 4.6: E-64 released from PEGDA microparticles fabricated with our 
microfluidic device remains bioactive over 14 days. (A) Plot of cathepsin K inhibition 
(DQ Gelatin Assay) treated with E-64 released from PEGDA microparticles and 
supernatant from unloaded microparticle control. (B) Plot of cathepsin L inhibition (Z-
LR-AMC Fluorogenic Peptide Substrate Assay) treated with E-64 released from PEGDA 
microparticles and supernatant from unloaded microparticle control. N=3. *p<0.05. 
4.3.7 Microfluidic Device Can Synthesize Tunable Release of E-64 from Microparticles 
 To assess what affects E-64 release kinetics from our loaded microparticles we 
varied polymer weight percent (10 wt% and 20 wt%), DTT concentration (5 mM and 10 
mM), and initial E-64 loading amount (167 μg and 333 μg). We found that 20 wt% 
microparticles released greater amounts of E-64 compared to 10 wt% microparticles over 
14 days (Figure 4.7c). We found that incorporation of 10 mM DTT resulted in greater E-
64 release compared to 5 mM DTT in each polymer wt% group over 14 days (Figure 
4.7d). Lastly, we found that greater initial loading concentration resulted in greater 
release of E-64 in the 20 wt% groups (Figure 4.7e). However, the 10 wt% group did not 
show any differences in E-64 release based on initial loading concentration (Figure 4.7e). 


























































Figure 4.7: Microparticles fabricated with our microfluidic device can be tuned to 
alter release of E-64 by altering polymer weight percent, DTT concentration, and 
initial loading concentration. Microparticles were fabricated with a combination of 10 
or 20 polymer weight percent (wt%), 5 or 10 mM DTT, and an initial loading of 167 or 
333 μg E-64 as shown in the figure legend in the top left. All microparticles were 
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fabricated with 500 μL/min continuous phase and 3 μL/min discontinuous phase. (A) 
Percent inhibition of E-64 loaded microparticle supernatant at discrete time points. (B) E-
64 release from E-64 loaded microparticles at discrete time points. Release quantified in 
µg/mL (left) and µM (right). (C) E-64 release as a function of polymer weight 
percentage. In this column of graphs, the DTT concentration and initial loading 
concentration are kept constant. (D) E-64 release as a function of DTT concentration. In 
this column of graphs, the polymer weight percent and initial loading concentration are 
kept constant. (E) E-64 release as a function of initial loading concentration. In this 
column of graphs, the polymer weight percentage and DTT concentration are kept 
constant. 
4.4 Discussion 
The goals of this work were to develop and characterize a novel microfluidic 
device that could load and release therapeutic molecules. This study outlines the 
development process of a novel microfluidic device platform. We characterized that our 
novel microfluidic device has the capability to synthesize uniformly sized microparticles 
in a variety of sizes, which broadens their applicability to for many fields and 
applications. Additionally, we demonstrated that we can load therapeutic molecules into 
the discontinuous phase for incorporation into the microparticle network for sustained 
release without any additional steps. Furthermore, we outlined the redevelopment of a 
currently available fluorogenic substrate assay for detection of small molecule release.  
This work has contributed a novel microfluidic device platform that can 
synthesize uniformly sized microparticles in a variety of sizes (Figure 4.2). Our 
microfluidic device has the capacity to fabricate microparticles with a diameter between 
25 and 400 μm (Figure 4.2d and 4.2e), which is wider than size ranges accomplished with 
other microfluidic devices [26,156]. We found that microparticle size was inversely 
proportional to both discontinuous and continuous flow rates, which aligns with our 
hypotheses. As the continuous phase speed is increased, there is an increase in shear 
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stress imposed on a microparticle droplet, which is directly responsible for the reduction 
in microparticle size [26]. Similarly, in order to synthesize a range of microparticle sizes 
dependent on the speed of the discontinuous phase, there must be a large difference in 
flow rate between the two phases in order to achieve a substantial sheer force on the 
microparticle droplet [26].  
Our novel microfluidic device is similar to devices constructed in the Xia 
laboratory, which consist of poly(vinyl chloride) tubing, a syringe needle, and a glass 
capillary tube [26]. They have previously shown that microparticle size is inversely 
proportional to the continuous flow rate [26], which we also demonstrated in this work. 
However, they were not able to generate a wide variety of microparticle sizes by 
adjusting the discontinuous flow rate [26]. By their own admission, this was likely due to 
a relatively weak continuous phase net force in the system [26]. Essentially, the 
discontinuous and continuous flow rates were too similar and therefore could not 
generate a sufficient gradient of shear force on microparticle droplets [26]. However, in 
our novel microfluidic device platform, were able to generate a difference in speed of two 
orders of magnitude (3 µL/min vs. 500 µL/min) and fabricate microparticles between 24 
µm and 285 µm by varying the discontinuous phase speed alone.  
In addition to testing phase speed, we also tested surfactant concentration to 
modulate microparticle size. In our novel microfluidic device, there is a thermodynamic 
driving force towards homogenization of the system whereby all microparticles coalesce 
and minimize contact with the oil-based continuous phase [27]. To overcome this 
thermodynamic driving force, surfactants are added to stabilize microparticles. Without 
the addition of surfactants, when microparticle droplets come into close contact the 
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continuous phase between them will be depleted and allow the microparticle droplets to 
coalesce [27]. However, in the presence of surfactants on the two microparticle droplets, 
steric repulsion of the surfactant molecules will prevent the depletion of the continuous 
phase, which lengthens the time to continuous phase depletion and stabilizes both 
microparticles droplets against coalescence [27].  
Previous groups that have investigated surfactants in the context of microfluidic 
devices have found that microparticle stability increases with increasing amounts of 
surfactants, which result in microparticle sizes of decreasing size [28,155]. However, 
eventually with increasingly greater amounts of surfactant will cause a microparticle size 
plateau, at which point the microparticle droplet can no longer associate with any extra 
surfactant molecules. The surfactant threshold varies depending on microparticle droplet 
size, the surfactant used, and the size of the microfluidic device [28]. In this work, we 
found that 20% and 40% span-80 produced similarly sized microparticles, which was the 
opposite of our initial hypothesis. Thus, 20% and 40% span-80 are likely above the 
threshold for our particular system. More investigative work would need to be performed 
to find the threshold of surfactant concentration for our novel microfluidic device 
platform.  
We further characterized our novel microfluidic device beyond microparticle size 
range. We confirmed that our microfluidic device could fabricate microparticles capable 
of degradation (Figure 4.3). Specifically, we found that the 10 wt% 10 mM DTT 
microparticle formulation degraded prior to all other formulations, which aligns with our 
hypothesis that lower polymer weight percent and higher DTT concentration would result 
in the fastest degradation. Similarly, previous work has demonstrated that microparticle 
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degradation rate is proportional to DTT levels and inversely proportional to polymer 
weight percentage of the microparticle network [143]. This is due to a combination of 
factors. First, lower polymer weight percent creates a larger mesh size that allows greater 
swelling and thus more access to water and subsequent hydrolytic degradation. Similarly, 
the incorporation of DTT into the linear PEGDA network also causes a greater mesh size 
due to the increased distance between crosslinks. Furthermore, the incorporation of DTT 
into the PEGDA network increase the susceptibility of the resulting ester bond, which is 
the site of hydrolytic degradation [142]. Nevertheless, only a single formulation was able 
to fully degrade 77 days after fabrication. Thus, as designed our microparticles will 
remain at the site of injection longer than is necessary for therapeutic molecule release. 
Additionally, this suggests that degradation may not play a large factor in therapeutic 
molecule release. Thus, higher amounts of DTT can be incorporated into the 
microparticle network for faster degradation and potentially greater therapeutic molecule 
release. Previous work has demonstrated that release of loaded therapeutics can be 
modulated by the rate of hydrolytic degradation [134] and is therefore an important 
aspect to examine following changes to the microparticle polymer network.  
In addition to fabricating degradable PEGDA microparticles, we demonstrated 
that our microfluidic device has the capacity to fabricate microparticles with additional 
biomolecules. Expressly, we were able to fabricate PEGDA microparticles with heparin, 
a negatively charged glycosaminoglycan (Figure 4.2c). We used heparin as a model 
glycosaminoglycan, but it has been extensively used in biomaterials for the purpose of 
protein sequestration, protein release, protein conformation protection, and maintenance 
of protein bioactivity [19,20,35–37,153]. Other glycosaminoglycans of interest that may 
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be compatible with this system include hyaluronic acid (HA). HA can bind CD44 a 
transmembrane glycoprotein found on mesenchymal stem cells (MSCs) [174], which 
have been widely investigated to treat a variety of diseases ranging from diabetes to 
osteoporosis [175]. Additionally, other groups have demonstrated that integrin-binding 
peptides can be incorporated into microparticles for delivery of islet cells for the purpose 
of alleviating the symptoms of diabetes [156]. Delivery of islet cells within a 
microparticle carrier may allow them to remain undetected by the immune system, which 
would prolong their presence and therapeutic efficacy [156]. Lastly, we demonstrated 
that fluorescent tags such as AlexaFluor633 are compatible with our microfluidic device 
platform despite the use of UV light, which could be useful for in vivo tracking protocols 
of therapeutic drugs or cell-based deliveries.   
Initial trials of our microfluidic system for drug release included the addition of 
cystatin C into the discontinuous phase for incorporation into microparticles for in vitro 
release and eventual use in treating upregulated cathepsin proteases. However, we 
consistently detected very low release of cystatin C from our microparticles. Using 
fluorescently tagged cystatin C, we discovered that cystatin C predominately remained in 
the syringe after injection into the microfluidic device. Thus, cystatin C was not 
compatible with our microfluidic device and E-64, the small molecule analog of cystatin 
C was investigated for its potential use. The experimental outcomes with cystatin C are 
further described in Appendix A.  
To determine if E-64 was compatible with our microfluidic device platform, we 
used the standard protocol for the DQ gelatin and Z-FR-AMC fluorogenic substrate 
assays. We verified that our microfluidic device could fabricate microparticles loaded 
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with E-64 based on the inhibitory effect of microparticle supernatant. Additionally, we 
were able to confirm that bioactive E-64 was released over 14 days (Figure 4.6). 
However, in order to quantify E-64 release, we were required to construct a standard 
curve with cathepsin and E-64 that could be fit with trend line. Using the same E-64 
standard curve, we found that cathepsin L and cathepsin K interact with E-64 differently 
(Figure 4.4). Specifically, we found that cathepsin K interacts with E-64 such that a one-
phase decay trend line could be fit and E-64 release from microparticles could be 
calculated. On the other hand, interaction with cathepsin L resulted in clustered values at 
lower E-64 concentrations and the inability to fit a trend line. This difference aligns with 
the literature that has shown that cathepsin L and cathepsin K have different dissociation 
constants with both their substrates and their inhibitors [11,108,176]. Thus, cathepsin K 
and the DQ gelatin fluorogenic substrate assay was chosen to quantify E-64 release from 
microparticles. 
 In addition to designing a novel microfluidic device, we also redesigned a 
currently available fluorogenic substrate assay for E-64 quantification in solution. E-64 is 
the small molecule analog of the endogenous cysteine cathepsin inhibitor [38] and has 
been shown to irreversibly bind cathepsins L, S, and K [39,40]. Previously, therapeutic 
use of E-64 had been limited to systemic, soluble injections of known amounts because 
E-64 is unable to be quantified by other standard methods [24,25]. For example, 
antibodies to E-64 do not exist and therefore an ELISA cannot be used. E-64 does not 
contain a ring structure and therefore cannot be detected using an absorbance reading on 
a plate reader [41]. Furthermore, E-64 cannot be detected on Bicinchoninic Acid assay 
(BCA) or Pierce Coomassie assay, which are to commonly used protein quantification 
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assays. Thus, the reinvention of the currently available DQ gelatin fluorogenic substrate 
assay allows our laboratory and others to more easily quantify E-64 release from 
biomaterial carriers. 
Following the redevelopment of the currently available DQ gelatin fluorogenic 
substrate assay, we also examined the limitations of this new method. We found that 
microparticle components and fundamental materials required of our microfluidic device 
have the ability to obstruct our desired data measurements in large quantities. For 
example, PEGDA, a widely adopted polymer for biomaterial applications can inhibit 
cathepsin K upwards of 40% over control (Figure 4.5). However, this high level of 
inhibition was seen under conditions that mimicked complete and instantaneous 
degradation of our microparticles. Because our microparticles did not degrade within the 
time we were investigating E-64 release, the inhibition we detected was therefore due to 
E-64 and is not an artifact of the assay. However, this demonstrates that it is important to 
include unloaded microparticles as a control group. This will allow the user to distinguish 
the effect of the therapeutic inhibitor alone and the effect of the biomaterial carrier alone. 
Thus, an experiment that requires successive sample addition would require extra 
controls in order to obtain an accurate reading. 
After developing a method to quantify E-64 release from our microparticles, we 
found that modifying polymer weight percentage, DTT concentration, and initial E-64 
loading concentration (Figure 4.7) could tune overall E-64 release from microparticles. 
On average, increased polymer weight percent, DTT concentration, and initial loading 
resulted in the highest amount of E-64 released from microparticles fabricated with our 
microfluidic device. We had hypothesized that increased polymer weight would result in 
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a decrease in E-64 release due to a greater likelihood that E-64 would be unable to move 
as quickly through the polymer network and diffuse into solution, similar to previous 
findings [134]. However, we found that higher polymer weight percent resulted in greater 
amounts of E-64 released. While this was counterintuitive, this could be the result of how 
E-64 oriented itself with PEGDA in the discontinuous phase and during fabrication. E-64 
could have caused interference with PEGDA crosslinking and resulted in a polymer 
network with a greater mesh size. Additionally, the higher polymer weight percent would 
likely prevent E-64 from coming into frequent contact with the syringe prior to 
introduction into the microfluidic device. This would result in less adsorption of E-64 to 
the syringe and therefore a greater amount of E-64 incorporated into microparticles. 
Similarly, lower polymer weight percent would increase the probability of E-64 
adsorption to the syringe which could cause it to be removed from the discontinuous 
phase and ultimately result in lower E-64 release. Additionally, hypothesized that 
increased DTT concentration would result in greater amount of E-64 released over 14 
days. We found that higher amounts of DTT did in fact result in greater amounts of E-64 
release in both the 10 wt% and 20 wt% groups. The incorporation of higher amounts of 
DTT create a larger mesh size and it therefore is less interference of E-64 diffusion out of 
the microparticle. Lastly, we hypothesized that a greater initial loading of E-64 into the 
discontinuous phase would result in significantly more E-64 released over 14 days,  
similar to previous literature [134]. However, only the 20 wt% 10 mM group released 
more E-64 with a greater initial loading. The other groups did not demonstrate significant 
differences in E-64 release relative to initial loading. This could be due to E-64 
adsorption to the syringe as mentioned previously.  
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Other work in the field has used injectable hydrogels to deliver small molecule 
matrix metalloproteinase inhibitor ß-cyclodextrin, which had been conjugated to 
hyaluronic acid [177]. They found that conjugation of the small molecule inhibitor 
resulted in sustained release over 21 days [177]. This system is different from the one 
described in this chapter in several ways. First, this group tested the release of ß-
cyclodextrin from a hydrogel instead of microparticles. The surface area to volume ratio 
is different between hydrogels and microparticles and thus it is not surprising that the 
results are different. Secondly, they conjugated ß-cyclodextrin to the polymer network 
and we used entrapment. Release of ß-cyclodextrin was dependent on the introduction of 
hyaluronidase, while our method was exclusively hydrolytically degradable. Thus, the 
release kinetics of each system are inherently different.  
Another group investigated co-release of small molecule anti-convulsant, 
adenosine, with protease inhibitor thylenediamine tetraacetic acid (EDTA) from protease-
degradable silk films [178]. EDTA has been shown to inhibit calcium dependent cysteine 
proteinase and some matrix metalloproteinases [178]. They demonstrated that percent 
release of small dyes from silk films increases with increasing concentrations of 
proteinase type XIV [178]. EDTA were encapsulated in the silk films and achieved 100% 
release over 5 days regardless of proteinase type XIV presence, which indicates that its 
release is dictated by diffusion alone [178]. In the presence of proteinase type XIV,  
adenosine release without co-release of EDTA results in 100% release over 4 days, while 
the addition of EDTA co-release achieves 100% release over 8 days in the presence of 
proteinase type XIV [178]. Relative to our system, we achieved sustained release of a 
small molecule inhibitor over a longer period of time (5 vs. 14 days). Ultimately, this 
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system differs from our platform in several ways and cannot be directly compared. They 
encapsulated EDTA in a natural silk film, which is sensitive to protease-mediated 
degradation while we encapsulated E-64 in a hydrolytically degradable synthetic PEG-
based microparticles.  
4.5 Conclusion 
 In conclusion, we have created a novel microfluidic device platform that can 
synthesize uniformly sized PEGDA-based microparticles in a wide range of sizes. 
Advantages of our fabrication system include reduced material waste due to 
monodispersed size distribution and ability to tune hydrolytic degradation based on initial 
polymer formulation. In addition, this work outlined the redevelopment of the DQ 
Gelatin Fluorogenic Substrate Assay for better assessment of E-64 released from 
biomaterial carriers. Together, the technologies developed in this chapter allow small 
molecule, broad cathepsin inhibitor E-64 to be released in a sustained manner for 
localized inhibition, causing a reduction in off-target effects, and decrease the amount of 
E-64 needed for therapeutic efficacy compared to systemic delivery. Together, the work 
in this chapter allowed us to synthesize an injectable therapeutic treatment that can be 
used to probe the proteolytic network in our rat model of rotator cuff tear in chapter 5 
(Aim 3). The 20 wt% 10 mM DTT 333 µg was the formulation that best matched the 
required level of E-64 release over one week required based on zymogram quantification 




CHAPTER 5  THE EFFECT OF SUSTAINED RELEASE OF E-64 
ON RELATIVE AMOUNTS OF ACTIVE PROTEASES FOUND 
WITHIN TENDON FOLLOWING FULL-THICKNESS ROTATOR 
CUFF TEAR IN A RAT MODEL 
5.1 Introduction 
Half of all shoulder injuries involve partial or full-thickness tear of one or more 
tendons of the rotator cuff [60]. Studies estimate that 34% of the population has a partial 
or full-thickness tendon tear in at least one shoulder [1]. Additionally, the risk of rotator 
cuff tear increases with age [1]. Patients living with a rotator cuff tendon tear experience 
pain, arm weakness, and limited mobility of the shoulder joint. Following rotator cuff 
tear, all tissues of the joint are affected. Specifically, the torn tendon becomes 
disorganized and loses collagen content [64]. The associated muscle experiences 
mechanical unloading and consequently becomes atrophied and develops fatty deposits 
between muscle fibers, which reduce muscle strength [70,179]. Lastly, the tendon tear 
disrupts the force balance of the shoulder joint and the articular cartilage of the 
glenohumeral joint is at an increased risk of developing osteoarthritis [5]. 
Surgical reattachment is often recommended for full-thickness tears and partial 
tears that have traversed 50% or more of the tendon [180,181]. To perform surgical re-
attachment, a bone tunnel is formed in the humeral head with a drill and the tendon is 
anchored to the humeral head with a suture. Surgical reattachment of the torn tendon 
primarily reestablishes the force balance of the rotator cuff but does not reverse 
degeneration present at the time of treatment. Surgically reattached tendons have 
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documented re-tear rates ranging from 30-94% [6,7]. One study found that the most 
common mode of reattachment failure (19 of 22 total) was the tendon pulling away from 
intact sutures on the humeral head [79]. Thus, investigation into preventing or reducing 
tendon degeneration could improve surgical reattachment outcomes.  
While degenerative damage seen after rotator cuff tear has been extensively 
documented, the biochemical processes that contribute to this extracellular matrix (ECM) 
degeneration are not fully known. As mentioned in previous chapters, families of 
proteases are responsible for a variety of homeostatic functions. Specifically, cathepsins 
and matrix metalloproteinases (MMPs) are responsible for extracellular matrix 
remodeling, bone resorption, and intracellular protein turnover [11,118,182]. Upregulated 
cathepsins and MMPs have been observed in a variety of degenerative diseases including 
tendinopathy, muscle atrophy, osteoarthritis [10,14,15,38,104,110,122–126,183]. 
Resident cells of the rotator cuff tissues (tendon, muscle, cartilage, and synovium) have 
been shown to release cathepsin and MMP proteases, which could contribute to the 
resulting degenerative damage [63,67,68,110,131,158,171]. An acute tear in one or more 
of the rotator cuff tendons causes an inflammatory response, which recruits neutrophils 
and macrophages to the site of injury [66]. Neutrophils and macrophages at the site of 
injury secrete proteases for the purpose of clearing debris, wound healing, and tissue 
remodeling [67–69]. Prolonged protease upregulation could be detrimental to tendon 
health and lead to degeneration. Thus, developing a treatment to inhibit upregulated 
proteases could preserve tendon tissue, aim in tendon healing, and also reveal information 
about how proteases contribute to tissue degeneration after rotator cuff tear.  
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In chapter 3 (Aim 1) of this work we used a rat model of rotator cuff tear to assess 
degenerative damage in joint tissues and characterize active proteases (both cathepsin and 
MMP families) spatially and temporally between the onset of injury and the 
manifestation of tissue degeneration. In tendon, we found significantly more active 
cathepsin L 1 week after injury and significantly more MMP-2 at 1 and 3 weeks after 
injury. Additionally, we detected significant cellular infiltration of inflammatory cells 
(macrophages and neutrophils) and significant degenerative changes in tendon 1 week 
after injury. This suggested that prolonged upregulation of proteases, possibly secreted by 
infiltrating inflammatory cells, could play a role in the degeneration of the supraspinatus 
tendon after rotator cuff tear. Overall, chapter 3 (Aim 1) provided target times for 
therapeutic intervention and a timeframe to probe for degenerative changes in each tissue. 
Thus, we used tendon as a model tissue in this study to investigate protease inhibitor 
treatment to decrease active cathepsin levels following an inflammatory injury (rotator 
cuff tear).   
Several clinical trials have investigated systemic delivery of cathepsin inhibitors 
as therapeutic treatments to reduce or halt tissue degeneration [16]. Drawbacks of 
systemic delivery include non-specific inhibition of proteases (which can normal 
interrupt homeostatic functions) and high levels of therapeutic drugs required to achieve 
detectable effect in the diseased tissue (which will only receive a small fraction of the 
initial dose) [18]. Presently, all clinical trials utilizing cathepsin protease inhibitors have 
been abandoned due to severe side effects including headache, gastrointestinal 
disturbance, lung fibrosis, and skin lesions [16]. An alternative strategy to systemic 
delivery is employing the use of a biomaterial vehicle, such as that developed in chapter 4 
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(Aim 2) of this thesis, for localized delivery of inhibitor therapeutics to the site of disease 
or injury. 
The objective of this aim was to understand how the proteolytic network the 
tendon tissue responds to local release of a cathepsin inhibitor (E-64) within the tendon 1 
week after injury.  The hypothesis of this aim is that sustained release of E-64 in vivo 
from PEG-based microparticles in the supraspinatus tendon will result in significantly 
less active cathepsin proteases after rotator cuff tear compared to injury only, soluble E-
64 treatment, and unloaded microparticle treatment. Previous work has shown that active 
cathepsin proteases can cleave and activate MMPs [31] and chapter 3 (Aim 1) of this 
thesis demonstrated that cathepsins and MMPs were simultaneously active and 
upregulated in tendon after rotator cuff tear. Thus, we hypothesize that decreased levels 
of active cathepsin proteases will also result in significantly less active MMP proteases.  
5.2 Materials and Methods 
5.2.1 Fabrication of Microparticles for Tendon Injection Practice 
The PEGDA used to fabricate microparticles in this chapter was from the same 
batch used in chapter 4. See section 4.2.1 for detailed methods on PEGDA synthesis and 
characterization. Additionally, see section 4.2.2 for detailed methods on the construction 
of the microfluidic device. For this particular method, DTT was not added into the 
discontinuous phase. 
Following fabrication of nondegradable 20 weight percent (wt%) PEGDA 
microparticles, they were subsequently stained with aniline blue dye (5 mg/mL) and 
gently vortexed. The microparticles were centrifuged at 2,000 xg for 5 minutes and 
 115 
excess aniline dye was removed with a serological pipette. The microparticles were 
repeatedly washed with phosphate buffered saline (PBS, Fisher) until the solution was 
clear, but the microparticles remained blue. In order to load the greatest number of 
microparticles into the syringe for injection, the microparticles were centrifuged down 
and excess volume was removed prior to syringe loading. Microparticles (volume: 10 µL) 
were taken up in 0.3 mL insulin syringes (BD) for injection.  
5.2.2 Tendon Injection Practice 
Rats maintained by the Physiological Research Laboratory (PRL) were obtained 
to practice tendon injections. Practice rats were similar in age and weight relative to 
previous studies [30]. Rats were euthanized with CO2 prior to inducing the rotator cuff 
tear injury. Rotator cuff injury was induced using a previously established method in 
chapter 3 (Aim 1) [19,30,88], which can be found in section 3.2.1. After transection of 
the deltoid muscle to visualize the rotator cuff tendons, we used curved forceps under the 
supraspinatus tendon to elevate the tendon for better visualization and stabilize the tendon 
for better injection handling. We injected our nondegradable, 20 wt% aniline blue stained 
PEGDA microparticles into and along the tendon, such that the angle of the needle was 
nearly parallel to the tendon. Additionally, the use of curved forceps prevents the tendon 
from immediate retraction after transection and allowed for visual verification of aniline 
blue loaded microparticle within tendon. After injection, the supraspinatus and 
infraspinatus tendons were transected. The same procedure was done on the contralateral 
side prior to tissue isolation for histology. Macroscopic images of the supraspinatus 
tendon after aniline blue loaded PEGDA microparticle injection were taken with a 
DinoXcope camera (Dino-Lite Digital Microscope). 
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5.2.3 Tendon Injection Histology 
The left and right supraspinatus muscles were isolated with their respective 
tendons. The muscles were fixed with 4% paraformaldehyde for 45 minutes at room 
temperature and washed with PBS for 10 minutes. The muscles were subsequently 
incubated in increasingly concentrated sucrose solutions with optical cutting temperature 
compound (OCT). The muscles were first incubated in 0% sucrose base solution (100 mL 
10x PBS, 100 mL OCT, 800 mL) for 30 minutes under vacuum. The muscles were 
incubated in 10% and 20% sucrose solutions for 30 minutes each under vacuum. Muscles 
were transferred to histology molds and covered with 100% OCT compound overnight 
under vacuum. The following day, muscles in their histology molds were frozen down. 
First, a metal beaker was filled with 2-methylbutane and placed into a Styrofoam cooler 
filled with ethanol. Dry ice was added to the ethanol and the entire system was allowed to 
equilibrize for at least 30 minutes. The histology molds were placed inside the metal 
beaker and allowed to float until the topmost layer of OCT turned white. The histology 
molds were subsequently submerged in the 2-methylbutane for an additional 5 minutes 
and stored at -80 °C overnight. Supraspinatus tendon/muscle was cross sectioned in 10 
µm slices using a cryostat (CryoStar NX70, Thermo Fisher) and stained with 
hematoxylin and eosin (H&E) (Richard Allan Scientific). Tissue sections were imaged 
using light microscopy (Nikon TE2000). 
5.2.4 Fabrication of Microparticles with Fluorescently-Tagged E-64 
The PEGDA used to fabricate microparticles in this chapter was from the same 
batch used in chapter 4. See section 4.2.1 for detailed methods on PEGDA synthesis and 
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characterization. Please refer to section 4.2.2 for detailed methods on the construction of 
the microfluidic device. For this particular method, we fabricated 20 wt% 10 mM 
microparticles loaded with 333 µg of fluorescently tagged E-64, which is outlined in 
section 4.2.2. Lastly, microparticles were loaded into syringes described in section 5.2.1. 
E-64 was fluorescently tagged with IRDye 800 CW Protein Labeling Kit (Licor). 
A vial of E-64 (1 mg, Millipore-Sigma) was resuspended at a final concentration of 40 
mg/mL and well mixed over low heat. In a low-binding tube 25 µm of E-64, 5 µm of 
potassium phosphate buffer, and 20 µm of dye was added and incubated at room 
temperature protected from light for 2 hours. This reaction was performed at a 1:10 molar 
ratio of dye to E-64 to ensure that any detected dye was bound to a molecule of E-64. 
Because the dye molecule is larger than E-64, separating free dye would not be possible. 
Following incubation, E-64 was sterile filtered (0.22 µm filter, Costar) and stored at -20 
°C until use.  
To allow for synthesis of sterile microparticles, after the microfluidic device was 
created on the bench top,  it was run with 70% ethanol from both ends for a minimum of 
15 minutes in a biosafety cabinet. All microparticle components were sterile filtered (0.22 
µm filter, Costar) at 10,000 xg for 3 minutes, while mineral oil was sterile filtered and 
span-80 was autoclaved. Microparticles were washed and resuspended in sterile PBS and 
loaded into syringes (reference section 5.2.1) in the biosafety cabinet to ensure sterility. 
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5.2.5 In vivo Release of Tagged E-64 
Rotator cuff injury was induced using a previously established method in chapter 
3 (Aim 1) [19,30,88], which can be found in section 3.2.1. Tendons were injected as 
previously described in section 5.2.2. [184] 
Following rotator cuff injury, both rat shoulders were shaved for better depth 
penetration on the near infrared microscope. Fluorescence measurements were taken at 
Days 0 (immediately after wound closure), 1, 3, 5, 7, 14, and 21 and the animals were 
allowed to recover after each time point. Near infrared (NIR) images of the supraspinatus 
tendon were captured using the Dixon laboratory custom NIR imaging system [184–186]. 
The NIR system consists of an EMCCD camera (Evolve eXcelon, Photometrics), a 
stereo-microscope (Olympus), and a xenon arc lamp (Sutter Instrument Company). Also, 
the stero-microscope is equipped with NIR band pass excitation and long pass emission 
filters. Fluorescence images were captured at 0.63x magnification at various time points 
with fixed camera exposure time of 250 ms for soluble tagged E-64 and 2,000 ms for 
tagged E-64 loaded microparticles using the MicroManager software. Using a custom 
MATLAB (Mathworks) code, the region of interest (ROI) for each image was 
determined by isolating the 5% most intense pixels. The pixels within the ROI were 
subsequently averaged to obtain the mean fluorescence intensity. Data points were fitted 
to a mono-exponential function (Origin software): f(t) = y0 + A * exp(-t/t), where y0 is 
the offset, t is time, A is normalized fluorescence at t = 0, and t is time constant. Due to 
the large difference in exposure time between the soluble and microparticle groups, 
relative background was subtracted prior to creating the heat maps. 
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5.2.6 Fabrication of Microparticles for Surgical Procedure 
The PEGDA used to fabricate microparticles in this chapter was from the same 
batch used in chapter 4. See section 4.2.1 for detailed methods on PEGDA synthesis and 
characterization. Please refer to section 4.2.2 for detailed methods on the construction of 
the microfluidic device. For this particular method, we fabricated 20 wt% 10 mM 
microparticles loaded with 333 µg of E-64, which is outlined in section 4.2.2. Lastly, 
microparticles were loaded into syringes described in section 5.2.1. 
5.2.7 Surgical Procedure and Outcome Measure Time Points 
Rotator cuff injury was induced using a previously established method in chapter 
3 (Aim 1) [19,30,88], which can be found in section 3.2.1. Refer to section 5.2.2 for 
details on tendon injection protocol.  
The treatments for this study included: E-64 loaded microparticles, soluble E-64 
injection, and unloaded microparticles. Soluble E-64 injection was equal to expected E-
64 release from loaded microparticles over 1 week based on in vitro release 
quantification outlined in Chapter 4 (Aim 2). All treatments were compared to injury only 
(historical data) [30]. A single time point (1 week) was chosen for this study based on 
previous data from Chapter 3 (Aim 1) that demonstrated significantly more active 
cathepsin L and MMP-2 proteases in injured tendon at 1 week [30].  
5.2.8 Multiplex Gelatin Zymography 
Refer to section 3.2.5 for details on supraspinatus tendon isolation and multiplex 
gelatin zymography methods.  
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5.3 Results 
5.3.1 Tendon Injection Practice 
 Initially we aimed to inject our aniline blue loaded PEGDA microparticles into 
the entire length of the supraspinatus tendon. However, after several dissections, we 
learned that the supraspinatus tendon anatomy is not perfectly conserved between 
animals. Specifically, we found the supraspinatus tendon could be so deep that it was flat 
against the scapula or more shallow and in the middle of the supraspinatus muscle. There 
is no way to determine the supraspinatus tendon anatomy prior to dissection.  Thus, due 
to the variable anatomy of the supraspinatus tendon within the muscle, it is incredibly 
difficult to consistently inject into the length of the tendon.  
 Consequently, we instead aimed to inject and therefore treat the proximal third of 
the tendon, which is visible during the surgical procedure, which can be seen in Figure 
5.1a. To verify that microparticles can be repeatedly injected into the proximal third of 
the tendon during the rotator cuff tear surgery, we used aniline blue loaded PEGDA 
microparticles in our practice rats. Figure 5.1a shows the intact supraspinatus tendon after 
injection with aniline blue loaded PEGDA microparticles, but before transection. Figure 
5.1b shows the supraspinatus tendon after aniline blue loaded PEGDA microparticle 
injection and transection. The supraspinatus tendon and muscle after dissection is 
captured in Figure 5.1c.  
 After aniline blue loaded PEGDA microparticle injection and subsequent isolation 
of the supraspinatus muscle (attached to the supraspinatus tendon), we prepared the tissue 
for cryosection. We performed an H&E stain on cross sections of our supraspinatus 
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tendon/muscle at various depths, seen in Figure 5.1d. The H&E stain allowed us to 
distinguish regions of the supraspinatus tendon/muscle. As can be seen in Figure 5.1, 
regions 1 and 2 are purely tendon tissue, while regions 3 and 4 contain both tendon and 
muscle tissue. Interestingly, the aniline blue loaded PEGDA microparticles took up the 
hematoxylin stain therefore could be visualized and quantified. In total, we found that 
93% of all sections contained at least 1 microparticle. Furthermore, we found that regions 
1 and 2 had an average of 5.2 ± 2.6 microparticles/section, while regions 3 and 4 had an 
average of 10.1 ± 6.8 microparticles/section. 
 
Table 5.1: Tendon Injection Practice Microparticle Quantification 
Percentage Of Histological Sections That 
Contained At Least 1 Microparticle 93 % 
Average Number Of Microparticles In 
Sections 1 And 2 
(Tendon Only Regions) 
5.2 ± 2.6 microparticles/section 
Average Number Of Microparticles In 
Sections 3 And 4 
(Tendon And Muscle Regions) 




Figure 5.1: Aniline blue loaded PEGDA microparticles were successfully injected 
into the medial third of the supraspinatus tendon. (A) Macroscopic image of the 
supraspinatus tendon after aniline blue loaded PEGDA microparticle injection, but before 
transection. (B) Macroscopic image of the supraspinatus tendon after aniline blue loaded 
PEGDA microparticle injection and transection. (C) Macroscopic image of dissected 
supraspinatus tendon/muscle after aniline blue loaded PEGDA microparticle injection. 
(D) Schematic of supraspinatus tendon anatomy within supraspinatus muscle (adapted 
from Miranda, et al. American Journal of Roentgenology. 2019). The numbers on  the 
schematic correspond to the histological sections of the supraspinatus tendon/muscle 
stained with H&E beneath. Scale bar = 100 µm. N=8 supraspinatus tendon/muscles 
analyzed. N=15 sections per supraspinatus tendon/muscle were imaged and quantified. 
100 μm
2 3 41




5.3.2 In vivo Release of Tagged E-64 
Soluble injection of tagged E-64 could not be detected within the rotator cuff after 
Day 1, which can be seen in the representative heat map in Figure 5.2a and the 
quantification in Figure 5.2d. Conversely, signal from tagged E-64 injected in 
microparticles could be detected in all  animals at Day 21 (Figure 5.2e). However, there 
was very large variability between animals, which is demonstrated by the two 
representative heat maps in Figure 5.2b and 5.2c. Additionally, three animals injected 
with tagged E-64 microparticles (rats 1, 2, and 5) demonstrated high detectable levels 
after a period of low detection which can be seen in Figure 5.2e. Two-way ANOVA 
analysis showed that there was a significant difference between tagged E-64 injected in 
soluble form versus in loaded microparticles (p = 0.0387). Specifically, we were able to 
detect tagged E-64 at the site of injection significantly longer when injected via 
microparticles compared to soluble injection. Additionally, there was significantly higher 




Figure 5.2: Tagged E-64 loaded in microparticles remains in the rotator cuff 
significantly longer than soluble tagged E-64. (A) Representative images of detected 
tagged soluble E-64 in the rotator cuff over time. (B) Representative images of detected 
tagged E-64 loaded microparticles in the rotator cuff over time. (C) Quantification of 
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tagged E-64 detection in rats injected with soluble tagged E-64 or tagged E-64 loaded 
microparticles. (D) Detection of tagged E-64 microparticle injection variability between 
rats. N=5. *p<0.05. 
5.3.3 Cathepsin Multiplex Gelatin Zymography of Supraspinatus Tendon 
 Active cathepsin L was detected in pH4 and pH6 cathepsin zymograms between 
37 and 25 kDa (Figure 5.3a-f) 1 week after injury in all tendons (including injured and 
uninjured contralateral control tendons). Densitometric analysis revealed significantly 
more active cathepsin L in injured supraspinatus tendon with E-64 microparticle 
treatment compared to uninjured contralateral control (Figure 5.3a and 5.3d). 
Densitometric analysis revealed significantly more active cathepsin L in injured 
supraspinatus tendon with soluble E-64 treatment compared to uninjured contralateral 
control (Figure 5.3b and 5.3d). Densitometric analysis revealed significantly more active 
cathepsin L in injured supraspinatus tendon with unloaded microparticle treatment 
compared to uninjured contralateral control (Figure 5.3c and 5.3d). Furthermore, we 
found that treatment with E-64 loaded microparticles yielded a 6 fold increase in active 
cathepsin L levels relative to uninjured contralateral control (Figure 5.3e). Similarly, we 
found that soluble E-64 treatment resulted in a 2.6 fold increase in active cathepsin L 
levels relative to uninjured contralateral control (Figure 5.3e). The unloaded 
microparticle group was included as a biomaterial control to isolate the contribution of 
microparticles alone to changes in relative levels of active cathepsin L. Injury and 
treatment with unloaded microparticles resulted in a 3 fold increase in active cathepsin L 
levels relative to uninjured contralateral control (Figure 5.3e). Additionally, we found 
proteases at high molecular weights in both cathepsin pH 4 and pH6 zymograms. 
However, bands with a molecular weight higher than 75 kDa were not analyzed due to 
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the inability to correctly identify the protease associated with these bands. For 
completeness, we included historical densitometric data of active cathepsin L following 
injury alone (no treatment), which was discussed in chapter 3 (Aim 1). We did not find 
any significant changes in active cathepsin L levels following any treatment relative to 
historically injury alone data (Figure 5.3d and 5.3e). 
 Cathepsin zymograms at pH 6 did not detect any active cathepsin K at the 
expected molecular weight of 75 kDa (Figure 5.4). However, active cathepsins at high 
molecular weights were detected (Figure 5.4). Their identity could not be determined 
without additional analysis with western blot. 
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Figure 5.3: Cathepsin multiplex gelatin zymography shows significant increase in 
active cathepsin L proteases after injury regardless of treatment. (A) Cathepsin pH4 
zymogram of tendons treated with E-64 loaded microparticles (E-64 MP). (B) Cathepsin 
pH4 zymogram of tendons treated with soluble E-64. (C) Cathepsin pH4 zymogram of 
tendons treated with unloaded microparticles (UL MP). (D) Densitometric quantification 
of active cathepsin L following all treatments. (E) Densitometric quantification of active 
cathepsin L following all treatments normalized to respective uninjured contralateral 
controls. Recombinant cathepsin L was used as zymography control. N=6. *p<0.05. Error 
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Figure 5.4: Cathepsin multiplex gelatin zymography shows no active cathepsin K 
after injury regardless of treatment. (A) Cathepsin pH6 zymogram of tendons treated 
with E-64 loaded microparticles (E-64 MP). (B) Cathepsin pH6 zymogram of tendons 
treated with soluble E-64. (C) Cathepsin pH6 zymogram of tendons treated with 
unloaded microparticles (UL MP). Recombinant cathepsin K was used as zymography 
control. N=6. 
 
5.3.4 MMP Multiplex Gelatin Zymography of Supraspinatus Tendon 
 Pro- and mature MMP-2 were detected in MMP zymograms (Figure 5.5a-c) 
between 50 and 75 kDa 1 week after injury in all tendons (including injured with 
treatment tendons and uninjured contralateral control tendons). Densitometric analysis 
revealed significantly more active MMP-2 in injured supraspinatus tendon with E-64 
microparticle treatment compared to uninjured contralateral control (Figure 5.5a and 
5.2d). Densitometric analysis revealed significantly more active MMP-2 in injured 
supraspinatus tendon with soluble E-64 treatment compared to uninjured contralateral 
control (Figure 5.5b and 5.5d). Densitometric analysis revealed significantly more active 
MMP-2 in injured supraspinatus tendon with unloaded microparticle treatment compared 
to uninjured contralateral control (Figure 5.5c and 5.5d). Furthermore, we found that 
treatment with E-64 loaded microparticles yielded an 8 fold increase in active MMP-2 
levels relative to uninjured contralateral control (Figure 5.5e). Similarly, we found that 
soluble E-64 treatment resulted in a 5.5 fold increase in active MMP-2 levels relative to 
uninjured contralateral control (Figure 5.5e). The unloaded microparticle group was 























changes in relative levels of active MMP-2. Injury and treatment with unloaded 
microparticles resulted in a 13 fold increase in active MMP-2 levels relative to uninjured 
contralateral control (Figure 5.5e). Bands with a molecular weight higher than 75 kDa 
were not analyzed due to the inability to correctly identify the protease associated with 
these bands. Additionally, we found active proteases at low molecular weights (~37 kDa) 
in all MMP zymograms. For completeness, we included historical densitometric data of 
active MMP-2 following injury alone (no treatment), which was discussed in chapter 3 
(Aim 1). We did not find any significant changes in active MMP-2 levels following any 
treatment relative to historically injury alone data (Figure 5.5d and 5.5e). 
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Figure 5.5: MMP multiplex gelatin zymography shows significant increase in active 
MMP-2 proteases after injury regardless of treatment. (A) MMP zymogram of 
tendons treated with E-64 loaded microparticles (E-64 MP). (B) MMP zymogram of 
tendons treated with soluble E-64. (C) MMP zymogram of tendons treated with unloaded 
microparticles (UL MP). (D) Densitometric quantification of active MMP-2 following all 
treatments. (E) Densitometric quantification of active MMP-2 following all treatments 
normalized to respective uninjured contralateral controls. Recombinant MMP-2 used as 
control. N=6. *p<0.05. Error bars = standard deviation. 
5.4 Discussion 
Following the identification of active proteases in supraspinatus tendon after 
rotator cuff tear in chapter 3 (Aim 1) and developing a microfluidic device platform for 
the fabrication of microparticles to locally deliver protease inhibitor, E-64, chapter 4 
(Aim 2) we began the work to test our treatment in our rat model of rotator cuff tear in 
this study. First, we found that we could consistently inject microparticles into the 
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infrared imaging, we found that soluble injection of tagged E-64 cleared the 
supraspinatus tendon area after 1 day following injection, while we were able to detect 
tagged E-64 loaded in microparticles out to day 21. Third, we found that treatment with 
E-64 loaded microparticles did not cause a significant decrease in active cathepsin L in 
supraspinatus tendon 1 week after injury and treatment. Additionally, active cathepsin L 
levels following treatment with soluble E-64 and unloaded microparticles was not 
significantly different from treatment with E-64 loaded microparticles.  
In the process of practicing tendon injection, we found that injection into the 
length of the supraspinatus tendon is technically difficult due to differences in tendon 
anatomy between animals. While examining other work that has targeted rotator cuff 
tendons for injection-based therapies, we found the employed methods of these groups 
described various injection protocols including injection into the subacromial space, the 
supraspinatus muscle, or simply into the rotator cuff repair site [42–45]. While the 
objective of all of these studies was to treat rotator cuff tendons, injection into adjacent 
tissues suggests that these groups also found that consistent injection into the length of 
tendon was technically challenging. Thus, we were required to modify our surgical 
approach in order to test how the injection of E-64 loaded microparticles influenced the 
regulation of active proteases exclusively in supraspinatus tendon following rotator cuff 
tear. 
Hence, we modified out strategy and found we could consistently inject into the 
proximal third of the supraspinatus tendon. Thus, we decided to inject, treat, and analyze 
only the proximal third of the supraspinatus tendon after rotator cuff tear. As can be seen 
in Figure 5.1a, the aniline blue microparticles are located within the proximal third of the 
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tendon after injection and remain there following transection (Figure 5.1b) and isolation 
(Figure 5.1c). Overall, we found that 93% of the sections from the proximal third portion 
of the injected supraspinatus tendon contained at least 1 microparticle. Therefore, we 
confirmed that our modified approach was sufficient to test our hypothesis that areas of 
the injured supraspinatus tendon that received sustained E-64 treatment via microparticle 
delivery would subsequently demonstrate a significant decrease in active cathepsin 
levels. 
We tested the in vivo release of tagged E-64 following injection into the 
supraspinatus tendon in soluble form or loaded into microparticles. We found that tagged 
E-64 injected in soluble form was unable to be detected after 1 day, while tagged E-64 
loaded into microparticles could be detected up to 21 days after injection. These results 
demonstrated that soluble injection of tagged E-64 is cleared from the rotator cuff area 
soon after injection and therefore cannot have a prolonged effect on injured tissue. 
However, injection of tagged E-64 loaded in microparticles was detected for 3 weeks 
after injection into the supraspinatus tendon. This prolonged residence in the rotator cuff 
would be necessary for localized, sustained release of E-64 to inhibit upregulated 
proteases following injury. 
However, as can be seen in Figure 5.2e there was very large variability between 
animals. This wide variability could have been caused by various factors. NIR imaging is 
limited by tissue depth, such that the accuracy of tagged E-64 detection decreased with 
increased tissue depth. The supraspinatus tendon is located beneath the trapezius, deltoid, 
and supraspinatus muscles [70,187,188]. While the trapezius and deltoid muscles were 
considered sufficiently thin by our laboratory having limited knowledge of the NIR 
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system, subsequent tissue dissection revealed to Dixon laboratory collaborators that this 
platform was not compatible with our rat model of rotator cuff tear. Essentially, released 
tagged E-64 migrating towards the surface of the skin will result in a much higher signal 
compared to equal quantities of tagged E-64 in the much deeper supraspinatus tendon. 
This limitation is likely the leading cause for the high variability of tagged E-64 detected 
in our rat model of rotator cuff tear. Even if perfect supraspinatus tendon injection was 
achieved, microparticles could still have the opportunity and means to migrate away from 
the injection site during subsequent movement by the animals over 3 weeks.  
In particular, rats 3 and 4 demonstrated steady decay of tagged E-64 detection, 
while rats 1, 2, and 5 demonstrated an increase in tagged E-64 detection after an initial 
decrease in signal. This could be possible if rats 3 and 4 had microparticles that moved 
towards the surface of the skin and released E-64 in a more expected manner. However, 
microparticles injected into rats 1, 2, and 5 could have remained at the injection site, 
beneath several layers of muscle and the increase in tagged E-64 detection was the result 
of several waves of E-64 release reaching the surface of the skin. Previously, NIR 
imaging has been used to image lymphatics in the knee, which are located beneath the 
skin and therefore are not limited by tissue depth and are easily imaged [184]. While NIR 
imaging is very sensitive and can detect low levels of tagged protein, it is limited by 
tissue depth [185]. Previous work with tissue phantoms in the Dixon laboratory have 
documented that their NIR imaging platform cannot accurately detect signal located 
deeper than 6 mm away from imaging source [185]. An alternative imaging platform that 
has been used by other groups is the In Vivo Imaging System (IVIS). IVIS imaging has 
been previously used to demonstrate exponential decay of tagged VEGF and BMP-2 
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proteins from biomaterial carriers [22,189]. While IVIS is not limited by tissue depth in 
small animals including rats and mice, it requires substantially larger quantities of tagged 
protein for detection [19]. Thus, groups have the option of injecting tagged proteins at a 
significantly higher dosage than therapeutically necessary in order to achieve IVIS 
detection, but it is possible that the therapeutic dosage and the detectable dosage would 
have different in vivo release profiles. Thus, as used previously neither imaging platform 
is compatible with our system. An alternative recommendation in order to accurately 
capture tagged E-64 in vivo release from soluble injection or microparticle injection 
includes performing several terminal procedures. Specifically, we would induce injury 
and inject tagged E-64 treatments as before, but instead of performing a longitudinal 
study, we would euthanize rats at pre-determined time points. Euthanizing the rats would 
allow us to remove the deltoid and trapezius muscles in order image the supraspinatus 
muscle without being limited by NIR depth penetration. 
In these studies, we tested E-64 in a soluble form and loaded in a microparticle 
vehicle to inhibit active cathepsin proteases. As a control, we also tested unloaded 
microparticles. In contrast to our hypothesis, all groups resulted in significantly more 
active cathepsin L relative to their uninjured contralateral controls regardless of treatment 
(Figure 5.3g). Additionally, no treatment resulted in significantly less active cathepsin L 
relative to untreated injury alone (historical data). Although these results are unexpected, 
the proteolytic network is incredibly complex and there are several inherent limitations of 
our zymography analysis. Previously, it was generally accepted that E-64 inhibits 
cathepsin proteases via covalently binding to the cathepsin active site [40]. However, 
more recently it has been shown that E-64 can disassociate from cathepsins during the 
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zymography process, which could allow an inhibited cathepsin to be reactivated in the 
zymogram, leading to a “false positive” level of activity [39]. Additionally, zymography 
alone does allow us to identify the high molecular weight bands seen in our zymograms 
to include in our quantification. Lastly, zymography analysis of the tendon requires 
breakdown of extracellular matrix proteins and lysis of tenocytes and any other cells 
associated, thus does not allow us to determine if active cathepsin L is upregulated 
intracellularly or extracellularly. The main purpose of our E-64 treatments was to inhibit 
active cathepsin proteases in the extracellular space to reduce tendon degeneration. The 
dosage of E-64 delivered is not enough to trigger endocytosis of E-64 [190], therefore 
intracellular cathepsin L would be unaffected by our therapeutic treatment, but would be 
quantified in our zymograms similarly to extracellular cathepsin L and potentially mask 
the effects of our E-64 treatment. Thus, if detected cathepsin L is predominately located 
intracellularly, our treatment could still result in a decrease in tendon degeneration 
despite no detectable differences in active cathepsin levels compared to injury alone.  
While zymography analysis is important in understanding how E-64 may be 
affecting upregulated cathepsins, extensive further analysis is required to fully understand 
the potential effects of our E-64 loaded microparticle treatment in our rat model rotator 
cuff tear. Zymography can identify active proteases, but western blot analysis has the 
capacity to identify the total amount of proteases regardless of activity, which would 
include inactive procathepsins. A series of western blots could identify changes in 
cathepsin levels, which may not be detected with zymography. Additionally, performing 
western blots would allow us to identify the high molecular weight bands seen in our 
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zymograms to include in our quantification and thus, more accurately quantify levels of 
active cathepsins between treatments. 
As mentioned previously, zymography does not distinguish intracellular versus 
extracellular cathepsins. Thus, we can perform in situ zymography [162] or 
immunohistochemistry with DQ gelatin [38] on histological tendon sections to garner a 
better understanding of where cathepsin proteases are upregulated to gain a better 
understanding of how our E-64 treatment may have influenced proteases after injury. 
Additionally, zymography does not provide any information on the source of the active 
proteases (resident tenocytes versus infiltrating inflammatory cells). Thus, performing in 
situ zymography [162] or immunohistochemistry with DQ gelatin [38] would provide 
more information on the source of the active proteases, which may be useful in 
developing tailored therapies in the future. Additionally, in parallel, the histological 
tendon sections could also be used to assess tendon degeneration following treatment. 
Should there be a decrease in supraspinatus tendon degeneration, it would indicate that a 
sufficient amount of extracellular cathepsin proteases were inhibited by our E-64 
treatment, which was unable to be detected by zymography. Histological analysis of 
tendon including hematoxylin and eosin staining and second harmonic generation would 
allow us to observe any morphological changes in tendon structure and collagen 
alignment [30].  
Previous examination of supraspinatus tendon after rotator cuff tear injury 
demonstrated significant upregulation of MMP-2 in addition to cathepsin L with 
significant tendon degeneration 1 week after injury (chapter 3, Aim 1)  [30]. In the 
absence of regulation, the destructive nature of MMPs would completely degrade the 
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extracellular matrix proteins that constitute tendon. MMP-1 activity has been shown to be 
significantly greater in human supraspinatus tendon following rupture [122] and MMP-1 
and -3 have been shown to be upregulated within synovial fluid following rotator cuff 
tendon tear in humans [123]. Furthermore, MMP expression can be readily increased in 
response to stimuli such as inflammatory cytokines [130] and can be secreted by 
inflammatory cells such as macrophages [67]. While E-64 is purely a cathepsin inhibitor, 
previous work has demonstrated that cathepsins have the capacity to cleave and activate 
MMPs [31]. Thus, investigating MMP-2 activity provide information on how these two 
families of proteases interact following rotator cuff tear. Similar to cathepsin zymograms, 
the MMP zymograms showed significantly more active MMP-2 in all groups relative to 
their uninjured contralateral controls regardless of treatment (Figure 5.5d). Despite 
evidence that cathepsins can cleave MMPs, because cathepsin proteases were similarly 
upregulated regardless of the E-64 treatment, we are unable to draw any conclusions 
about cross-activity between these two families of proteases.   
There were a variety of potential confounding factors in this study that likely 
contributed to the lack of evidence of cathepsin inhibition in vivo. While the tendon 
injection practice images demonstrate that we could consistently inject our microparticles 
into the tendon of a euthanized rat, the zymography analysis was performed on rats that 
had been given an injection and allowed to recover and survive for 1 week after injury. It 
is possible the E-64 loaded microparticles did not remain in the tendon in every rat for the 
entire 1 week after injury and treatment. This is further supported by the large variability 
seen in the in vivo release of tagged E-64 (Figure 5.2) and suggests that the high 
variability between animals treated with E-64 loaded microparticles could be due to 
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microparticle migration differences. To mitigate this confounding factor, we could add 
immobilization of the injured forelimb for the duration of the 1 week study. Previous 
work has demonstrated increased tendon healing following massive rotator cuff tear and 
immobilization with either botulinum toxin A (Botox) injections or cast immobilization 
[44].  
 
Figure 5.6: Quantification of active protease divided by date of surgery suggests it 
may be a contributing factor to variability. 
Additionally, Figure 5.6 demonstrates that the rats themselves could be an 
additional source of variation. As can be seen in Figure 5.6a, in rats treated with E-64 
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clear divide between the first and second surgery date despite the fact that the animals 
were delivered together and not treated differently. Interestingly, in this set of studies we 
see a general increase in the amount of active cathepsin L found in uninjured contralateral 
control tendons compared to our historical data (injury alone) seen in Figure 5.6a. The 
differences between uninjured contralateral control tendons injected with E-64 loaded 
microparticles is further exacerbated in Figure 5.6b when active cathepsin L levels in 
injured tendon were normalized. Interestingly, we did not see similar division in the rats 
treated with soluble E-64 or unloaded microparticles, which likely contributed to the low 
variability seen in Figure 5.6b.  
Furthermore, a potential limitation of this final study is the E-64 dosage. The 
amount of injected E-64 used in this final study (both in soluble and loaded microparticle 
form) was based on the amount of active cathepsin proteases found in the supraspinatus 
tendon 1 week after rotator cuff tear in chapter 3 (Aim 1). However, we do not know the 
relative amounts of active proteases between injury and 1 week. As shown in chapter 4 
(Aim 2), the majority of release occurs within 5 days, thus it is possible that there was an 
insufficient dose of E-64 by the 1 week time point that would yield significant inhibition 
of cathepsin proteases.  
Lastly, our injection protocol could be further improved by adding ultrasound 
imaging to our injection protocol. The Soslowsky laboratory has previously used 
ultrasound imaging to perform dry needling procedures on rat supraspinatus tendons 
without performing an open surgery [191]. The use of ultrasound imaging could be used 
to guarantee injection in the length of supraspinatus tendon for treatment throughout the 
tendon tissue. Additionally, the ultrasound imaging protocol could also be used for 
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precise injection and treatment into the most proximal portion of the supraspinatus 
muscle. It has been shown that the supraspinatus muscle undergoes degenerative changes 
asymmetrically, such that the muscle closest to the tendon and humeral head insertion 
will develop degenerative changes first and propagate to the more medial portions over 
time [192]. Lastly, the addition of ultrasound imaging would allow for repeated injections 
into the supraspinatus tendon or muscle because we would not be required to re-open up 
the animal. 
5.5 Conclusion 
This work is the first step in investigating protease contribution to joint tissue 
degeneration after rotator cuff tear. We established that we could consistently inject 
microparticles into the proximal third of the supraspinatus tendon in our rat model of 
rotator cuff tear and found that in vivo release of E-64 from microparticles is highly 
variable, which can affect the efficacy of our localized treatment. While our treatment 
with E-64 loaded microparticles did not yield reduced levels of active proteases, 
additional work is warranted to better determine the cellular source of active proteases 
and the localization of proteases (intra vs. extracellular) to improve the efficacy of our 
microparticle delivery treatment. After further refinement of this animal model, such a 
system could be used to probe the role of protease inhibition in both tendon degeneration, 




CHAPTER 6  CONCLUSIONS AND RECOMMENDATIONS 
6.1 Summary 
Rotator cuff tears account for half of all shoulder injuries [60]. It is estimated that 
34% of the population has a partial or full-thickness tear [1]. The risk of rotator cuff tear 
increases with age, such that over 50% of people over 60 years old have a partial or full-
thickness rotator cuff tear in at least one shoulder [1]. Patients suffering from a rotator 
cuff tendon tear experience pain, arm weakness, and limited mobility of the shoulder 
joint. If left untreated, a partial tear will likely propagate to a full-thickness tendon tear 
[61], while an untreated full-thickness tendon tear will eventually cause degeneration of 
the associated muscle, articular cartilage, and underlying subchondral bone of the 
shoulder [47].  
Currently available treatment strategies for patients that have suffered a rotator 
cuff tendon tear include regimented nonsteroidal anti-inflammatory drugs (NSAIDs), 
physical therapy, and eventually surgical reattachment of the torn tendon. However, 
surgical reattachment  of torn rotator cuff tendons does not reverse degeneration present 
at the time of surgery. Furthermore, instance of tendon re-tear following surgical 
reattachment has been found to correlate to muscle degeneration (muscle atrophy and 
fatty infiltration) at the time of surgery [76–78] and there are documented re-tear rates 
ranging from 30-94% [6,7]. Additionally, it has been shown previously in humans that 
the most common mode of reattachment failure is the reattached rotator cuff tendon 
pulling away from intact sutures on the humeral head [79]. Thus, degeneration of both 
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rotator cuff tendons and muscles may be contributing factors to surgical reattachment 
failure (tendon retear). 
While resulting degeneration caused by a torn rotator cuff tendon is clear, the 
exact biochemical processes that cause this degeneration is unknown. A possible cause 
for the extensive joint tissue degeneration observed following rotator cuff tear is the 
prolonged activation of proteases. Proteases are specialized enzymes whose primary 
function is to degrade proteins. Of particular interest are cysteine cathepsins and matrix 
metalloproteinases (MMPs), which play a role in many facets of homeostasis within the 
human body including extracellular matrix remodeling, bone resorption, and intracellular 
protein turnover [9–11]. However, these two families of proteases have also been 
observed to be upregulated in a variety of degenerative diseases in orthopaedics, 
including atrophy of the tibialis anterior muscle [12], osteoarthritis of the knee [13], and 
tendinopathy [14,15]. Upregulated proteases have been implicated in a variety of 
musculoskeletal diseases, which makes protease inhibitors an appealing potential 
treatment.  
Several protease inhibitors have been tested in human clinical trials to treat 
dysregulated cathepsins and MMPs, but all have been abandoned due to serious off-target 
effects including headache, gastrointestinal disturbance, lung fibrosis, and skin lesions 
[16,17]. Thus far, clinical trials have utilized systemic delivery of protease inhibitors, 
which act upon all encountered proteases equally, regardless of its role in normal 
homeostasis or disease progression. An alternative strategy to systemic delivery is 
employing the use of a biomaterial vehicle for localized delivery of inhibitor therapeutics 
to the site of disease or injury. Limiting treatment to the diseased or injured tissue would 
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provide necessary treatment without deleterious side effects. Microparticles are a 
frequently used biomaterial vehicle for therapeutic drug or protein delivery [134] because 
they can be injected directly into the tissue of choice.  
The goal of this dissertation work was to understand how proteases contribute to 
joint tissue degeneration (tendon, muscle, and cartilage) after rotator cuff tear. 
Understanding the spatial and temporal distribution of upregulated proteases after rotator 
cuff tear can best inform therapeutic treatments to prevent degeneration, which would 
result in improved surgical outcomes after rotator cuff tear re-attachment surgery. First, 
using a rat model of rotator cuff tear that has been shown to replicate degenerative 
damage seen in humans [23], we investigated active proteases in each joint tissue 
(tendon, muscle, and cartilage) over time. Second, we designed a novel microfluidic 
device to fabricate uniformly sized microparticles that can be loaded with protease 
inhibitors for subsequent use in vivo. Also, we reinvented a currently available 
fluorogenic substrate assay for the detection of E-64 (a broad, small molecule cathepsin 
inhibitor), which was our desired therapeutic. Lastly, we tested our E-64 loaded 
microparticles system on supraspinatus tendon tissue in our rat model of rotator cuff tear 
as a test bed to elucidate the effect of sustained release of a broad cathepsin inhibitor on 
active proteases.  
In chapter 3 of this dissertation, we used a rat model of massive rotator cuff tear 
injury to identify active, upregulated proteases in joint tissues (supraspinatus tendon, 
supraspinatus muscle, and humeral head cartilage) over time. Overall, we found that the 
temporal profiles of cathepsins and MMPs were regulated differently. Specifically, 
cathepsins were more active in the first week in all three tissues, while MMP-2 was 
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upregulated in supraspinatus tendon at 1 and 3 weeks, upregulated in supraspinatus 
muscle only at 3 weeks, and never significantly upregulated in humeral head cartilage. 
Additionally, we found that significant protease upregulation did not necessarily coincide 
with manifestation of visible tissue damage. While all three joint tissues had significant 
upregulation of proteases 1 week after injury, only the supraspinatus tendon had 
developed degenerative changes at that time point. We did not identify significant 
degeneration in the supraspinatus muscle or humeral head cartilage until 3 and 12 weeks 
after injury respectively. Overall, we demonstrated that our rat model of massive rotator 
cuff tear could mimic degenerative changes seen in humans in all three joint tissues, 
which could be used as a test bed for therapeutic treatments that aim to reduce and 
manage joint tissue degeneration prior to surgical reattachment of torn rotator cuff 
tendons. Additionally, characterization of the spatial and temporal profiles of cathepsin 
and MMP proteases provided a baseline to test protease inhibitor therapies in our rat 
model of massive rotator cuff tear. 
In chapter 4 of this dissertation we developed and characterized a novel 
microfluidic device. We determined that our microfluidic device could fabricate 
uniformly sized microparticles in a variety of sizes ranging from 25 to 400 µm. 
Additionally, our microfluidic device platform could covalently incorporate biomolecules 
such as heparin into microparticles. Crosslinkers such as DTT could also be added to our 
fabricated microparticles to allow for hydrolytic degradation. Furthermore, we 
redeveloped a currently available fluorogenic substrate assay for quantification of E-64 in 
solution. Additionally, we found that microparticle components can have varying effects 
on cathepsin K inhibition and interference with fluorescent readings. We found that E-64 
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loaded into the discontinuous phase of our novel microfluidic device was incorporated 
into the resulting microparticles and retained the ability to inhibit cathepsins K and L 
over at least 14 days. In addition, we found that we could vary E-64 release by varying 
polymer weight percentage (wt%), DTT concentration, and initial loading of E-64.  
Specifically, we found that microparticles with higher polymer weight percentage and 
DTT concentration released more E-64 over time. Interestingly, only one formulation 
demonstrated higher E-64 release with greater initial loading of E-64 in the discontinuous 
phase. In sum, we found that 20 wt% microparticles with 10 mM DTT and an initial 
loading of 333 µm released the greatest amount of E-64 over 14 days. Therefore, we 
chose this formulation for our subsequent studies.  
In chapter 5 of this dissertation we tested our E-64 loaded microparticles in our rat 
model of massive rotator cuff tear. We found that the anatomy of the supraspinatus 
tendon in rats is complex and variable between animals. Thus, we were unable to perform 
consistent injection into the length of the supraspinatus tendon in our rat model of rotator 
cuff tear. However, we found we could consistently inject microparticles into the 
proximal third of the supraspinatus tendon, which we visualized with H&E staining and 
light microscopy. Additionally, we tested the in vivo release of tagged E-64 in soluble 
form and loaded into microparticles. We found that tagged E-64 injected in soluble form 
was unable to be detected after 1 day, while tagged E-64 loaded into microparticles could 
be detected out to 21 days after injection. While tagged E-64 was detectable significantly 
longer when loaded into microparticles, there was very large variation between rats. 
Finally, we tested our E-64 loaded microparticles in our rat model of massive rotator cuff 
tear. We also tested soluble E-64 and unloaded microparticles as controls. Overall, we 
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found there was significantly more active cathepsin L and MMP-2 proteases compared to 
uninjured contralateral controls regardless of treatment. Additionally, we found no 
significant differences in active protease levels (cathepsin L or MMP-2) following 
treatment compared to injury alone (historical data). 
6.2 Conclusions 
The work outlined in this dissertation first identified specific protease targets 
within joint tissues over time. This information provided a baseline to develop a plan for 
more tailored treatment in our rat model of rotator cuff tear. Second, this thesis work 
provided two new technological advancements to subsequently be used to treat 
dysregulated proteases in vivo. Our novel microfluidic device allows us to fabricate 
suitably sized microparticles loaded with therapeutic molecules in a high throughput way. 
Additionally, we reinvented a currently available fluorogenic substrate assay that allows 
E-64 (whose uses had been previously limited by detection methods) to be investigated as 
a potential therapeutic treatment.  The culmination of this thesis work allowed us to test a 
localized protease-inhibitor based treatment to treat upregulated proteases in 
supraspinatus tendon in an established rat model of rotator cuff tear. The contribution of 
this body of work provides a therapeutic strategy to improve the current gold standard of 
treatment following rotator cuff tear. Reduced joint tissue degeneration prior to surgical 
reattachment would ultimately result in fewer instances of re-tear and overall improved 
surgical outcomes. 
The objective of chapter 3 was to assess degenerative damage in joint tissues 
following rotator cuff tear in a rat animal model and characterize active proteases (both 
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cathepsin and MMP families) spatially and temporally between the onset of injury and 
the manifestation of tissue degeneration. We found significantly more active cathepsin L 
in supraspinatus tendon at 1 week after injury and significantly more active MMP-2 at 1 
and 3 weeks after injury. Additionally, we found significantly more cathepsin L in 
supraspinatus muscle at 1 and 3 weeks after injury, while we found significantly more 
active MMP-2 at 3 weeks. Lastly, humeral head cartilage demonstrated significantly 
more active cathepsin L and K at 1 week after injury. In addition to observing protease in 
joint tissues over time, our rat model of massive rotator cuff tear also developed 
significant degeneration in each joint tissue. After 1 week, the supraspinatus tendon had 
observable changes in collagen structure and alignment. The supraspinatus muscle 
developed significant fibrous tissue between muscle fibers [19] after 3 weeks, which is 
indicative of substantial degeneration. Degeneration of humeral head cartilage was 
identified via the development of localized loss of cartilage (focal defects) in 4 out of 8 
animals. Interestingly, we also found that focal defects did not develop within the same 
region of the humeral head unlike what has been seen previously in a rat model of 
osteoarthritis of the knee [165]. This suggests that areas of cartilage degeneration are 
influenced by usage and activities specific to the individual.  
Additionally, we found neutrophils and macrophages had infiltrated the 
supraspinatus tendon by 1 week following injury. However, the cellular source of 
proteases has yet to be fully identified and are likely a combination of several tissue-
resident cells, as well as cells recruited due to injury, as proteases released in one area can 
diffuse throughout the joint. Resident cells of the joint tissues, including tendon, muscle, 
cartilage, and synovium have all shown to be capable of producing proteases 
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[63,110,131,158,171]. In addition to joint tissue cells, recruited inflammatory cells, such 
as macrophages and neutrophils, have the capacity to release proteases [67,68]. 
Investigation of the cellular source of these proteases would provide information for more 
targeted therapeutic intervention. 
The validation of an animal model of massive rotator cuff tear that recapitulates 
characteristic joint tissue degeneration seen in humans would be exceedingly valuable to 
test therapeutic treatments that could preserve joint tissue health and improve success 
rates of rotator cuff tendon reattachment surgeries. A more comprehensive understanding 
of biochemical changes to joint tissue over time following rotator cuff tear will better 
inform ideal intervention times and treatments for each tissue. These results demonstrate 
concomitant degeneration in a number of rotator cuff tissues after traumatic injury and 
suggest that early intervention addressing multiple tissues simultaneously may be 
required to prevent joint degeneration after rotator cuff tear.  
The objective of chapter 4 was to develop a novel microfluidic device to fabricate 
uniformly sized PEGDA microparticles and characterize release of E-64 in vitro over 
time using different fabrication parameters in our microfluidic device system. Our novel 
microfluidic device has the capacity to fabricate uniformly sized microparticles ranging 
from 25 to 400 µm, which is wider than size ranges accomplished with other microfluidic 
devices [26,156] and therefore can be useful for a larger number of applications. 
Additionally, we found that we could incorporate DTT into the microparticle network to 
fabricate hydrolytically degradable microparticles, which is relevant to many biomedical 
applications that do not want biomaterial carriers to remain in the body for longer than 
necessary for treatment. Also, we demonstrated that our novel microfluidic device 
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platform could also incorporate biomolecules such as heparin into the microparticle 
network, which has been used for a variety of applications including protein 
sequestration, protein release, protein conformation protection, and maintenance of 
protein bioactivity [19,20,35–37,153].  
Additionally, we demonstrated that we could load therapeutic molecules into the 
discontinuous phase for incorporation into the microparticle network for sustained release 
without any additional steps. Specifically, we were able to load and release small 
molecule, broad cathepsin inhibitor E-64 directly into the discontinuous phase for 
subsequent microparticle release. Furthermore, we found that we could tune E-64 release 
by varying polymer weight percent (10 wt% and 20 wt%), DTT concentration (5 and 10 
mM), and initial loading concentration (167 µg and 333 µm). On average, increased 
polymer weight percent, DTT concentration, and initial loading resulted in the highest 
amount of E-64 released from microparticles fabricated with our microfluidic device. We 
had hypothesized that increased polymer weight would result in a decrease in E-64 
release due to a greater likelihood that E-64 would be unable to move as quickly through 
the polymer network and diffuse into solution, similar to previous findings [134]. 
However, we found that higher polymer weight percent resulted in greater amounts of E-
64 released. Additionally, hypothesized that increased DTT concentration would result in 
greater amount of E-64 released over 14 days. We found that higher amounts of DTT did 
in fact result in greater amounts of E-64 release in both the 10 wt% and 20 wt% groups. 
The incorporation of higher amounts of DTT create a larger mesh size and it therefore is 
less interference of E-64 diffusion out of the microparticle. Lastly, we hypothesized that a 
greater initial loading of E-64 into the discontinuous phase would result in significantly 
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more E-64 released over 14 days. Interestingly, contrary to previous literature [134], 
higher amounts of E-64 loading did not result in greater amounts of E-64 release except 
for the 20 wt% 10 mM group. The other groups did not demonstrate significant 
differences in E-64 release relative to initial loading. Overall, we found that the 20 wt% 
10 mM 333 µm initial E-64 loading resulted in the greatest amount of E-64 release over 
14 days, which was subsequently used for in vivo testing in chapter 5 because it was 
sufficient E-64 release to achieve a 1:1 molar ratio with cathepsin L levels quantified in 
chapter 3. Thus, our novel microfluidic device platform has practical applications in a 
variety of fields including drug delivery and tissue engineering.  
In addition to designing a novel microfluidic device, we also redesigned a 
currently available fluorogenic substrate assay for E-64 quantification in solution. E-64 is 
the small molecule analog of the endogenous cysteine cathepsin inhibitor [38] and has 
been shown to irreversibly bind cathepsins L, S, and K [39,40]. Previously, therapeutic 
use of E-64 had been limited to systemic, soluble injections of known amounts because 
E-64 is unable to be quantified by other standard methods [24,25]. For example, 
antibodies to E-64 do not exist and therefore an ELISA cannot be used. E-64 does not 
contain a ring structure and therefore cannot be detected using an absorbance reading on 
a plate reader [41]. Furthermore, E-64 cannot be detected on Bicinchoninic Acid assay 
(BCA) or Pierce Coomassie assay, which are to commonly used protein quantification 
assays. Thus, the reinvention of the currently available DQ gelatin fluorogenic substrate 
assay allows our laboratory and others to more easily quantify E-64 release from 
biomaterial carriers. 
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The objective of Aim 3 was to investigate how the proteolytic network responds 
to local cathepsin inhibition within the tendon 1 week after injury. Using a near infrared 
dye, we tagged E-64 for the purposes of assessing in vivo release over time.  Specifically, 
we injected tagged E-64 in soluble form and tagged E-64 loaded microparticles into the 
supraspinatus tendon in our rat model of rotator cuff tear. We were unable to detect 
tagged E-64 that had been injected in soluble form after 1 day. This indicates that it had 
been cleared from the area in that time. Conversely, we were able to detect tagged E-64 
that had been injected in loaded microparticles over 21 days. This indicated that the 
injected microparticles had persisted in the rotator cuff area to allow for sustained 
detection of E-64 over 21 days. However, the release curves from animals injected with 
tagged E-64 loaded microparticles was highly variable, which suggests that each animal 
was not experiencing similar treatment.  
This wide variability could have been caused by various factors. NIR imaging is 
limited by tissue depth, such that the accuracy of tagged E-64 detection decreased with 
increased tissue depth. The supraspinatus tendon is located beneath the trapezius, deltoid, 
and supraspinatus muscles [70,187,188]. While the trapezius and deltoid muscles were 
considered sufficiently thin by our laboratory having limited knowledge of the NIR 
system, subsequent tissue dissection revealed to Dixon laboratory collaborators that this 
platform was not compatible with our rat model of rotator cuff tear. Essentially, released 
tagged E-64 migrating towards the surface of the skin will result in a much higher signal 
compared to equal quantities of tagged E-64 in the much deeper supraspinatus tendon. 
This limitation is likely the leading cause for the high variability of tagged E-64 detected 
in our rat model of rotator cuff tear. Even if perfect supraspinatus tendon injection was 
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achieved, microparticles could still have the opportunity and means to migrate away from 
the injection site during subsequent movement by the animals over 3 weeks.  
Furthermore, we assessed active cathepsin levels following massive rotator cuff 
tear injury and treatment with E-64 loaded microparticles, soluble E-64, or unloaded 
microparticles in our rat model using multiplex gelatin zymography. All treatment groups 
resulted in significantly more active cathepsin L and MMP-2 relative to their uninjured 
contralateral controls regardless of treatment. Additionally, no treatment resulted in 
significantly less active cathepsin L relative to untreated injury alone (historical data). 
However, there are inherent limitations to multiplex gelatin zymography and additional 
analysis is warranted to fully understand the effect of our E-64 treatment in our rat model 
of rotator cuff tear. Previously, it was generally accepted that E-64 inhibition of cathepsin 
proteases via covalent binding to the cathepsin active site [40]. However, more recently it 
has been shown that E-64 can disassociate from cathepsins during the zymography 
process, which could allow an inhibited cathepsin to be reactivated in the zymogram, 
leading to a “false positive” level of activity [39].  
The purpose of our E-64 treatment was to inhibit extracellular cathepsin proteases 
to reduce collagen digestion and reduce tendon degeneration. The zymography process 
requires the complete breakdown of extracellular matrix proteins and lysis of tenocytes 
and any other associated cells and consequently cannot distinguish intracellular or 
extracellular active proteases. The dosage of our E-64 treatment (both in soluble and 
microparticle form) were below levels required to trigger endocytosis of E-64 [190] and 
therefore intracellular cathepsin proteases would be unaffected. However, preservation of 
tendon structure in the presence of high levels of active cathepsin proteases would 
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indicate that the amount of extracellular cathepsin proteases was reduced and our 
treatment served its purpose. Thus, performing histology and immunohistochemistry 
would be required to better determine the location of the upregulated active proteases. 
Overall, the proteolytic network is incredibly complex and further analysis would be 
required to draw any concrete conclusions about the effect of sustained release of E-64 
the preservation of supraspinatus tendon after injury and its effect on the proteolytic 
network of our rat model of massive rotator cuff tear.  
Lastly, the zymography analysis was performed on rats that had been given an 
injection and allowed to recover and survive for 1 week after injury. It is possible the E-
64 loaded microparticles did not remain in the tendon in every rat for the entire 1 week 
after injury and treatment. This is further supported by the large variability seen in the in 
vivo release of tagged E-64 and suggests that the high variability between animals treated 
with E-64 loaded microparticles could be due to differences in microparticle localization 
over time. 
6.3 Future Directions 
The research in this dissertation contributes foundational knowledge to develop 
therapeutic strategies to halt joint tissue degeneration after rotator cuff tear and 
potentially improve surgical outcomes following tendon re-attachment surgery. The 
results of Aim 1 (chapter 3) verified that our rat model of massive rotator cuff tear could 
mimic late-stage degeneration seen in humans including collagen disorganization in 
tendon, significant atrophy and fibrous infiltration in muscle, and osteoarthritic changes 
to humeral head cartilage. Additionally, this work provided foundational knowledge of 
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the temporal and spatial regulation of two important families of proteases after rotator 
cuff tear. This information allows for the development of targeted treatments that treat 
specific proteases at the location and time that they are detrimental to tissue health and 
integrity. There are many diseases that could benefit from a better understanding of the 
temporal and spatial regulation of dysregulated proteases for targeted therapeutic 
intervention. Cathepsins have been implicated in several diseases including arthritis, 
osteoporosis, atherosclerosis, obesity, tendinopathy and cancer [14,16,39,69,109]. 
Similarly, prolonged upregulation of active MMPs have been implicated in several 
diseases including cancer, nephritis, fibrosis, tendinopathy, osteoarthritis, muscle atrophy 
[110,122–126,193]. We have demonstrated that there is potentially crosstalk between the 
cathepsin and MMP families of proteases and previous work has shown that cathepsins 
have the ability to cleave and activate proMMPs [31]. Thus, it will be important to 
investigate combination inhibitory treatments that would treat both cathepsins and 
MMPs. Specifically in the supraspinatus tendon of our rat model of rotator cuff tear, an 
ideal treatment would involve sustained release of cathepsin inhibitors over at least one 
week and sustained release of MMP inhibitors over at least 3 weeks. With our novel 
microfluidic device platform, we can synthesize two different types of microparticles for 
a combination treatment to target upregulated cathepsin and MMP proteases in our rat 
model of rotator cuff tear.  
In chapter 4 (Aim 2) of this dissertation work we developed a novel microfluidic 
device and outlined the redevelopment of a fluorogenic substrate assay for the detection 
of E-64. We demonstrated that our novel microfluidic device platform can fabricate 
uniformly sized microparticles with a diameter between 25 and 400 μm, which is wider 
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than size ranges accomplished with other microfluidic devices [26,156]. Additionally, we 
showed that we could incorporate DTT into our microparticle network to allow for 
hydrolytic degradation of the PEGDA network, in order to prevent a negative response 
such as foreign body giant cells and fibrous encapsulation, which may otherwise hinder 
mobility of the shoulder joint [194]. Furthermore, we showed that our novel microfluidic 
device has the ability to incorporate additional biomolecules directly into the 
microparticle network without additional steps. We used heparin as a model biomolecule, 
but heparin has been used been extensively used in biomaterials for the purpose of 
protein sequestration, protein release, protein conformation protection, and maintenance 
of protein bioactivity [19,20,35–37,153]. Most important to this dissertation work and 
essential for chapter 5 (Aim 3) was the verification that small molecule broad cathepsin 
inhibitor E-64 could be pre-loaded into the discontinuous phase of our novel microfluidic 
device and be incorporated into resulting microparticles. We confirmed that E-64 was 
loaded into microparticles and remained bioactive over at least 14 days. We also 
demonstrated that we could tune E-64 release based on polymer weight percentage, DTT 
concentration, and initial loading.  
To expand potential uses of our novel microfluidic device system, we will 
investigate the upper limits of DTT incorporation into our PEGDA-based microparticles. 
We will do this by testing increasing amounts of DTT in our discontinuous phase until 
microparticles can no longer be formed by our microfluidic device. We will subsequently 
perform a degradation study to determine how quickly our PEG-based microparticles 
degrade relative to DTT concentration. Lastly, we will investigate how microparticles 
with higher amounts of DTT incorporation and therefore faster degradation modulate E-
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64 release. The advantage of having a broader range of microparticle degradability is that 
it provides another lever for modification that similarly broadens potential uses of our 
microfluidic device.  
Overall, our novel microfluidic device platform has practical applications in a 
variety of fields including drug delivery and tissue engineering. Additionally, the 
microfluidic device platform can be modified for increasingly complex microparticle 
fabrication. For example, heparin microparticles can be fabricated and loaded into the 
discontinuous phase with PEGDA polymer for encapsulation to create a core-shell 
microparticle, which our laboratory has done previously with older methods [37]. An 
advantage of using the microfluidic device system is more uniform fabrication of 
microparticles and faster time to completion. Other groups have also made increasingly 
complex microfluidic devices. One group used a microfluidic device to fabricate 
microparticles with a hollow core and demonstrated pH dependent release of two 
different cancer drugs [195]. Additionally, another group has created a microfluidic 
device in series to fabricate triple emulsions, whereby three microparticles can be 
encapsulated within one larger particle for a sustained of therapeutic drugs or 
simultaneous delivery of multiple therapeutic drugs [196].  
Our novel microfluidic device is not limited to cathepsin inhibition via E-64 
release. This platform can also be applied to treat other diseases characterized by 
dysregulated cathepsins including rheumatoid arthritis, osteoarthritis of the knee, and 
osteoporosis of the spine [13,16,131]. However, the tunability of E-64 release would be 
specific to this particular design and may not necessarily match trends with other 
therapeutic molecules. The addition of any additional biomolecules could cause a 
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significant difference in degradation time and release profile. For example, based on our 
work in chapter 3 (Aim 1) we are also interested in investigating the compatibility of 
broad MMP inhibitor, TIMP-3 with our novel microfluidic device system. We would not 
expect negatively charged heparin containing microparticles loaded with positively 
charged, broad MMP inhibitor TIMP-3 to be identical to trends seen with E-64 because 
the microparticle design is different and TIMP-3 is a protein, not a small molecule. 
Furthermore, the release profiles will also be affected by electrostatic interactions 
between negatively charged heparin and positively charged TIMP-3 (isoelectric point ~ 
9.04) [197]. E-64 did not have an electrostatic attraction to any microparticle component 
in this work studies. Essentially, our work with E-64 provides a guideline of test 
parameters that may have an effect on therapeutic release. This would provide a starting 
point for others who are interested in utilizing our novel microfluidic device platform for 
drug delivery. 
Additionally, potential uses of our novel microfluidic device can be expanded to 
include the use of other biomolecules, crosslinkers, or even encapsulated cells for other 
therapeutic purposes. Other biomolecules of interest that can be included into our 
microparticle network include the integrin binding recognition sequences RGD and 
GFOGER [21,140]. The addition of these integrin binding peptides would expand the use 
of our novel microfluidic device to include the ability to fabricate microparticles with 
encapsulated cells. Of particular interest to our laboratory is the encapsulation and 
delivery of mesenchymal stem cells (MSCs) for in vivo delivery. MSCs have been shown 
to have the ability to modulate inflammation by secretion of various paracrine factors 
(their secretome) [198]. Additionally, the Garcia laboratory has previously shown that 
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they could encapsulate human islet cells in PEG-based microparticles containing RGD 
peptides and fabricated with a microfluidic device [156]. Moreover, our novel 
microfluidic device should have the capacity to covalently incorporate both therapeutic 
proteins and protease degradable crosslinkers for on-demand treatment of dysregulated 
proteases. The Garcia laboratory has previously shown that they can covalently 
incorporate VPM (protease-sensitive crosslinker) in a PEG-based microparticle fabricated 
with a microfluidic device [199].  
Overall, the main advantages of our novel microfluidic system are the ability to 
customize the resulting microparticles, reduced number of steps (which saves fabrication 
time), and all components added to the discontinuous phase will be incorporated into 
microparticles (which reduces material waste). Our novel microfluidic device has the 
potential to fabricate uniformly sized microparticles of various sizes, incorporate 
biomolecules and crosslinkers, load and release therapeutic molecules, encapsulate cells 
for therapeutic use, is economically priced, and easy to construct and use, which would 
make it widely available to those who wish to use it.  
In addition to developing a novel microfluidic device platform, we also outlined 
the redevelopment of a currently available fluorogenic substrate assay to detect and 
quantify E-64 in solution. E-64 is an inexpensive, broad cathepsin inhibitor and its 
therapeutic use had previously been limited to soluble injections due to the inability to 
quantify E-64 release in vitro from biomaterial carriers. Presently, with the 
redevelopment of the DQ gelatin fluorogenic substrate assay, E-64 use can be broadened 
to include its use with biomaterial vehicles. Furthermore, our methods of how we 
identified and developed the DQ gelatin fluorogenic substrate assay as opposed to the Z-
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FR-AMC fluorogenic substrate assays demonstrates a potential workflow to help others 
develop assays for therapeutic molecules that are also limited by in vitro detection and 
quantification. Overall, we demonstrated that not all assays and proteases respond equally 
and biomaterial carriers may interfere with the detection method. Thus, it is vital that 
others who are interested in using similar methods perform these same assessments.   
Finally, in chapter 5 (Aim 3) of this dissertation work we used the supraspinatus 
tendon as a model tissue to probe the proteolytic network in our rat model of massive 
rotator cuff tear. We were able to consistently inject microparticles in the proximal third 
of the supraspinatus tendon. However, our protocol could be further improved by adding 
ultrasound imaging to our injection protocol. The Soslowsky laboratory has previously 
used ultrasound imaging to perform dry needling procedures on rat supraspinatus tendons 
without performing an open surgery [191]. The use of ultrasound imaging could be used 
to guarantee injection in the length of supraspinatus tendon for treatment throughout the 
tendon tissue. Additionally, the ultrasound imaging protocol could also be used for 
precise injection and treatment into the most proximal portion of the supraspinatus 
muscle. It has been shown that the supraspinatus muscle undergoes degenerative changes 
asymmetrically, such that the muscle closest to the tendon and humeral head insertion 
will develop degenerative changes first and propagate to the more medial portions over 
time [192]. Lastly, the addition of ultrasound imaging would allow for repeated injections 
into the supraspinatus tendon or muscle because we would not be required to re-open up 
the animal.  
We found treatment with E-64 in soluble form and loaded into microparticles did 
not cause a significant decrease in active cathepsin L or MMP-2 levels compared to 
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injury alone. However, our rat model of massive rotator cuff tear is still a valuable 
platform to explore the proteolytic network. Ideally, we could develop a combination 
treatment of inhibitor loaded microparticles in order to  treat each joint tissue 
(supraspinatus tendon, supraspinatus muscle, and humeral head cartilage) with cathepsin 
and/or MMP inhibitors as dictated by Aim 1 with microparticles fabricated using our 
novel microfluidic device outlined in Aim 2. This study would determine if localized 
sustained release of protease inhibitors could reduce joint tissue degeneration after rotator 
cuff tear, which could be used as therapeutic treatment to ultimately improve surgical 
reattachment outcomes. Furthermore, this large study would provide more information on 
the role that proteases play in joint tissue degeneration following rotator cuff tear.  
Additionally, our animal model can be used to probe the complexities of the 
proteolytic network. Previous work has found that treatment with E-64 resulted in a 
significant decrease in active cathepsin L levels in cancer cells but paradoxically elevated 
levels of cathepsin  S [38]. This highlights the fact that the proteolytic network is 
incredibly complex and cannot be expected to adhere to deductive reasoning and must be 
probed and investigated in order to develop therapies with desirable outcomes, such has 
joint tissue preservation. Furthermore, our rat model of massive rotator cuff tear is also a 
model of acute inflammation. To better understand the protease contribution between 
resident cells and infiltrating inflammatory cells, we could also incorporate treatment 
with clodronate liposomes, which deplete macrophages and neutrophils [172,199]. 
Following clodronate liposome treatment, the only source of proteases should be resident 
cells. Thus, we hypothesize that clodronate liposome treatment will cause a decrease in 
upregulated protease amounts (cathepsins and MMPs) due to the elimination of a 
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protease source. However, based on the documented complexity of the proteolytic 
network, it would need to be tested. 
Our rat model could also be used to study the effectiveness of our inhibitor-loaded 
microparticle treatments prior to surgical reattachment, which would more closely mimic 
the human condition. Specifically, we would induce massive rotator cuff tear injury in 
our rat model and simultaneously deliver localized inhibitor treatment. After sufficient 
time to allow significant degeneration to occur (relative to injury with no treatment), we 
would perform the  reattachment surgery. This would allow us to  assess the efficacy of 
our inhibitor treatment to prevent joint tissue degeneration prior to surgical reattachment 
and determine if the localized inhibitor treatment improved surgical outcomes.  
 Furthermore, the methods outlined in this dissertation can be used to develop 
animal models with other diseases characterized by dysregulated proteases including 
cancer, osteoporosis, and osteoarthritis. For example, the Guldberg laboratory developed 
a medial meniscal transection (MMT) rat model to induce osteoarthritic changes to knee 
cartilage after 3 weeks. This model has demonstrated consistent defects in the medial 
third of cartilage in a rat model of osteoarthritis[161]. Additionally, mouse models of 
osteoarthritis have demonstrated osteoarthritic severity in the knees to correlate to 
cathepsin K concentration [158]. Additionally, MMP-2, -9, and -13 have been shown to 
be more active in osteoarthritic cartilage compared to healthy cartilage in both humans 
and rats [124,125]. In this example, following investigation of active proteases 
temporally via multiplex gelatin zymography, we could use our novel microfluidic device 
to fabricate microparticles to sustain inhibition of upregulated proteases within knee 
cartilage.  
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APPENDIX A: TROUBLESHOOTING CYSTATIN C RELEASE 
FROM NOVEL MICROFLUIDIC DEVICE 
A.1. Cystatin C Release From Novel Microfluidic Device 
Introduction: Cystatin C is the endogenous inhibitor of the cysteine cathepsin family of 
proteases [11]. It is produced by almost every nucleated cell in the body for the purposes 
of inhibiting upregulated extracellular proteases [109]. Thus, we initially investigated 
cystatin C release from our novel microfluidic device for subsequent use in Aim 3 of this 
work. 
Methods: The microfluidic device was fabricated as described previously in Chapter 4.2. 
The discontinuous phase consisted of PEGDA, DTT, and L0290 photoinitiator (TCI). 
The L0290 photoinitiator was dissolved in phosphate buffered saline (PBS) to a final 
concentration of 20 mg/mL. PEGDA and DTT were resuspended in L0290 photoinitiator 
and allowed to incubate at 37 °C for 30 minutes in the absence of light to allow for 
Michael Type addition crosslinking. Following this incubation, heparin was added to the 
polymer solution and incubated for 30 minutes at 37 °C. Subsequently, 500 µg of 
Cystatin C (BBI) was added to the polymer solution and incubated at 37 °C in the 
absence of light for an additional 30 minutes. The polymer solution was loaded into a 1 
mL syringe (Hamilton) and covered in foil to prevent light exposure and premature 
crosslinking. Resulting microparticles were washed, placed in 1.7 mL lowing binding 
tubes, and put on rotor at 37 °C. To determine cystatin C release, microparticles were 
centrifuged and supernatant was collected and stored at -20 °C. The supernatant was 
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replaced with an equal volume of ammonium bicarbonate buffer. Supernatant samples 
were tested for cystatin C release using ELISA (R&D Systems). 
Results: After 10 days of release, we calculated that 12.6 ± 2.1 ng/mL of cystatin C had 
been released, which was 2.5% of what was originally loaded into the discontinuous 
phase.  
Discussion: Cystatin C is able to be loaded into microparticles fabricated with our novel 
microfluidic device platform. However, based on the zymography results in Aim 1, to 
achieve a molar ratio of 1:1 with cathepsin L in supraspinatus tendon 150 µg (150,000 
ng) of cystatin C is required to be released from our microparticles over 7 days. Thus, our 




Figure A.1: Cystatin C was released from microparticles fabricated with our novel 
microfluidic device. Cumulative release of cystatin C equaled 12.6 ± 2.1 ng/mL, which 
is approximately 2.5% of the initial 500 µm loaded into the discontinuous phase. N=3. 
A.2. Compare Cystatin C Release From Injected Hydrogel And Novel 
Microfluidic Device 
Methods: The microfluidic device was fabricated as described above in Appendix A.1. 
The microfluidic device was allowed to run until half of the polymer solution was 
remaining in the discontinuous phase syringe. The syringe containing the discontinuous 
phase was injected into 50 µm hydrogel molds and crosslinked under UV light for 10 
minutes. Resulting microparticles were washed, placed in 1.7 mL lowing binding tubes, 
and put on rotor at 37 °C. Resulting hydrogels were placed in 1.7 mL lowing binding 
tubes, and put on rotor at 37 °C. To determine cystatin C release from microparticles, 
they were centrifuged and supernatant was collected and stored at -20 °C. To determine 
cystatin C release from hydrogels, the supernatant was collected and stored at -20 °C. The 
supernatant was replaced with an equal volume of ammonium bicarbonate buffer all 1.7 






















mL low binding tubes. Supernatant samples were tested for cystatin C release using 
ELISA (R&D Systems). 
Results: After 5 days of release, we calculated that microparticles had released 0.00393 ± 
0.00375 ng/mL of cystatin C, while hydrogels released 0.130 ± 0.226 ng/mL of cystatin 
C. 
Discussion: The lack of cystatin C from hydrogels indicated to us that the majority of 
cystatin C added to the discontinuous phase was not entering the microfluidic device, 
which would explain why resulting microparticles released very little cystatin C. This 
suggested that cystatin C was remaining inside the syringe. 
 
Figure A.2: Very low levels of cystatin C was released from hydrogels injected into 
molds with the syringe used in our novel microfluidic device platform. Cumulative 
release of cystatin C from our microparticles equaled 0.00393 ± 0.00375 ng/mL. 
Cumulative release of cystatin C from hydrogels equaled 0.130 ± 0.226 ng/mL. 
N=3/group. 




















A.3. Cystatin C Location Test 
Methods: Cystatin C was fluorescently tagged with AlexaFluor633 (AF633, Invitrogen). 
Cystatin C was dissolved in 0.1 M Na2HPO4 solution (pH = 6) at a 10 mg/mL 
concentration and reacted with 10 mM EDC and 5.7 μM AF633 at room temperature for 
90 minutes. Fluorescently tagged cystatin C was subsequently dialyzed for two days, 
freeze dried, and stored at -20 °C until use. The microfluidic device was fabricated and 
run as described above in Appendix A.2. Resulting microparticles and hydrogels were 
placed on a 96 well plate to determine if tagged cystatin C was incorporated into the 
network. Additionally, we tested the components of the microfluidic device and untagged 
cystatin C in order to distinguish any autofluorescence.  
Results: All components tested demonstrated basal levels of fluorescence except the PBS 
that was used to rinse the syringe used in the discontinuous phase. 
Discussion: This study demonstrated that cystatin C did in fact remain in the syringe 
used for the discontinuous phase of our microfluidic device. Thus, cystatin C was not 
compatible with our system. A limitation of this study is that it is possible the fluorescent 
tag is responsible for adsorption to the syringe. To answer this question in future studies, 
we could the same study with unbound AF633 dye. 
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Figure A.3: Tagged cystatin C predominately remained inside the syringe used to 
inject the discontinuous phase of the microfluidic device platform. Detectable 
amounts of cystatin C was not incorporated into resulting microparticles or hydrogels. 














































APPENDIX B: EXAMPLE CALCULATION OF E-64 RELEASE 
WITH DQ GELATIN FLUOROGENIC SUBSTRATE ASSAY AND 
E-64 STANDARD CURVE 
Methods: First, the DQ gelatin assay is run with undiluted supernatant samples with an 
E-64 standard curve (refer to section 4.2.6 for details). The supernatant samples that have 
a fluorescent intensity reading at or above the standard curve value at 500 ng/mL were 
used to calculate release immediately. Samples that had a fluorescent intensity below the 
standard curve value at 500 ng/mL were diluted and re-run. Next, we subtracted the blank 
from the standard curve values and supernatant sample values. All the data is compiled 
and input into GraphPad as shown in Figure B.1a. The standard curve values are then 
analyzed in GraphPad. Specifically, we hit Analyze à XY analyses à non-linear 
regression (curve fit) à exponential à one-phase decay. The results tab will show the 
values for Y0 (Y value when X is zero), P (plateau, the Y value at infinite time), and K 
(the rate constant) shown in Figure B.1b. These values are required for the one-phase 
decay equation shown in Figure B.1c. After determining how much E-64 was in the 
supernatant sample based on the curve fit, multiply any samples by their respective 
dilution factor. Be sure to keep in mind that supernatant samples that were re-run have 
their own E-64 standard curve. Using cumulative release, plot the E-64 release curve 
similar to the one shown in Figure B.1d. 
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Figure B.1: Example Calculation of E-64 Release with DQ Gelatin Fluorogenic 
Substrate Assay and E-64 Standard Curve. (A) Screenshot of XY plot of Cathepsin K 
activity from E-64 standard curve (B) Screenshot of one-phase decay analysis (C) One-
phase decay equation (D) Example cumulative release plot of E-64 loaded microparticles. 
 
Y = (Y0 – P) * exp (-K*X) + P
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